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In recent years, there has been an emergence or re-emergence of Chikungunya virus 
(CHIKV), a member of the alphavirus. The virus is one of the arboviruses, and it is 
classified as a neglected tropical disease in more than 55 different countries in the 
world, including many African and Asian countries, Europe, Americas, and Australia. 
In 2008, it was listed in the US National Institute of Allergy and Infectious Disease 
(NIAID) category C priority pathogen due to its morbidity and mortality rates. In 
addition to damaging global health, the virus also imposes a huge economic burden on 
affected countries. However, there is currently no licensed vaccine or effective drug to 
combat the disease. Up to now, there have been few studies focusing on finding 
potential inhibitors of CHIKV. Taking advantage of all available data about CHIKV and 
a combination of different computational methods, this study aimed to discover and 
develop an approach leading to identifying inhibitors against this virus. The study 
targeted the non-structural proteins, nsP3 macrodomain and nsP2 protease, which play 
crucial roles in the viral replication and transcription (Chapter 2 and Chapter 3), and the 
envelope glycoprotein complexes responsible for virus entry and attachment (Chapter 
4). Initially, this study searched for potential binding pockets of the CHIKV protein 
structures. A combination of computational tools including molecule docking, virtual 
screening, molecule dynamics simulations, and binding free energy calculations were 
used in this approach. A number of lead compounds to fight CHIKV disease were 
identified. The insights into the interactions between CHIKV inhibitors and their targets 
were elucidated. Our findings open a way which would be helpful for the further 
research on antiviral rational drug design, especially design of inhibitors for CHIKV 






TABLE OF CONTENTS 
 
CERTIFICATION ............................................................................................................ ii 
PUBLICATIONS ............................................................................................................. iii 
ACKNOWLEDGEMENTS ............................................................................................. iv 
ABSTRACT .................................................................................................................... vii 
LIST OF FIGURES ......................................................................................................... xi 
LIST OF TABLES ......................................................................................................... xvi 
ABBREVIATIONS ....................................................................................................... xix 
CHAPTER 1. INTRODUCTION ................................................................................ 1 
1.1 Overview of Chikungunya virus ....................................................................... 1 
1.1.1 Global expansion of Chikungunya disease ................................................... 1 
1.1.2 The spread of CHIKV ................................................................................... 3 
1.1.3 Virus lifecycle ............................................................................................... 4 
1.1.4 Clinical symptoms ......................................................................................... 5 
1.1.5 Diagnosis ....................................................................................................... 6 
1.1.6 CHIKV genome and structure ....................................................................... 6 
1.2 Current treatment for CHIKV infection .......................................................... 10 
1.2.1 Specific inhibitors of CHIKV ..................................................................... 11 
1.2.2 Current approach for CHIKV vaccine ........................................................ 15 
1.2.3 Alternate approaches ................................................................................... 17 
1.3 Current research in CHIKV drug discovery ................................................... 17 
1.3.1 Cell-based high throughput screening approaches ...................................... 17 
1.3.2 In silico approaches ..................................................................................... 17 
1.4 Structure-based drug discovery for CHIKV ................................................... 18 
1.4.1 Overview of computer-aided drug discovery .............................................. 18 
1.4.2 Protein-ligand docking assists in drug discovery ........................................ 20 
1.4.3 Molecular dynamics simulations in drug discovery ................................... 30 
1.4.4 Binding free energy calculations ................................................................. 36 
1.5 Project background and aims .......................................................................... 43 
CHAPTER 2. DISCOVERY OF INHIBITORS TARGETING CHIKV NON-
STRUCTURAL PROTEIN 3 .......................................................................................... 45 




2.1.1 Function and role of the nsP3 of CHIKV ................................................... 45 
2.1.2 Early attempts to discover CHIKV nsP3 inhibitors .................................... 46 
2.2 Overview of this study .................................................................................... 47 
2.2.1 Molecular docking and virtual screening .................................................... 48 
2.2.2 MD simulations ........................................................................................... 49 
2.2.3 Binding free energy calculations ................................................................. 50 
2.3 Results and discussion .................................................................................... 50 
2.3.1 Docking results with ADP-ribose ............................................................... 50 
2.3.2 Identification of inhibitors for the nsP3 macrodomain ............................... 54 
2.3.3 MD simulations ........................................................................................... 61 
2.3.4 Binding free energy calculations for the ligands binding to the nsP3 protein
 73 
2.3.5 Analysis and selecting leads for biological testing ..................................... 75 
2.4 Conclusions ..................................................................................................... 77 
CHAPTER 3. DISCOVERY OF INHIBITORS TARGETING CHIKV NON-
STRUCTURAL PROTEIN 2 .......................................................................................... 79 
3.1 Introduction ..................................................................................................... 79 
3.1.1 Functional importance of the nsP2 in drug design ...................................... 79 
3.1.2 Early attempts to discover CHIKV nsP2 inhibitors .................................... 80 
3.2 Overview of this study .................................................................................... 83 
3.3 Results and discussion .................................................................................... 84 
3.3.1 Molecular docking and virtual screening .................................................... 84 
3.3.2 MD simulations ........................................................................................... 95 
3.3.3 Binding free energy calculations for the ligands binding to the nsP2 enzyme
 109 
3.3.4 Analysis and selecting leads for biological testing ................................... 111 
3.4 Conclusions ................................................................................................... 112 
CHAPTER 4. DISCOVERY OF INHIBITORS TARGETING CHIKV ENVELOPE 
GLYCOPROTEINS ...................................................................................................... 114 
4.1 Introduction ................................................................................................... 114 
4.1.1 Envelope glycoproteins as potential targets for CHIKV drug discovery .. 114 
4.1.2 Early research targeting envelope glycoproteins ...................................... 115 




4.2 Overview of this study .................................................................................. 117 
4.3 Results and discussion .................................................................................. 118 
4.3.1 Molecular docking and virtual screenings ................................................ 118 
4.3.2 Identification of potential binding pockets using different methods ........ 125 
4.3.3 Analysis of interactions between hit compounds and their binding pockets
 126 
4.3.4 Sampling convergence in AutoDock Vina ................................................ 130 
4.3.5 Analysis and selection of hit compounds for biological testing ............... 131 
4.4 Conclusions ................................................................................................... 133 
CHAPTER 5. DISCUSSION OF FINDINGS ......................................................... 134 
5.1 Selection of lead compounds for biological testing for CHIKV ................... 134 
5.2 Identification of potential binding sites in a protein target ........................... 137 
5.3 Evaluation of computational approaches and their combination .................. 138 
CHAPTER 6. EXPERIMENTAL PROCEDURES AND METHODS ................... 140 
6.1 General procedure for molecular docking and virtual screening .................. 140 
6.1.1 Docking protocol ....................................................................................... 141 
6.1.2 Prediction of binding sites on protein ....................................................... 144 
6.1.3 Applying a docking procedure .................................................................. 145 
6.2 Molecular dynamics simulations .................................................................. 147 
6.2.1 Simulations for protein .............................................................................. 149 
6.2.2 Simulations for ligands ............................................................................. 150 
6.3 Binding free energy calculations ................................................................... 150 
CHAPTER 7. OUTLOOK AND FUTURE DIRECTIONS .................................... 152 
7.1 NSP3 macrodomain protein .......................................................................... 152 
7.2 NSP2 protease enzyme .................................................................................. 154 
7.3 Envelope glycoproteins ................................................................................. 155 
REFERENCES .............................................................................................................. 158 






LIST OF FIGURES 
 
Figure 1.1. Global expansion of CHIKV (taken from the website of Centers for Disease 
Control and Prevention (http://www.cdc.gov/chikungunya/geo/index.html) with 
countries and territories where chikungunya cases have been reported with 
endemic or epidemic, updated 24th of February, 2015). ........................................... 2 
Figure 1.2. Replication cycles of CHIKV. The picture is reproduced from Rashad A. et 
al8 with permission). ................................................................................................. 5 
Figure 1.3. Genome organisation of CHIKV (adapted from Singh S. K. and Unni S. K.22).
 ................................................................................................................................... 7 
Figure 1.4.  Structure of the CHIKV, showing the structure of virus particles in a T=4 
icosahedral symmetry (A) and the components of a single unit with a nucleocapsid 
consisting of spikes (made by envelope glycoproteins), virus membrane, and 
transmembrane (TM) helix; and a capsid covering genome RNA inside (B), 
(adapted from Sun S. et al.65) .................................................................................. 10 
Figure 1.5. Less common structures of some potential inhibitors for CHIKV. ............. 14 
Figure 1.6. Applications of CADD to the various stages of drug development (adapted 
from Tang Y. et al.170)............................................................................................. 19 
Figure 1.7. Representation of the strategy used for protein-ligand docking. ................. 21 
Figure 1.8. How MD simulations proceed (adapted from Durrant D. et al246). ............. 31 
Figure 1.9. Thermodynamic cycle for calculating relative binding free energies between 
two ligands bound to the same protein (from Michel J. et al300). ........................... 38 
Figure 2.1. X-ray crystal structure of the macrodomain of CHIKV in complex with 
ADP-ribose.73 .......................................................................................................... 47 
Figure 2.2. Schematic diagram of in silico approaches. ................................................ 47 
Figure 2.3. Re-docking ADP-ribose (A) into the active site of the nsP3: (B) The best 
docking pose of ligand ADP-ribose is represented as a stick model (coloured by 
atom type) while the protein nsP3 is shown in the solvent surface (coloured by 
interpolated charge with a probe radius of 1.4 Å). (C) The interactions of this pose 
and the nsP3 residues show hydrogen bonding interactions at the binding site of the 




Figure 2.4. Superimposition of the ADP-ribose after docking (in red, the top pose) and 
its structure in the co-crystal structure (in blue) at the active site of nsP3. The 
heavy-atom RMSD between the two structures is 0.6 Å. ....................................... 53 
Figure 2.5. Representation of three binding pockets identified in the nsP3 with top hit 
compounds binding in the pockets. Pocket 1 is the ADP-ribose binding site with 
ligand NCI_25457 (A, in burgundy), NCI_345647_a (B, in red), and NCI_61610 
(C, in pink). Pocket 3 shares some residues with Pocket 1 with ligand NCI_670283 
(E, in yellow). Pocket 2 is in the other side of Pocket 1 with ligand NCI_127133 
(D, in dark green). ................................................................................................... 56 
Figure 2.6. Structures of the top hit compounds, obtained from screenings for the nsP3.
 ................................................................................................................................. 58 
Figure 2.7. Binding pose and interactions of hit compounds in the nsP3 macrodomain: 
(A) NCI_25457 in Pocket 1: HBs with Val113 and π-π interaction with Trp148; 
(B) NCI_61610 in Pocket 1: HBs with Gly112 and π-π interaction with Trp148; 
(C) NCI_127133 in Pocket 2: HBs with Asp133; (D) NCI_670283 in Pocket 3: 
Hydrophobic contacts only. The ligands (in cyan) and the residues surrounding the 
ligands (in grey) were displayed in sticks and coloured by atoms (carbon in cyan in 
ligand or in grey in residues, nitrogen in blue, oxygen in red). .............................. 61 
Figure 2.8. The backbone RMSD profiles for the apo protein nsP3 and its different 
complexes during MD simulations: (A) Complexes of the nsP3 and top-hit 
compounds; (B) Complexes of the nsP3 and tenth-hit compounds. ....................... 64 
Figure 2.9. RMSF values of Cα atoms of the apo protein nsP3 and its different 
complexes during MD simulations: (A) Complexes of the nsP3 and top-hit 
compounds; (B) Complexes of the nsP3 and tenth-hit compounds. ....................... 65 
Figure 2.10. Hydrogen bonding interactions between the nsP3 and ligands: (A) Ligand 
NCI_61610 at Pocket 1 and (B) Ligand NCI_670283 at Pocket 3, with 
representation of ligands and key residues for interactions surrounding the ligands 
(in stick). ................................................................................................................. 69 
Figure 2.11. Superimposition of the different conformations of ligand and complexed 
ligand NCI_61610-nsP3 during simulation with the initial structure (red: at 0 ns, 
grey: at 10 ns, green: at 20 ns, pink: at 30 ns, orange: at 40 ns, and blue: at 50 ns).




Figure 3.1. Proposed mechanism of protease catalytic of the nsP2 (adapted from 
Andrew T. R. et al).350 ............................................................................................ 80 
Figure 3.2. Structures of some potential inhibitors for the nsP2. ................................... 82 
Figure 3.3. Binding pose and interactions of compounds 22-25 in the nsP2 protease: 
(A) Compound 22 in Pocket 1: HBs with Glu1043, Lys1045 and Lys1239; (B) 
Compound 23 in Pocket 1: HBs with Lys1045 and His1222; (C) Compound 24 in 
Pocket 1: HBs with Tyr1079 and Asp1246; (D) Compound 25 in Pocket 1: HBs 
with Glu1204 and His1222. Compound 22, 23 and 25 were in good position in the 
pocket, except compound 24 was in the rear and nearly out of the pocket. The 
ligands (in cyan) and the residues surrounding the ligands (in grey) were displayed 
in sticks and coloured by atoms (carbon in cyan in ligand or in grey in residues, 
nitrogen in blue, oxygen in red, sulphur in organge). ............................................. 86 
Figure 3.4. Representation of docked structures of top hit compounds in different 
virtual screenings at five different binding sites of the nsP2 protease with Pocket 4 
being the active site of the nsP2 protease. Ligand NCI_61610 (A) and NCI_293778 
(B1) in Pocket 1; ligand NCI_293778 (B2) in Pocket 2; ligand NCI_37553 (C) in 
Pocket 3; ligand NCI_293778 (B3) in Pocket 4; and NCI_293778 (B4) in Pocket 5. 
Ligand NCI_293778 (B) with different conformations, B1-B4 could bind to 
different pockets Pocket 1, 2, 4, and 5, respectively. .............................................. 89 
Figure 3.5. Structures of some top hit compounds for the nsP2. ................................... 92 
Figure 3.6. Binding poses and interactions of hit compound NCI_293778 at different 
binding pockets and key residues for interactions at each pocket: (A) At Pocket 1: 
HBs with Lys1239; (B) At Pocket 2: π-π interactions with Tyr1177; (C) At Pocket 
4: π-π interactions with Trp1084; (D) At Pocket 5: Hydrophobic contact only. The 
ligands (in cyan) and the residues surrounding the ligands (in grey) were displayed 
in sticks and coloured by atoms (carbon in cyan in ligand or in grey in residues, 
nitrogen in blue, oxygen in red. .............................................................................. 93 
Figure 3.7. Superimposition of three crystal structures, namely the CHIKV nsP2 
protease (PDB id: 3TRK, in blue), the VEEV nsP2 protease (PDB id: 2HWK, in 
red), and the structure of SINV (PDB id: 4GUA, in grey). The conserved catalytic 
residues, cysteine and histidine (in licorice), Cys1013 and His1083 in the CHIKV 
nsP2 protease (in blue), Cys477 and His546 in the VEEV nsP2 protease (in red); 




Figure 3.8. The backbone RMSD profiles for the apo protein nsP2 and its different 
complexes during MD simulations from 4 ns to 53 ns: (A) Complexes of the nsP2 
and top-hit compounds; (B) Complexes of the nsP2 and tenth-hit compounds. ..... 98 
Figure 3.9. RMSFs values of Cα atoms of the apo protein nsP2 and its different 
complexes during MD simulations: (A) Complexes of the nsP2 and top-hit 
compounds; (B) Complexes of the nsP2 and tenth-hit compounds. ....................... 99 
Figure 3.10. Hydrogen bonding interactions between the nsP2 enzyme and ligands: (A) 
Ligand NCI_37553 at Pocket 3, (B) Ligand NCI_67436 at Pocket 5; with 
representation of ligands and key residues for interactions surrounding the ligands 
(in licorice), showing the interactions maintained between the ligands and residues 
of protein through strong HBs interactions. .......................................................... 103 
Figure 3.11. The docked structure of ligand NCI_293778vst4 (in green) in Pocket 1 of 
the nsP2 protease, showing the residues forming Pocket 1 and the ligand-protein 
interactions (in grey). ............................................................................................ 104 
Figure 3.12. Superimposition of the different conformations of ligand NCI_37553 and 
complexed with the nsP2 at Pocket 3 of the nsP2 during simulations with respect to 
the initial structure (red: at 0 ns, grey: at 10 ns, green: at 20 ns, pink: at 30 ns, 
orange: at 40 ns, and blue: at 50 ns). ..................................................................... 106 
Figure 4.1. Structure of the envelope glycoprotein complexes: (A) The immature 
structure (PDB id: 3N40); (B) The mature structure (PDB id: 3N42). These 
structures are similar and the only difference is in the furin loop. ........................ 117 
Figure 4.2. Representation of docked structures of top hit compounds in different 
virtual screenings showing the location of the pockets: (A) Pocket 1 with ligand 
NCI_293778 (L1) and Pocket 2 with ligand NCI_67436 (L2) in the immature 
structure (PDB id: 3N40); (B) Pockets in the mature structure (PDB id: 3N42): 
ligand NCI_293778 (conformation L1) in Pocket 1, ligand NCI_67436 (L2) in 
Pocket 2, ligand NCI_61610 in Pocket 3 (L3), and ligand NCI_293778 
(conformation L4) in Pocket 4. ............................................................................. 123 
Figure 4.3. Hydrogen bonding analysis of compounds with the immature structure in 
docking: (a) NCI_61610, (b) NCI_84100_a, (c) NCI_116702, (d) NCI_156219_b, 
(e) NCI_227186_a. The key residues involved in the interactions between 
glycoproteins and ligands are shown. The ligands (in cyan) and the residues 




(carbon in cyan in ligand or in grey in residues, nitrogen in blue, oxygen in red, 
sulphur in organge). .............................................................................................. 128 
Figure 4.4. Hydrogen bonding analysis of compound with the mature structure: (a) 
NCI_7524_a, (b) NCI_61610, (c) NCI_156219_b, (d) NCI_227186_b, (e) 
NCI_84100_b. The key residues involved in the interactions are also shown. The 
ligands (in cyan) and the residues surrounding the ligands (in grey) were displayed 
in sticks and coloured by atoms (carbon in cyan in ligand or in grey in residues, 
nitrogen in blue, oxygen in red, sulphur in organge). ........................................... 130 
Figure 6.1. A diagram of the docking procedure in AutoDock Vina. .......................... 141 






LIST OF TABLES 
 
Table 1.1. Prevalence of CHIKV in terms of year and infected countries. ...................... 2 
Table 1.2. Some potential inhibitors for CHIKV. .......................................................... 11 
Table 1.3. Potential vaccines for CHIKV. ...................................................................... 16 
Table 1.4. Docking programs with corresponding search algorithm and scoring function.
 ................................................................................................................................. 26 
Table 1.5. Strengths and weaknesses for docking and MD simulations280-281 ............... 35 
Table 1.6. Values of the β parameter as a function of the chemical nature of the ligand, 
according to Hansson et al.320 ................................................................................. 42 
Table 1.7. Values for the β parameter in Equation 1.17, according to AlmlÖf M. et 
al.326 ......................................................................................................................... 43 
Table 2.1. Poses in the docking of ADP-ribose into the nsP3. RMSD refers to the 
heavy-atom RMSD from the co-crystal structure for ADP-ribose with the nsP3. . 51 
Table 2.2. Analysis of interactions between the best docked of ADP-ribose and the 
nsP3 macrodomain. ................................................................................................. 51 
Table 2.3. Comparison of the identified hydrogen bonding interactions in the nsP3-
ADP-ribose docked complex with the previously published data. In Ref [73], key 
residues including bonding residues (in bold), were identified by experimental 
work with the crystal structure of complex nsP3-ADP-ribose (3GPO) while 
residues in Ref [70] were determined by MD simulations of ADP-ribose in the 
nsP3 based on the above crystal structure. .............................................................. 53 
Table 2.4. Results of the top ten compounds of different virtual screens for the nsP3. 
The binding affinities are shown in kcal/mol. ......................................................... 55 
Table 2.5. Pocket residues in the nsP3 macrodomain. ................................................... 56 
Table 2.6. Chemical structures of five top hit compounds for the nsP3 macrodomain 
and their properties. ................................................................................................. 62 
Table 2.7. Hydrogen bonding analyses on the trajectories sampled in MD simulations 
of hit compounds for the nsP3. ............................................................................... 66 
Table 2.8. Hydrophobic contact analyses on the trajectories sampled in the MD 




Table 2.9. Re-docking results for complex nsP3-NCI_61610 with different 
conformations of the nsP3 protein taken from the different timepoints in 
simulations at Pocket 1. .......................................................................................... 72 
Table 2.10. Virtual screening results for blind docking into Pocket 1 with different 
conformations of the nsP3 taken from the different timepoints in simulations. The 
binding affinities are shown in kcal/mol. ................................................................ 72 
Table 2.11. Average binding free energies (kcal/mol) of top-hit compounds and tenth-
hit compounds for the nsP3 calculated by LIE method using data trajectories from 
the MD simulations: ΔG1 (in kcal/mol using α = 0.18, β = 0.43, and γ = 0) or ΔG2 
(in kcal/mol using α = 1.043, β = 0.43, and γ = 0).328 ΔG is the predicted binding 
affinity by Vina (in kcal/mol). ................................................................................ 74 
Table 2.12. Potential lead compounds for the nsP3 proposed for biological testing. .... 76 
Table 3.1. Docking results of the best compounds for the nsP2 taken from previous 
study [from Singh K. D. et al351] with the binding affinities (kcal/mol). ............... 85 
Table 3.2. Results of the top ten hit compounds from the blind dockings for the nsP2. 
The binding affinities ΔG are in kcal/mol. .............................................................. 87 
Table 3.3. Results of the top ten compounds of focused dockings for the nsP2. The 
binding affinities are in kcal/mol. ........................................................................... 88 
Table 3.4. The important residues in each pocket of the nsP2 protease with the key 
residues in bold involved in forming HBs and hydrophobic contacts between the 
protein and ligands. ................................................................................................. 90 
Table 3.5. Chemical structures of hit compounds for nsP2 and their properties............ 96 
Table 3.6. Hydrogen bonding analyses on the trajectories sampled in the MD 
simulations for hit compounds in complexed with the nsP2 protease. The HBs with 
occupancy more than 10% are in highlighted in bold. .......................................... 100 
Table 3.7. Hydrophobic contact analyses on the trajectories sampled in the MD 
simulations for hit compounds in complexed with the nsP2 protease. ................. 102 
Table 3.8. Re-docking results for complex nsP2-NCI_67436 with different 
conformations of the nsP2 taken from the different timepoints of simulations at 
Pocket 5. The binding affinity is in kcal/mol. ....................................................... 107 
Table 3.9. Virtual screening results for blind docking into Pocket 1 with different 
conformations of the nsP2 taken from the different timepoints of simulations. The 




Table 3.10.  Average binding free energies (kcal/mol) of top-hit compounds and tenth-
hit compounds for the nsP2 calculated by LIE method using data trajectories from 
the MD simulations: ΔG1 (in kcal/mol using α = 0.18, β = 0.43, and γ = 0) or ΔG2 
(in kcal/mol using α = 1.043, β = 0.43, and γ = 0).328 ΔG is the predicted binding 
affinity by Vina (in kcal/mol). .............................................................................. 110 
Table 3.11. Potential lead compounds for the nsP2 proposed for biological testing. .. 112 
Table 4.1. Results of the top ten compounds of blind dockings with locations of pockets 
in the immature (PDB id: 3N40) and mature forms (PDB id: 3N42). The binding 
affinities ΔG are in kcal/mol. ................................................................................ 119 
Table 4.2. Results of the top ten compounds of blind dockings for the immature 
structure. The binding affinities are in kcal/mol. .................................................. 120 
Table 4.3. Results of the top ten compounds of blind dockings for the mature structure. 
The binding affinities are in kcal/mol. .................................................................. 121 
Table 4.4. Results of the top ten compounds of focused dockings for the immature and 
mature structures. The binding affinities are in kcal/mol. .................................... 122 
Table 4.5. Residues making up the pockets for two structures, the immature (PDB id: 
3N40) and mature structure (PDB id: 3N42). ....................................................... 124 
Table 4.6. Comparison of locations of identified binding pockets in both structures 
using different methods, blind dockings and the receptor cavities tool in Accelrys 
Discovery Studio program, and compared with previous study. .......................... 125 
Table 4.7. Key residues for interactions in both envelope glycoprotein structures at each 
of binding site. ....................................................................................................... 127 
Table 4.8. Potential lead compounds for the envelope glycoproteins proposed for 
biological testing. .................................................................................................. 132 
Table 6.1. Default values of docking parameters. ........................................................ 143 
Table 6.2. Parameters of a grid box in different docking and virtual screenings for the 
nsP3 protein. .......................................................................................................... 145 
Table 6.3. Parameters of a grid box in different docking and virtual screenings for the 
nsP2 protease. ........................................................................................................ 146 
Table 6.4. Parameters of a grid box in different docking and virtual screenings for 







1D First Dimension 
2D Two Dimension 
3D Three Dimension 
AMBER Assisted Model Building with Energy Refinement 
CADD Computer-Aided Drug Design 
CC50 50% Cytotoxic Concentration 
cDNA Complementary DNA 
CHARMM Chemistry At Harvard Molecular Mechanics 
CHIKV Chikungunya Virus 
cryo-EM Cryo-Electron Microscopy 
DNA Deoxyribonucleic Acid 
dsRNA Double-stranded RNA 
EC50 50% Effective Concentration 
ECSA East Central South African  
EEEV Eastern Equine Encephalitis Virus 
elec Electrostatic 
ELISA Enzyme-Linked Immunosorbent Assay  
FEP Free Energy Perturbation  
GAFF Generalized AMBER force field 
GARD Generally Applicable Replacement for RMSD 
GROMACS GROningen MAchine for Chemical Simulations 
GTP Guanosine 5'-Triphosphate 
H-A Hydrogen bond acceptor 
HBs Hydrogen Bonds 
H-D Hydrogen bond donor 
HSP Heat shock protein 
IC50 50% Inhibitory Concentration 
ID Identification 
IgG Immunoglobulin G  




IMP dehydrogenase Inosine 5'-Monophosphate Dehydrogenase 
IRES Internal Ribosome Entry Sequence 
IU International Unit 
Kd Dissociation Constant 
Ki Inhibitory Constant  
L Ligand 
LIE Linear Interaction Energy 
logP A calculated octanol-water partition coefficient 
MC Monte Carlo 
MD Molecular dynamics 
MM-GBSA Molecular Mechanics-Generalized Born Surface Area  
MM-PBSA Molecular Mechanics-Poisson Boltzmann Surface Area  
MW Molecular weight 
NAMD Not (just) Another MD Program 
NCBI National Center for Integrative Biomedical Informatics 
NCI National Cancer Institute 
NIAID National Institute of Allergy and Infectious Diseases  
NMR Nuclear Magnetic Resonance 
NSAIDs Non-Steroidal Anti-Inflammatory Drugs 
NTP N: number of particles, T: temperature, P: pressure 
OAS3 Oligoadenylate Synthetase 3 
OPLS Optimized Potentials for Liquid Simulations 
ORFs Opening Reading Frames  
P  Protein 
PDB id Protein Data Bank Identification Code 
pKa The logarithm of the acid dissociation constant  
PL Protein-Ligand 
PME Particle Mesh Ewald 
RC Replication Complex  
RMSD Root Mean Square Deviation 
RMSF Root Mean Square Fluctuation 




ROC Receiver Operating Characteristic  
ROC AUCs Area under ROC curves 
RT-LAMP Real-Time Loop-Mediated Isothermal Amplification  
RT-PCR Reverse Transcription Polymerase Chain Reaction  
SASA Solvent accessible surface area 
SFV Semliki Forest virus  
SINV Sindbis virus 
siRNA Small interfering RNA 
SO Swam Optimization  
TI Thermodynamic Integration  
TIP3P Transferable intermolecular potential 3 points 
TM Transmembrane 
UB Urey-Bradley  
US United States 
vdW van der Waals  
VEEV Venezeulan Equine Encephalitis Virus 
VMD Visual Molecular Dynamics 
VST Virtual Screening 
WNDR Weighted Desolvation Non-Polar Ratio  






CHAPTER 1.   INTRODUCTION 
 
1.1 OVERVIEW OF CHIKUNGUNYA VIRUS 
 
1.1.1 GLOBAL EXPANSION OF CHIKUNGUNYA DISEASE 
 
Chikungunya disease is caused by the chikungunya virus (CHIKV), one of the 
arthropod-borne viruses (arboviruses, or virus spread by mosquitoes) that has emerged1-2 
or re-emerged3-4 in recent years. This virus is considered a neglected tropical disease; in 
2008, it was listed as a category C priority pathogen by the US National Institute of 
Allergy and Infectious Diseases (NIAID) due to its morbidity and mortality rates.5 The 
CHIKV produces a dengue-like illness, which may lead to misdiagnosis. The disease is 
non-fatal,6 however its debilitating symptoms such as fever, rash, headache, myalgia 
(muscle pain), and arthralgia cause enormous health problems,7 affecting millions of 
people in nearly 55 different countries around the world.8 Importantly, the 
polyarthralgia can exist in some infected patients for months.7, 9-10 The history of the 
virus shows the first recorded case was in Tanganyika, Africa, in 1952.11 An 
explanation for the name CHIKV is that it was derived from a local dialect, meaning 
“that which bends up”11 in order to describe the stooped posture of patients who suffer 
from joint pains for weeks to years.6, 11 The virus has been largely neglected due to its 
sporadic re-emergence,4, 6 however it has recently attracted interest given a rise in 
epidemics occurring since 2006 in different countries; from Africa to Asia, Europe, 
Americas, and Australia, spread by infected travellers.6, 10, 12 The expansion of the virus 
has drawn global attention with the prevalence listed in Table 1.1 and Figure 1.1. Some 
extensive and expanding epidemics occurred in some large cities, affecting potentially 
millions of people. However, there is currently no cure for the CHIKV. 




Figure 1.1. Global expansion of CHIKV (taken from the website of Centers for Disease 
Control and Prevention (http://www.cdc.gov/chikungunya/geo/index.html) with 
countries and territories where chikungunya cases have been reported with endemic or 
epidemic, updated 24th of February, 2015). 
 
Table 1.1. Prevalence of CHIKV in terms of year and infected countries. 
Year Infected countries or regions Outbreak 
1950s Tanganyika,
11, 13 Uganda,14 Thailand,15 
Phillipines16  
1960s 
India, Sri Lanka, Myanmar and Thailand,17 
Cambodia,18 Vietnam, Laos,19 Pakistan, 
Malaysia,20 Taiwan,6 and Phillipines15 
≥ 100,000 cases 
and caused 200 
dealths 
1970s  India and Southeast Asia15  
1980s Thailand, Philippines, and Indonesia21   
1990s Malaysia
22-24 (514,271 cases),  
Congo25 (50,000 cases)  
2001-2003 
Indonesia, Cambodia, Vietnam, Myanmar, 
Pakistan, Thailand,15 the Indian Ocean islands of 
the Mauritius, Mayotte, Seychelles, Madagascar, 
and La Reunion22  
 
2004 Comoros5 (5,000 cases)  
2005-2006 
The Indian Ocean islands of the Mauritius (15,760 
cases), Mayotte (6,346 cases), Seychelles, and La 
Reunion (244,000 cases/total population of 
770,000),26 Indonesia,19 Guinea,27 India,28-29 US30 
Indian Ocean 
(300,000 cases 
with 237 deaths) 
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Year Infected countries or regions Outbreak 
2006-2007 
Europe, US, Australia,31 Maldives (11,879 cases), 
Gabon (48,000 cases)32, Mayotte (6,346 cases, 
Mauritius (15,760 cases), Italy (248 cases), Sri 
Lanka (40,000 cases), Indonesia (15,000 cases),33 
Cameroon,34 India29, 35 
India  
(1.4-6.5 million)  
2008-2009 
India (95,000 cases in 2008; 68,000 cases in 
2009), Singapore (1,033 cases),36 Thailand,37-38 
Malaysia39 (7,000 cases), Taiwan,40 US,41-42 
Indonesia,33 Bangladesh43 
 
2010 France44, China,45 Thailand,17 Canada, Myanmar33  
2011 India, Cambodia18  
2012 Australia
46, Bhutan,47 Canada, Cambodia,18 Papua 
New Guinea48 
 
2013 Caribbean, Canada, Thailand49   
2014 France,50 Europe, US, Caribbean51  
2015 US52  
 
1.1.2 THE SPREAD OF CHIKV 
 
CHIKV is transmitted from human-mosquito-human (urban cycle) or animal-mosquito-
human (sylvatic cycle) by the bite of infected mosquitoes.22 The virus is classified into 
three genotypes: the Asian, West African, and East Central South African (ECSA).6 
Genetic analyses revealed that the CHIKV originated in Africa and expanded to Asia. 
The spread of CHIKV from Asian and African countries to other areas is due to an 
association of various factors; namely worldwide distribution of the transmission 
vectors, climatic conditions, and inadequate mosquito control. The global expansion of 
this disease is solely primarily due to an increase in international travel, with disease 
transportation from infected travellers.1-3, 22 The mosquito species, Aedes aegypti was a 
principal vector in many outbreaks, while Aedes albopictus, the Asian tiger mosquito, 
has been considered a primary re-emergence factor since 2005.5-6, 22 The vector switch 
was found to be a result of reduced populations of Aedes aegypti, meaning that viral 
transmission was primarily caused by the larger Aedes albopictus population.3 
Furthermore, a number of adaptive mutations have allowed for exploitation of the new 
epidemic vector.53 In particular, a mutation in the E1 envelope protein, Ala226Val, was 
responsible for a dramatic increase in CHIKV infectivity for Aedes albopictus since 
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2005 in Africa and Asia.54-56 In addition, a substitution of lysine by glutamic acid at the 
position 211 of the E1 resulted in adaption of the virus to the Aedes albopictus.5, 22, 53  
Recently, the E2-Ile211Thr substitution was shown to help the virus adapt to Aedes 
albopictus, as this mutation could set up the foundation for the E1-Ala226Val mutation 
that provides the enhanced infectivity of CHIKV.33 Also, the E2-Gly60Asp was a 
determinant factor in CHIKV infectivity for both these species.57 
 
1.1.3 VIRUS LIFECYCLE 
 
As with other alphaviruses, the CHIKV life cycle begins with attachment to a host cell 
via receptor mediated endocytosis in clathrin coated vesicles,8, 22, 58 a process described 
in Figure 1.2. Under the acidic pH of the endosome, there are conformational changes in 
the structures of the envelope glycoprotein complexes. The complex E1 and E2 
heterodimers dissociate to form the E1 trimers. The trimers use the hydrophobic fusion 
loop to insert into the host membrane, and refold to form a hairpin-like structure. The 
nucleocapsid and viral genome are then released into the host cell cytoplasm. During 
translation, the nsP123 (a polyprotein precursor) from the viral genome binds to the 
nsP4 to form the replication complex (RC). The RC then produces the full length minus 
strand (negative strand RNA) required for replication. When the nsP123 concentration 
increases, the nP123 is cleaved to non-structural proteins nsP1, nsP2, nsP3, and nsP4. 
As these non-structural proteins and the host cell proteins serve as the plus strand 
(positive strand) in replication, they produce the 26S subgenomic RNAs and genomic 
(49S) RNAs. The 26S subgenomic positive stranded RNA encodes the polyprotein 
precursor for structural proteins. The cleavage process takes place in the Golgi complex, 
and then the products (non-structural proteins and structural proteins) are transported to 
the plasma membrane. The viral RNA is packaged into the nucleocapsid, and the mature 
virions bud out of the plasma membrane. 
.  




Figure 1.2. Replication cycles of CHIKV. The picture is reproduced from Rashad A. et 
al8 with permission).  
 
1.1.4 CLINICAL SYMPTOMS 
 
Following the transmission, CHIKV replicates and expands to liver and joints.5 There 
are similar symptoms with other viruses, such as dengue fever, yellow fever, or Ross 
River fever. After an incubation period of 2-4 days, acute clinical symptoms start with 
the onset of high fever, rigors, headache, fatigue, nausea, vomiting, myalgia, and rash.5 
In particular, intense joint pain (polyarthralgia) is the most characteristic which 
incapacitate patients.5 This acute stage lasts from 1-10 days. The chronic stage depends 
on the acute stage, and is characterized by polyarthralgia. It can last from weeks to 
years,8 which affects individual patients, and results in social health impacts10 due to 
debilitating infection in large working population. Neurological disorders59 and eye 
infection60 are also reported in infected patients, while  meningoencephalitis and 
Chapter 1. Introduction 
6 
 





Since no vaccines or effective therapeutics are available, early detection and proper 
diagnosis are becoming increasingly important in treating the CHIKV disease. Viral 
culture is considered a gold standard for CHIKV diagnosis. It is based on innoculation 
of mosquito cell cultures, mammalian cell cultures, or mice.61 However, for a rapid 
diagnosis, techniques such as a detection of reverse transcription polymerase chain 
reaction (RT-PCR), real-time RT-PCR, real-time loop-mediated isothermal 
amplification (RT-LAMP) are recommended.1, 62 More frequently, serodiagnostic 
methods;63-64 such as enzyme-linked immunosorbent assay (ELISA), indirect 
immunofluorescent method, hemagglutination inhibition, or neutralization techniques 
were used effectively as reliable techniques in the identification and characterization of 
CHIKV. The detection of immunoglobulin M (IgM) and immunoglobulin G (IgG) 
antibodies using capture enzyme-linked immunosorbent assay (MAC-ELISA) is a rapid 
and reliable technique in serology. 
 
1.1.6 CHIKV GENOME AND STRUCTURE 
 
A full understanding of the structure and genome of CHIKV is crucial for the 
development of drugs to combat the virus. CHIKV is a positive-sense and single-
stranded RNA virus in the alphavirus genus, Togaviridae family.65 In 1984, Simizu et al 
used African and Asian strains of CHIKV to analyse the structural proteins of CHIKV.66 
In 2002, Khan et al identified the full genomic sequence of CHIKV (S27, African 
prototype),67 opening up further investigations into the elucidation of the structure and 
genome of this virus. CHIKV’s genome includes two opening reading frames (ORFs) 
that consist of 11,805 nucleotides in total without including the cap at the 5' end, a l-
poly (A) tract, and a poly (A) tail at 3' end.67 The first ORF has 2474 amino acids 
encoding non-structural proteins (nsP1, nsP2, nsP3, and nsP4) at the 5' region, while the 
second consists of 1244 amino acids encoding structural proteins (the capsid C, 
envelope glycoproteins E1, E2, E3, and 6K). Between these two ORFs, there is a 
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junction region. In addition, there is a 7-methylguanosine group capped at the 5' end and 
the polyadenylated group at the 3' end. The arrangement of the genome can be as 
follows: 5'-cap-nsP1-nsP2-nsP3-nsP4-(junction region)-C-E3-E2-6K-E1-poly(A)3' 
(Figure 1.3).  
 
Figure 1.3. Genome organisation of CHIKV (adapted from Singh S. K. and Unni S. K.22). 
 
The role and function of non-structural and structural proteins of CHIKV have been 
examined based on information of other alphaviruses, such as Sindbis virus (SINV) and 
Semliki Forest virus (SFV). According to these studies, the non-structural proteins of 
CHIKV play an important role in the formation of the transcription/replication complex 
of the virus and the negative strand synthesis.58, 68-70  
 
Studies of SFV and SINV nsP1 indicate that nsP1 is a multifunctional protein.71 It is 
involved in the formation of the virus cap,70, 72-73 and directing RNA replication 
complex to membranes or liposomes,74 as well as associating with endosomes and 
lysosomes at the cytoplasmic surface of membranes.72, 75 It has also been implicated 
with both guanine-7-methyltransferase and guanylyltransferase activities.74  
 
Investigations of nsP2 from SINV and SFV show that the nsP2 has multiple enzymatic 
activities.76-77 Primarily, it belongs to the papain superfamily of cysteine protease.78 It 
has functions of proteolytic enzyme at C-terminal domain whereas at the N-terminal 
domain, it posses the activities of ATPase and GTPase,76-77 RNA helicase,79 and RNA 
triphosphatase.80 Moreover, it is involved in the regulation of synthesis of the 26S 
subgenome81-82 and activates the switch from early to late stages,82 as well as playing a 
role in the translocation of 50% of the translated nsP2 into the nucleus.83 The nsP2 plays 
a vital role in the replication of virus; which combined with the exhibition of some 
degree of sequence specificity,76 has resulted in it being an attractive target for drug 
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design. More recently, the crystal structure of nsP2 protease of CHIKV was solved 
(PDB id: 3TRK). 
 
The specific functions, roles, and activities of the nsP3 protein remain relatively elusive; 
however, genetic and functional analysis of the nsP3 from SINV revealed that it is a 
phosphoprotein participating in the process of synthesis of the minus strand and the 
subgenome of the virus.69, 73, 84 It has been reported that deletion of phosphorylation 
sites in the SFV nsP3 decreases the level of RNA synthesis.85 The nsP3 protein consists 
of two domains; the N-domain which is highly conserved, and the C-domain which is 
not.73 There is an “X domain”, or macrodomain (a first 160 amino acid domain with 
unknown function), present at the N-terminal region of the nsP3 with a determined 
crystal structure (PDB id: 3GPG).73 The structure on its conserved adenosine binding 
site was also obtained (PDB id: 3GPO).73 In addition, it was found that the mutation of 
amino acids at the position Asn10 and Ala24 in ADP-ribose binding of the nsP3 
macrodomain in SINV affects the replication and viral RNA synthesis, though it has no 
effect on the binding region.86-87 
 
Several attempts have been made on SINV to propose the roles of the nsP4 in the RNA-
dependent RNA polymerase activity88 and in replication, and transcription of the virus.88-91 
The results showed that the N-terminal Tyr residue of the nsP4 of SINV may be 
substituted with Phe, Trp, or His without changing the wild-type phenotype in cultured 
cells. However, other substitutions, except for Met, were lethal or quasilethal.91 The 
nsP4 is also stable and remains active during the infection cycle.89 Previous research on 
the mutants reported that the mutations in the nsP4 were Glu191 subtituted for Leu and 
Glu315 to Gly, Val, or Lys, together with one mutation in the nsP1 (Thr349 to Lys); 
which suppress the minus strand RNA synthesis.91 Arg183 of SINV nsP4 polymerase 
was found to have an important role in alphavirus minus strand RNA synthesis.92 
 
Most studies of the structural proteins of CHIKV are based on the biology and 
pathogenesis of the virus, as infection is mediated by these glycoproteins. The E2 is 
responsible for receptor binding, while membrane fusion is supported by the E1.93 In 
2008, Santhosh et al56 found the mutation in E1 Ala226Val, leading to the epidemic 
outbreaks of CHIKV in India. Ongoing insights into the structure of CHIKV have been 
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revealed by two crystal structures of surface glycoprotein complexes; namely precursor 
p62-E1 heterodimer (PDB id: 3N40), and the mature E3-E2-E1 (PDB id: 3N42) 
determined in 2010.93 The E3 protein plays an important role in the proper folding of 
p62 and the formation of the p62-E1 heterodimer,94-95 but the E3 is not in the 
component of mature CHIKV.66 The 6K associates with the complex p62-E1 and is 
transported to the plasma membrane before assembly.65 The assembly process takes 
places due to the interactions of the genomic RNA and the nuclear capsid protein. The 
6K protein facilitates particle morphogenesis, but it is not stoichiometrically 
incorporated into virions.65 The structural change of envelope glycoproteins in 
membrane fusion was investigated by Li et al.96 The resulting roles of the E2 in receptor 
interactions, and the existence of epitopes, are essential for the design of a vaccine 
against this virus.  
 
Recently, structural analysis of CHIKV at pseudo-atomic level resolution was 
reported,65 by combining electron cryo-microscopy (cryo-EM) techniques for the whole 
virus and X-ray crystallography for the component of structural proteins, together with 
the published crystal structure of the CHKV E1-E2 glycoprotein heterodimer.93 A 5.3 Å 
resolution cryo-EM map of CHIKV-like particles was interpreted, and the mechanisms 
of neutralization of antibodies were proposed. The study revealed that like other 
alphaviruses, CHIKV has an icosahedral spherical structure with T=4 quasi-icosahedral 
symmetry (diameter of about 60-70 mm, Figure 1.4 A). This structure consists of 80 
spikes: including 20 icosahedral “i3” spikes (located on the icosahedral 3-fold axes), 
and 60 quasi-3-fold “q3” spikes (located in general positions) with a quasi-3-fold axis.65 
The spikes i3 and q3 are significantly different, possibly indicating different stages of 
generation of fusogenic E1 trimers. The complete q3 spike combines with one-third of 
an i3 spike to form a single T=4 icosahedral asymmetric unit (Figure 1.4 A). These 
spikes are made by the envelope glycoproteins E1, E2, and together with virus 
membrane, transmembrane (TM) helix, and a capsid covering genome RNA to form a 
nucleocapsid (Figure 1.4 B). The E1 glycoprotein is composed of 439 amino acids 
including 404 N-terminal residues, 30 residues which comprise the TM helix, and 5 
amino acids which form the cytoplasmic domain, as well as an N-linked glycosylation 
site at Asn141. The E1 is divided into three domains, namely domain I, II, and III, with 
domain I located in between domain II and III. The E2 consists of 364 residues, a 26 
Chapter 1. Introduction 
10 
 
residue TM helix, and 33 residues cytoplasmic domain. The E2 also has three domains, 
domain A, B, and C, which are known as distinct immunoglobulin-fold domains. 
Domain A takes part in receptor-binding process, lying in between domain B and 
domain C. Domain B covers the fusion loop in domain II of E1 in the mature structure. 
Under the pH acidic environment, the virus becomes fusogenic by combining three E1 
to make a trimer. The fusion loop is then exposed to insert into the host cell membrane. 
Therefore, hiding the “fusion loop” may interfere with the virus entry and infection of 
human tissue. 
 
Figure 1.4.  Structure of the CHIKV, showing the structure of virus particles in a T=4 
icosahedral symmetry (A) and the components of a single unit with a nucleocapsid 
consisting of spikes (made by envelope glycoproteins), virus membrane, and 
transmembrane (TM) helix; and a capsid covering genome RNA inside (B), (adapted 
from Sun S. et al.65)  
 
1.2 CURRENT TREATMENT FOR CHIKV INFECTION 
 
There is no effective vaccine or antiviral agent currently available for CHIKV 
infection.10 Treatment is mostly based on alleviating symptoms by using analgesics 
(non-salicylate analgesics), antipyretics,1, 6 anti-inflammatory agents (corticosteroids 
and non-steroidal anti-inflammatory (NSAIDs));6, 9, 21 along with taking bed rest, and 
undertaking an extra fluid diet.1 Some agents for the treatment of acute CHIKV include 
Methotrexate; NSAIDs: Rofecoxib, Celecoxib, Parecoxib; corticosteroids: Prednisolon; 
antirheumatic: Sulfasalazine and Methotrexate; non-salicylate analgesics: Paracetamol, 
Morphine; traditional herbal medicine: Fernelia spp species.  
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1.2.1 SPECIFIC INHIBITORS OF CHIKV 
 
While some inhibitors have been shown to be effective against CHIKV in vitro, 
currently, there is no antiviral drug available for CHIKV treatment. Further biological 
testing (in vivo) is required. These inhibitors are listed in Table 1.2, along with the 
current update of inhibitory effects and the clinical trials.  
 
Table 1.2. Some potential inhibitors for CHIKV. 




IC50 = 1.1 µg/ml 
      
      
Chloroquine (1) was reported as in vitro antiviral 
compound more than 35 years ago.97 However, 
recently, a mouse model showed that this compound 
enhances virus replication, and aggravates the 
disease.9, 98 Chloroquine phosphate has also been 
used for chronic chikungunya arthritis with anti-
inflammatory, rather than antiviral effects.99-101 Some 
studies revealed that chloroquine was considered as 
an entry inhibitor as it could interact with the 
endosome-mediated internalization process in the 
infection cycle.98, 102 Chloroquine was tested in Phase 
III clinical trials in France in 2006; however, this 
compound was terminated in 2007 with no anti-




EC50 = 83.3 µg/ml 
Ribavirin (2) is well-known as an antiviral inhibitor 
in vitro.103 The mechanism is varied between 
different viruses, such as interaction with 
intracellular viral RNA production, inhibition of 
inosine 5'-monophosphate dehydrogenase (IMPDH), 
leading to depletion of cellular GTP pools, and action 
as a potent mutagen for some RNA viruses (error 
catastrophe mechanism), even though the precise 
mechanism is still unclear.9 Ribavirin can be used 
either alone or in combination with α-interferon to 
get a synergistic effect in vitro against CHIKV 
(concentration of α-interferon 3.9 IU/ml, and 
ribavirin 18.75 μg/mL).104-105 However, up to now, 
no evidence on clinical efficacy of ribavirin on 
CHIKV or ribavirin in combination with α-interferon 






Arbidol (3) was developed 20 years ago in Russia for 
treatment of acute respiratory infections.8 This 
compound elicits a broad effect on RNA, DNA, 
enveloped, and non-enveloped viruses.106 The 




















IC50 = 12.2 µM 
 
fusion,107  blocking the viral entry into the target cells 
through inhibition of glycoprotein conformational 
changes.108-110 In 2011, arbidol and its derivatives 
were used for in vitro testing for CHIKV. The results 
reported that arbidol could inhibit CHIKV but very 
weak effects even though the IC50 value is much 
lower than the toxic concentration (IC50 = 12.2 μM, 
CC50 ≥ 200 μg/mL).111 Evidence from in vivo studies 
is required to validate activity of arbidol on CHIKV.8 
Mycophenolic acid  
 
(4) 
IC50 = 0.2 µM 
 
 
Mycophenolic acid (4) was discovered approximately 
100 years ago.112 It is an inhibitor for the enzyme 
IMPDH involved in de novo biosynthesis of guanine 
nucleotide.113 It was known as having good activity  
with antiproliferation, anticancer, as an antiviral 
agent, and an immunosuppressant.8 Recently, this 
compound showed inhibition of the CHIKV 
replication using virus-induced cell death.114 
However, the compound was reported as suffering 
from a metabolic drawback associated with rapid 
conjugation of the C-7 phenolic hydroxyl group with 




EC50 = 1.5 µM 
 
Trigocherrin A (5) is a natural compound, isolated 
from the bark of Trigonostemon cherrieri Veillon 
(Euphorbiaceae),115 a tree in New Caledonia, or the 
species found in tropical Asia, India, and Sri Lanka 
to New Guinea.8 Recently, in testing CHIKV 
inhibitory effect, this compound showed inhibition of 
viral replication function on virus-induced cell death, 




EC50 = 0.24 µM 
Harringtonine (6) is an alkaloid compound, isolated 
from Cephalotaxus harringtonia tree in Japan.8 It 
displayed CHIKV inhibition, by affecting the early 
stages of infection after cellular endocytosis.117 Also, 
it was found to affect the CHIKV RNA production 
inside the infected cell and viral protein expression 
through the nsP3 and the E2 proteins.117 This 
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Some other compounds are less common, thus requiring further testing to be considered 
promising lead compounds (Figure 1.5). However, they were not approved for human 
use. For example, quinine (7) inhibited the in cellulo growth of CHIKV.9 Increasing 
concentrations of quinine affected the nsP1, as mutations were observed suggesting an 
impairment of the function of the viral guanylyltransferase activity. Another compound, 
named 6-azauridine (8), showed its inhibition on both DNA and RNA virus replication, 
and orotidine monophosphate decarboxylase, an enzyme involved in the de novo 
biosynthesis of pyrimidine, cytidine, and thymidine.118 Trigowiin A (9) and prostratin 
(10) were isolated from the bark of Trigonostemon howii of the Euphorbiaceae species 
in central Vietnam during the biological testing for CHIKV.119 This compound showed 
a weak anti-CHIKV activity, however, it possessed its selectivity for CHIKV, against 
the SINV and SFV. Prostratin119 showed better inhibitory effects on CHIKV than (9) in 
a CHIKV inhibition assay. 12-o-tetradecanoylphorbol 13-acetate (11) was reported to 
inhibit CHIKV through the activation of the signal transduction enzyme protein kinase 
C, also selective for CHIKV inhibition.119 Lupenone (12) and β-Amyrone (13) are 
isolated from the leaves of Anacolosa pervilleana (Madagascan plant). (12) showed 
moderate anti-CHIKV activity in a virus-cell-based assay,120 while (13) had a moderate 
anti-CHIKV activity in the assay. Polycytidylic acid or poly(I:C) (14) is a synthetic 
double-stranded RNA (dsRNA) analogue. It displayed an immunostimulant action as an 
inducer for the interferon via interaction with the toll-like receptor 3 in CHIKV 





































































































































Chapter 1. Introduction 
15 
 
1.2.2 CURRENT APPROACH FOR CHIKV VACCINE 
 
With the widespread distribution of CHIKV, there is a need for a safe and effective 
vaccine. Currently, there is no effective vaccine for CHIKV although there have been 
some efforts on this approach. An understanding of antibody-mediated and cell-
mediated immune responses is important for vaccine development.5 Unfortunately, 
there is very little information pertaining to the interaction of CHIKV infection and 
adaptive immune system in re-infection.5, 8 Some potential vaccines which need to be 
developed are listed in Table 1.3.122  
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Table 1.3. Potential vaccines for CHIKV. 
Type of vaccine 
 





123  A whole virus grown in monkey cell cultures 1970s Phase II: discontinue 
Tween 80-ether extraction124 A whole virus grown in monkey cell cultures 1970s Preclinical 
Vero adapted formalin inactivated vaccine125 A virus on Vero cells 2006 Preclinical  
Live-attenuated 
vaccines 
181/clone 25 vaccine strain126 Serial passage CHIKV strain in culture cells 1986 Phase II 




Chimeric virus vaccine128 
VEEV (attenuated vaccine strain TC-83), an 
attenuated strain of EEEV or SINV and the 
structural protein genes of CHIKV 
2008 Preclinical 
Recombinant adenovirus vaccine129  
A non-replicating complex adenovirus vector 
encoding the structural polyprotein cassette of 
the CHIKV 
2010 Preclinical 
CHIKV-IRES vaccine130-131 A cDNA clone generated from the wild-type La Reunion strain 2010 Preclinical 
DNA vaccines132-133 Single or three individual plasmids 2008 Preclinical 
Subunit protein vaccines134-137 Recombinant CHIKV envelope proteins  2012 Preclinical 
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1.2.3 ALTERNATE APPROACHES  
 
Some other approaches are targeting virus entry and maturation, viral nucleic acids, and 
cellular receptors. For example, agents used on each interference can be listed as 
follows: using furin inhibitors, or decanoyl-RVKR-cholormethyl ketone to impair the 
maturation of the E2 glycoprotein;9, 140 small hairpin RNA molecules to interfere 
RNAs;141 2',5'-oligoadenylate synthetase (OAS3),142-143 cellular IMPDH enzyme,114 and 
visperin144 in controlling CHIKV replication or human antibodies. Recently, silencing 
of HSP-90 (a chaperone protein related to heat shock) using small interfering RNA 
(siRNA) has been shown to disturb CHIKV replication in cultured cells.145  
 
1.3 CURRENT RESEARCH IN CHIKV DRUG DISCOVERY  
 
1.3.1 CELL-BASED HIGH THROUGHPUT SCREENING APPROACHES 
 
Recently, high throughput screening methods have been developed to identify potential 
CHIKV inhibitors. For example, a CHIKV replicon and a concomitant screen with SFV 
surrogate infection model were used to screen 356 natural compounds, and clinically 
approved drugs.146 A cell-based high throughput screening assay using resazurin against 
a kinase inhibitor library of 4,000 compounds, combined with the image-based high 
content assay approach was applied.147 A phenotypic assay was also used to identify 
one natural compound that partially blocks nsP2 activity and inhibits CHIKV 
replication in vitro.148  
 
1.3.2 IN SILICO APPROACHES 
 
In recent years, in silico approaches are promising to save time and the cost of the drug 
discovery process. With the availability of the crystal structures of several proteins of 
the CHIKV genome and other related alphaviruses, structure-based approaches using 
molecular docking and virtual library screening can be applied to identify potential 
inhibitors (hits) from a large database of compounds. These hit compounds may be 
experimentally tested, or used to investigate a structure-activity relationship to optimize 
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the compound’s activity. Generally, drug targets are key proteins which is identified 
through cellular and protein biochemical processes associated with the disease. These 
biomolecules are known as being involved in signalling or metabolic pathways that are 
specific to the disease process149-150 For CHIKV, non-structural proteins and envelope 
glycoproteins were considered potential targets.8 Non-structural proteins of the virus 
play an integral role in viral replication and transcription, so they are attractive targets 
for designing potent inhibitors of CHIKV.151 Recently, two crystal structures, namely 
the nsP2 protease (PDB id: 3TRK) and the nsP3 macrodomain (PDB id: 3GPG)73 have 
been available for use as a starting point in antiviral research. Homology models for 
structure nsP4 was also proposed to provide structures for drug design.152 The envelope 
glycoprotein complexes were determined by X-ray crystallography, the immature form 
(PDB id: 3N40) and the mature form (PDB id: 3N42).153 These complexes are also of 
interest as targeting the envelope glycoproteins can affect the virus entry. 
 
1.4 STRUCTURE-BASED DRUG DISCOVERY FOR CHIKV  
 
1.4.1 OVERVIEW OF COMPUTER-AIDED DRUG DISCOVERY 
 
In fighting disease, drug discovery and development are very expensive and time-
consuming processes.154 The drug discovery process involves different stages such as 
target identification (target ID), hit identification (hit ID), lead discovery and 
optimization, biological testing (preclinical trials), and clinical trials.149, 155 Therefore, 
utilizing computational techniques not only increases the efficiency and effectiveness of 
research, but also saves time and reduces costs; in particular during lead discovery and 
lead optimization.  
 
The field of computer-aided drug design (CADD) was started in the 1960s and in the 
late 1980s up to now, this has been growing and has become an integral part of drug 
discovery with the development of computer hardware and software, and the increasing 
availability of protein structures of biochemical targets of pharmaceutical interest 
(Figure 1.6).156 There have been a number of studies reported on describing specific 
computational methods, clarifying their role and importance, and highlighting recent 
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advances, as well as their successful applications and challenges.156-169 These contain 
many applications of this approach in antiviral drug design, in particular in analysis of 
viral protein target. The prediction and simulation of conformational, steric, and 
physicochemical properties helps to elucidate the characteristics of the target. The 
binding pockets and interactions may be identified using computational approaches. 
Rationalization of drug action and virtual screening to identify potential inhibitors, 
together with the structure-activity relationship of these ligands, were applied.163  
 
Figure 1.6. Applications of CADD to the various stages of drug development (adapted 
from Tang Y. et al.170).  
 
Computational approaches in CADD can be classified into two main groups: the ligand-
based approaches and the structure-based approaches. 
 
Ligand-based approaches: This is an indirect approach which is useful in the case of a 
lack of an experimental receptor structure together with the difficulty of designing a 
reliable model.171 Ligand-based methods are particularly valuable in the early stage drug 
discovery.163 These approaches rely on known active compounds and utilize their 
similar descriptors taken from their molecular characteristics, properties, and biological 
activity data to elucidate the structural and physicochemical properties of the ligands.163 
Molecular characteristics may be physicochemical descriptors in one dimension, 1D 
(e.g., molecular weight, atom counts, logP, and pKa); two dimensions, 2D (e.g., 
topological descriptors); and three dimensions, 3D (physicochemical properties such as 
location, constraints, and shape descriptors). Ligand-based approaches introduce a 
definition of a pharmacophore as the ensemble of steric and electronic features, 
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necessary to account for the common molecular interactions with the protein target, and 
to trigger (or to block) its biological response.154, 163 A pharmacophore model describes 
the three-dimensional chemical features, using pharmacophoric descriptors such as 
hydrogen bond donors, hydrogen bond acceptors, hydrophobic, aromatic, positive 
ionizable groups, and negative ionizable groups. There are many different ways to build 
a pharmacophore model. It can be based on chemical structures of known active 
compounds from different chemical scaffolds or diverse chemical structures for 
compounds (with IC50 or Ki values ranging over more than three orders of magnitude). 
Similarities of molecular properties such as pharmacophore features, shaped-based 
models or a quantitative structure-activity relationship are also utilized. The underlying 
assumption here is that ligands having similar physiochemical properties are likely to 
show comparable activity spectra. 
 
Structure-based approaches: Unlike the ligand-based methods, structural data of a 
protein target is a prerequisite in a structure-based approach.166 The full three-
dimensional (3D) structure of the protein may be obtained from X-ray crystallography 
or nuclear magnetic resonance (NMR) techniques. In the case where the structure of 
protein is unknown, homology modeling can be used based on the similarity of the 
genomic sequences with other viruses.150 Protein-ligand docking and structure-based 
virtual screening are examples of these approaches. They utilize information of the 
protein structure to identify and optimize drug candidates by examining molecular 
interactions between ligands and target macromolecules, as detailed below.154  
 
1.4.2 PROTEIN-LIGAND DOCKING ASSISTS IN DRUG DISCOVERY 
 
Pioneered in the early 1980s,172 protein-ligand docking has developed as an integral part 
of drug discovery.173 It has become an invaluable tool that assists efficiency in drug 
discovery to understand interactions of protein-ligand complexes.174-176 In the 2000s, a 
series of reviews summarized the methodology, and highlighted the successful 
applications, recent advances, and challenges of this approach.162, 166-167, 173, 177-187  
 
Given a small molecule and a protein target of a virus, docking attempts to insert the 
small molecule into a binding site of the protein target. In other words, the aim of 
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docking is to get the “best match” of a protein-ligand complex,178 or to accurately 
predict the orientation and conformation of a small molecule (ligand), i.e. the lowest 
binding energy (known as binding mode or binding pose), and then estimate binding 
affinity of the ligand into a known structure (Figure 1.7).  
 
Figure 1.7. Representation of the strategy used for protein-ligand docking. 
 
Therefore, protein-ligand docking includes two processes: docking (geometric sampling 
of potential ligand/protein binding mode); and scoring (using an equation and specific 
parameters to estimate a ligand binding affinity). Consequently, a protein-ligand 
docking program consists of these two essential components: sampling (ligand sampling 
and protein flexibility) and scoring. There are three main kinds of sampling setups: first, 
the protein and ligand are kept rigid, only translational and rotational manipulations of 
the ligand are investigated; second, the protein is rigid and ligand is assumed to be 
flexible (all degrees of freedom of the ligand are explored); and third, the protein is fully 
or partly flexible as well as the ligand. Some popular docking programs are DOCK188, 
AutoDock,189 FlexX,190 GOLD,191 and GLIDE;192 most of which utilise the flexible 
ligand and a rigid receptor approach.  
 
To make protein-ligand docking more practical, improvements from docking with rigid 
structure to partly or full flexible receptor have been undertaken during the last years.173, 
176-179, 183, 186 However, protein flexibility is still the major hurdle where ligand sampling 
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is concerned. In addition, there has been no universally applicable scoring function 
available. Therefore, finding the most appropriate algorithm for the prediction of 
protein-ligand binding of each specific target is a major focus of research. Many search 
algorithms and scoring functions have been developed over the years, alongside 
numerous scoring functions, taking into consideration speed and accuracy.173  
 
1.4.2.1 Search algorithms 
 
As previously mentioned, most docking programs account for ligand flexibility. In order 
to search for precise conformation and configuration, an optimal search algorithm 
should explore all of degrees of freedom to sample sufficiently so as to include the true 
binding modes. These algorithms may be classified into three main groups: systematic 
searches (incremental construction, conformational search, exhaustive or databases), 
random or stochastic methods (Monte Carlo, genetic algorithms or evolutionary 
algorithm, Tabu search), and deterministic or simulation searches (molecular dynamics 
and energy minimization).173, 176-177, 179, 186 Some algorithms implement a hybrid 
approach combining two or all three of the methods.  
 
Systematic search: In this search algorithm, all of the degrees of freedom of ligand are 
investigated. It can systematically rotate all rotatable bonds of a ligand through 360° 
using a fixed increment, to obtain all possible combinations for evaluation. This 
approach is, however, succeptable to a combinatorial explosion in computational cost. 
Another approach is that the ligand is divided into different fragments or a core 
fragment and flexible parts (sidechains), and then these components are docked into the 
active site. The results will be covalently linked together (other incremental search 
algorithms) or rebuilt the ligand from fragments (Hammerhead algorithm). Libraries of 
pre-generated conformations may be utilized to tackle the combinatorial explosion problem. 
 
Random (or stochastic) search: The search makes random changes for a single ligand 
or a population of ligands. A pre-defined probability function is used to evaluate the 
ligand. The common groups are Monte Carlo (MC) and genetic algorithms. In the MC 
method, following random changes and energy minimization for the generated 
conformations, the Boltzmann probability function is used as the criteria of evaluation. 
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If a change in temperature is also combined to increase the probability, this is called 
Simulated annealing. In the genetic algorithms or evolutionary algorithms, the theory of 
the evolution in biological system is applied to search for the correct ligand binding 
mode.162 The Tabu search is another method to explore areas of conformational space, 
and the value of root mean square deviation (RMSD) between the calculated molecular 
coordinates, and every molecule’s previously recorded conformation should be less than 
a cutoff value to be accepted. Swam optimization tries to search for a search space for 
the ligand using Swam Intelligent method by taking the information of the best 
positions of its neighbors.162 
 
Deterministic (simulation) method: These algorithms use molecular dynamics (MD) 
simulation or energy minimization to explore the conformations. The ensembles of 
populations are generated and are docked rather than a single conformer. MD is the 
most popular approach, however has weaknesses in its inability to cross high-energy 
barriers within simulation timescale, leading to arrest of ligands in a local minima of the 
free energy surface.177 To overcome this, simulations can be carried out for the different 
parts of a protein-ligand system at different temperatures, or ligand starting positions. 
Energy minimization is often used in combination with other approaches. 
 
The search algorithms for protein flexibility in docking are still limited, though there are 
some reviews and studies on it.193-197 MD and MC, are usually applied for a search of 
protein conformations. Another strategy is the use of rotamer libraries to model protein 
conformational space based on experimental data, and favourable sidechain 
conformations. A protein ensemble grid is different approach in which the algorithm 
uses an ensemble of conformations of protein for docking rather than a single one, and 
then maps them on a grid representation.   
 
1.4.2.2 Scoring function 
 
For a docking process to be successful, the adopted scoring function is the deterministic 
factor for obtaining an accurate prediction of conformation of a protein-ligand complex, 
and a correct ranking of final structures. In other words, scoring is used to predict the 
binding affinities, and differentiate between correct and incorrect orientations, and 
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conformations (poses). The ideal docking program should satisfy both computational 
efficiency and reliability. Therefore, speed and accuracy are two key components of a 
scoring function. Free-energy simulation can be based on atomistic MD simulation, 
applied for quantitative modeling of protein-ligand interactions, and binding affinity 
predictions; however, this approach is expensive. Most docking programs still do not 
include entropic effects explicitly. There are different scoring functions which are 
classified in terms of shape, chemical complementation, force fields, empirical results or 
system knowledge. The three main categories are force-field-based, empirical, and 
knowledge-based scoring functions.162, 166, 173, 176-177, 179, 181-182, 186, 198-199 Beside these 
scoring functions, some other approaches to improve scoring such as consensus scoring 
(combining the information from multiple scoring functions), or clustering, and 
entropy-based scoring methods.162 
 
Force-field-based scoring: This type of scoring function tries to model many types of 
interactions involved in protein-ligand binding by utilizing physics-based functional 
forms, and parameters derived from experiments or quantum mechanical simulations.166 
There are different types of force field scoring functions. They have similar functional 
forms but their force field parameters are different, for example G-Score with Tripos 
force field,200 and AutoDock with AMBER force field.176 Most of them only consider a 
single protein conformation to make it possible to omit calculation of the internal 
protein energy. In molecular mechanics force fields, the binding free energy is 
calculated as a sum of two energies, receptor-ligand interaction energy (van der Waals 
(vdW) and electrostatic interactions) and internal ligand energy (steric strain induced by 
binding). In AMBER force fields, the vdW term is referred to a Lennard-Jones potential 
function (such as 12-6 Lennard-Jones).166 The general AMBER force field (GAFF) 
including some parameters is suitable for simulating small molecules.201 The 
CHARMM force field is similar to AMBER force fields, but has some additional terms. 
The CHARMM22 force field is is usually used for modelling protein. The recent 
CGenFF force field can be applied as a general force field for small molecules.202 The 
disadvantage of standard force-field-based scoring function is that it does not include 
solvation, and entropic term explicitly.176 
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Empirical scoring: This type of scoring uses a sum of various empirical energies to 
estimate the binding energy. A set of weighted empirical energy terms may be 
composed of vdW, electrostatic, hydrogen bonding energy, desolvation term, entropy, 
and hydrophobicity term.162 This scoring is far simpler than force-field-based scoring, 
however, it depends on the molecular data sets used to perform regression and fitting, 
leading to reproducibility of the experimental binding affinity data. 
 
Knowledge-based scoring: The binding affinity can be calculated based on the 
information of experimental protein-ligand complexes data. This is estimated as a sum 
of free energies of protein-ligand atom-pair interactions (the potential mean force). The 
frequencies or probability distributions of interatomic distances between two atoms are 
converted into distance-dependent interaction free energies of protein-ligand atom pairs 
using the inverse Boltzmann method.162  
 
Some popular docking programs together with their searching algorithms and their 
scoring functions are summarized in Table 1.4. 
 
In conclusion, there are many docking programs with different scoring functions. 
However, no single one is the best. The ideal scoring function is still not available. The 
problem is that all of the scoring functions mentioned above, are based on different 
assumptions and simplifications, and do not fully take into account of entropic and 
solvation effects. Compromises between the conformational searching algorithms and 
scoring functions could improve docking algorithms, however, it may not improve 
binding affinity prediction. Thus, it is difficult to obtain a chemical accuracy, and the 
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Table 1.4. Docking programs with corresponding search algorithm and scoring function.  
Docking 
program 
Fees Ligand searching 
algorithm 
Scoring function 
DOCK188 No (academics); Yes (profit) Incremental build 
Force field or  
contact score 





Lamarckian algorithm Combining 
knowledge-based 
potentials and empirical 
scoring functions 
FlexX190 Yes Fragmentation and Incremental construction Empirical score 
GOLD191 Yes Genetic algorithm Empirical score 
Glide192 Yes Exhaustive search  (Monte Carlo) Empirical score 
FRED204 Yes Conformational ensembles (Rigid body docking) 




sampling and local 
minimization (Metropolis 
Monte Carlo) 
Mixed force field and 
empirical score 
 
1.4.2.3 Setting up a docking protocol 
 
To perform docking, preparations of protein and ligand are indispensable. For the target 
protein, the structure is usually obtained by X-ray crystallography or by NMR structure 
determination. The structure may be apo, holo (complexed with another compound) or 
if the structure is not available, it may be predicted by threading or homology modeling. 
If the function of protein is unknown, it is crucial to search for possible binding sites in 
the structure (discussed below). Some crucial factors should be considered to check the 
structure carefully. Initially, structural integrity is needed to check. Polar hydrogen 
atoms are also added. The next step is to assign proper protonation and tautomeric states 
of ionizable residues including aspartate (Asp), glutamic acid (Glu), arginine (Arg), 
lysine (Lys), and histidine (His). The orientation of asparagine (Asn) and glutamine 
(Gln) residues also require checking. The active site or binding site needs to be defined 
before docking, and the treatment of water molecules in docking is considered. Water 
molecules may affect the formation of the complex as they can form hydrogen bonds 
with the ligand and the protein. Geometry refinement of the protein/receptor-ligand is 
required to correct small artefacts in the protein or ligand such as strained bond 
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lengths/angles or intermolecular steric clashes.187 Energy minimization of the structure 
should be used. Preperation of the ligand, like the protein, requires great care. Ligands 
can be taken from various sources, such as a database or electronic vendor catalogues. 
Filtering using the drug-like properties is recommended to eliminate molecules, with 
unfavourable properties: such as poor solubility, pharmacokinetics characteristics 
relating to adsorption, distribution, metabolism and excretion; oral bioavailability and 
toxicity. The most popular filter used in drug design is Lipinski “rule of five”206 that is, 
molecular weight (MW) lower than 500 daltons, logP less than 5, number of hydrogen 
bond donors less than 5 and number of hydrogen bond acceptors less than 10.207 Usual, 
compounds are represented in 2D format and then converted to a 3D representation. 
Several methods are available for generation of a 3D structure. Special care must take 
into account of tautomeric and protonation states, stereochemistry of chiral centres. The 
next step is docking with sampling to generate different binding poses; scoring and 
ranking. Most docking programs as mentioned previously, focus on docking with rigid 
docking and flexible ligands. Protein flexibility may be treated for some specific 
sidechains of protein residues.  
 
1.4.2.4 Prediction of binding sites  
 
In structure-based drug design with molecular docking and virtual screening 
approaches, the question of where in the structure of the protein the ligand binds is of 
interest. Therefore, it is a requirement to understand the structure and function of a 
protein target, in particular, knowledge of locations that small molecules (ligands) could 
bind in the structure is of key importance to help rationally design of ligands, to fit with 
high binding affinities and specificity that can modulate the functions of this target.208-
210 A binding process is the sum of many contributions such as environment (pH, ionic 
strength), and presence of water molecules, in which the shape complementarity of 
protein and ligand together with their physicochemical properties are balanced.209 
Proteins can change conformations upon ligand binding, which may influence the steric 
accessibility of a binding cleft and can interfere with the ability of an algorithm to 
identify a potential binding site.208 Small molecules are known to usually bind in the 
largest pockets on the surface of protein, and their binding free energies is a result of 
enthalpy-entropy compensation.209  
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There have been many different approaches developed to identify binding sites of a 
protein, depending on whether the co-crystallised structure of a protein-ligand complex 
is known or not.209 Thus, these approaches can use a co-crystallisation of a protein with 
a ligand if available, use structural or sequence similarity with a known binding site, or 
use in silico prediction methods. For computational methods, some algorithms utilize 
protein surface analysis to identify ligand binding pockets in the protein. The others use 
probe clustering and energy contour analysis which is based on analysis of binding 
energies of probes placed on a grid around the protein.210 Other types of characteristics 
such as surface accessibility, the net charge on the protein residues in a protein as a 
function of pH, and sequence conservation can be used. MD simulations are also used 
to generate dynamic ensembles of protein conformations for binding site detection. In 
general, computational approaches for prediction of binding sites on a protein can be 
classified into three main groups: geometric-based (using geometrical pocket 
description or free accessible volume calculation to identify the sterically favoured 
cavities among all clefts on the protein’s surface); energetic-based (finding energetically 
favoured positions, e.g. by calculation of interactions with different probes and the 
protein’s surface); and knowledge-based (using structure and sequence comparison to 
generate templates of similar sequence or functionality to identify evolutionarily 
conserved regions to rank cavities generated with geometric approaches). The 
geometric-based methods are fast and easy to use while the others are more time-
consuming and require user expertise.209 
 
1.4.2.5 Structure-based virtual screening 
 
The most notable application of protein-ligand docking is structure-based virtual 
screening.211 It has become increasingly important to improve the speed and efficiency 
of drug discovery and development.211-215 The main purpose is to reduce the large 
number of compounds from databases and select the most promising compounds for 
biological testing.176 It is known as a fast tool for drug design which is valuable to 
discover lead compounds complementary to experimental methods, for example high-
throughput screening. A large volume of studies have shown its importance and 
successful application in this field of drug design and development.211-224 Some popular 
programs available for this purpose are DOCK,188 FlexX,190 GOLD,191, 225 AutoDock189, 
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226 and AutoDock Vina.203, 227 However, based on docking, virtual screening has similar 
challenges in accuracy of scoring and ranking. If many ligands are docked, the time for 
scoring and ranking in screening a large sample is of utmost important. More reliable 
scoring functions should include calculations for nonbonded interactions such as cation-
π interaction, CH-π interaction, and π-π stacking interactions.224 The choice of ligand 
libraries for screening is also of concern. Several databases are available, for instance, 
the National Cancer Institute (NCI) Diversity Set 
(dtp.nci.nih.gov/branches/dscb/diversity_explanation.html), NCBI PubChem (pub-
chem.ncbi.nlm.nih.gov), eMolecules (www.emolecules.com) and ZINC228 composed of 
a variety of compounds or libraries of natural products,229 metabolome,230-231 and 
nutraceuticals.232 If in the case of a new target, where no information about binding sites 
for ligands is known, blind docking for the entire protein is applied to identify sites that 
ligands bind tightly. Other computational approaches can be used to predict the binding 
sites as discussed previously. Validation of the approaches is the most critical due to the 
inaccuracies of the scoring functions, which will affect the results of ranking. The main 
factors should be taken into account are the quality of the obtained docking poses, and 
the ability of the methods to discriminate known active and inactive compounds after 
docking in the same target. False-positive hits or decoy molecules have similar physical 
structures but are chemically distinct from ‘true’ hits, and can be used as competitive 
binders to a protein.233-235 
 
1.4.2.6 Validation of docking method 
 
Docking is usually validated by the ability to reproduce the experimental data in 
predicting the binding pose, and binding affinity to distinguish the active and inactive 
compounds. The commonly accepted criterion for docking success is pose selection by 
a comparison of the RMSD between the docked structure (top scoring pose) and the 
experimental structure (the co-crystal structure). With the protein-ligand co-crystal 
structure, a docking protocol can be evaluated and improved. However, the errors 
exiting in the bound structures due to the poorly refined ligand geometries could lead to 
misleading interpretation of key binding interactions. They can be errors in the ligand 
structure (for instance missing atoms, incorrect bond orders or other connectivity 
issues); or incorrect bond distances, angles or dihedral angles; or conformational errors 
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(for example, cis- or twisted amides, distorted rings, non planar aromatic groups, or 
groups of planar structures of not being planar); incorrect orientations or bad steric 
clashes between protein and ligand. Therefore, it has become commonly to apply 
protein preparation tools to structure.236 If the RMSD value is no more than 2 Å, it is 
considered a docking success.167, 179, 184, 237-238 Moreover, other criteria to validate 
docking include Generally applicable replacement for RMSD (GARD),238 enrichment 
factors, receiver operating characteristic (ROC) factors,227 area under ROC curves 
(ROC AUCs),239 and binding affinity calculations.240 Using a decoy set of inactive 
compounds to dock and after ranking by scoring, enrichment is calculated by dividing 
the ratio of active molecules in the entire dataset by the ratio of active molecules in the 
top 5 or 10% of the top ranked molecules. The enrichment plot or ROC curves are 
plotted. The sensitivity of a given docking/scoring combination and specificity are 
shown in ROC plots.  
 
1.4.3 MOLECULAR DYNAMICS SIMULATIONS IN DRUG DISCOVERY 
 
Given the structure of a macromolecule and its complexes, molecular dynamics (MD) 
simulation is one of the computational approaches to investigate the motions of a 
system of particles.241 MD simulation of biological macromolecules (proteins) of 
interest was introduced in 1977.242 Since then, this technique has become a powerful 
computational method, quickly showing wide application to many fields, and constant 
improvement quantitatively and qualitatively in structure-based drug discovery to 
understand drug-receptor interactions.243-246 Especially with the recent advances in 
algorithms and computer hardware and software, long-timescale from microsecond to 
millisecond for thousands of atoms has been achieved.247 The interaction for the 
particles is calculated and included sequentially to the time of simulating. The result of 
the process (MD trajectory) provides information on the atomic level of positions, 
velocities and energies. Statistical mechanics related to distribution and motion of atoms 
are required to connect microscopic simulations with macroscopic observables such as 
changes of conformations, binding free energy, and mechanism of reaction. MD 
simulation has been applied to a wide range of biological problems, including protein 
folding,248-249 protein-ligand interactions,250 electron transfer state in photosynthesis,251 
enzyme reactions,252-253 determination of protein structures from NMR,254 refinement of 
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protein X-ray crystal structures,255 and calculation of free energy changes from 
mutations in proteins.245-246, 252, 254, 256 
 
Classical all-atom MD simulations use a Newtonian equation of motion (F = ma 
(Equation 1.1), with F is the force on the particle, m is its mass, and a is its acceleration) 
to simulate the movement of each atom in the system. The MD method starts with the 
initial set of coordinates obtained from X-ray crystal structures, NMR structures or 
theoretical models (homology models), or a combination of these. Given the atomic 
model, the interactions for all atoms must be defined. The Newtonian equation is 
subsequently applied to calculate the force after the systems are minimized to eliminate 
high energy interactions, such as steric clash, prior to simulation. The integration of the 
equations of motion after equilibration generates an ensemble of equilibriated states, 
including coordinates and velocities of the atoms as a function of time. The simulations 
require three components: initial coordinates (obtained from experimental structures or 
from models, or some combination of both), a potential (obtained from a force field and 
the coordinates), and algorithms for propagation.244 The process of how an MD 
simulations proceeds is set out in Figure 1.8.  
                  
Figure 1.8. How MD simulations proceed (adapted from Durrant D. et al246). 
 
1.4.3.1 Force fields 
 
The mathematical functions describing the potential energy of a system and their related 
parameters are called a “force field”, which is set to describe the interactions between 
atoms and molecules. A typical molecular CHARMM force field for a molecular system 
Initial atomic model 
Calculate molecular forces acting on each atom 
Move each atom according to those forces 
Advance simulations time  
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is estimated as follows in Equation 1.2. In brief, a molecular force field usually include 
six terms; namely the bond, angles, dihedral, improper dihedral angles, nonbonded, and 
Urey-Bradley (UB) terms.  
U��R�⃗�� = � Kb(b − b0)2
bonds
+ � Kθ(θ − θ0)2 + � K∅[1 + cos(n∅ − δ)]
dihedralsangles
+ � Kφ(φ− φ0)2
impropers
+ �KUB�r1,3 − r1,3;0�
2
UB














Equation 1.2. Equation used to calculate the atomic forces in MD simulations, from 
MacKerell A. D. et al,202, 257 where Kb, 𝐾θ, 𝐾𝜒, 𝐾𝜑 and KUB are the bond, angles, 
dihedrals angles, improper dihedral angles and Urey-Bradley force constants, 
respectively. b, θ, ∅, φ, r1,3 are the bond length, bond angle, dihedral angle, improper 
torsion angle, and the Urey-Bradley 1,3-distance, respectively; with the subscript zero 
means the equilibrium values. The Urey-Bradley is a harmonic term, used for bond-
stretching or angle bending in distance between atoms 1 and 3 (the two terminal atoms) 
in an angle. It is important to more accurately model in vibration spectra.258 n and δ are 
the values of dihedral multiplicity and phase. The nonbonded includes the van der 
Waalsand electrostatic interactions. The van der Waals interaction is using Lennard-
Jones 6-12 potential with Rmin,ij is the radius in the Lennard-Jones term; qi and qj are the 
partial atomic charge of atom i and j, respectively.𝜀𝑖𝑖 is the effective dielectricconstant, 
and rij is the distance between atoms i and j. 
 
The different force fields have a critical influence on the results of MD simulations.245  
The most common currently used force fields are AMBER,259 CHARMM,257 
GROMOS260 and OPLS.261 The choice of force field usually depends on the preference 
of the molecular simulation suite.244 Among of the most commonly-used simulation 
packages are the AMBER,262 CHARMM,263 GROMACS264 and NAMD.265 These 
programs share common basic features, but differences lie in their capacities, and 
underlying philosophies.244  
 
1.4.3.2 Setting up and running MD simulations 
 
To set up and run a MD simulation, some important ingredients should be considered 
carefully: such as the initial atomic coordinates of the system, the choice of force field, 
simulation program (integration method), time steps, type of ensemble, boundary 
conditions, salvation, and time length of the simulation.266-267 The length of simulation 
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time depends on the investigated system and the aim of the study. The integration 
method will decide parameter of time steps. Any change to these factors will affect the 
outcomes of the simulation, as well as the requirements of computational time.268 In 
addition, the type of ensemble must be selected. Traditional MD for biomolecular 
systems often use NTP (N, number of particles, T, temperature, and P, pressure) or 
isothermal-isobaric ensemble, which include the constant NTP. Furthermore, in MD 
simulations, treatment of electrostatic interactions (long range coulombic forces) is very 
important.267 Nowadays, one can use the Ewald summation method, such as the 
Particle-Mesh Ewald (PME) for electrostatics.269-270  
 
Moreover, boundary conditions and solvent models are required. Due to the influence of  
interactions at the boundaries of the system on energy calculations, the boundaries must 
be taken into account. The most common way in simulation of biomolecular systems is 
using periodic boundary conditions. Periodic boundaries cover the system in a cell 
(typically a cubic box or a sphere or other geometric shape), and surround it with mirror 
replica cells of the system. The size of the box must be large enough so that the 
molecule does not “see” itself.267 The interaction energies can be calculated across the 
cell boundaries, so the boundary effect is minimized. Two types of solvent models are 
commonly used, namely implicit (or continuum) and explicit models. The implicit 
solvation means the solvent is represented with a continuum medium. Two common 
algorithms used to calculate the solvent electrostatic effects are the Poisson Boltzmann 
surface area (PBSA) and the Generalized Born surface area (GBSA) model.244 These 
models are less expensive, but the major problem is that they do not take into account 
entropic effects, and their difficulty in dealing with heterogeneous environment, which 
affect many biological processes. On the other hand, the explicit solvation is the model 
in which the solvent molecules and counterions are treated as explicitly surrounding the 
biomolecule.244 This method is the most accurate, however it is also time-consuming. 
Among different water models developed, TIP3P water model is adopted for the 
CHARMM force field.271-272  
 
In general, a MD simulation consists of minimization, equilibration, and production 
steps. The initial system is minimized to relax potential steric clashes in the structure. 
The minimized structure is then equilibrated. When equilibration is reached, the values 
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of average temperature, pressure, and energies are stabilized. The production phase will 
be the next step and used to calculate the desired properties.  
 
1.4.3.3 Analysis of a MD simulation 
 
The results of MD simulations are analyzed using trajectories to gain insights into the 
structure; such as protein stability and flexibility. The frequently used analyses are 
global measures by calculating a RMSD273 and a root mean square fluctuation (RMSF) 
or B-factors;274 secondary structure analysis, hydrogen bonds (HBs), and hydrophobic 
contacts; clustering analysis, quasi-harmonic, and principal component 
analyses/correlation function, and binding free energy calculation.244  
 
RMSD is usually used to investigate the global stability of the system,275 while RMSF is 







+ �yim − yil�
2





Equation 1.3. The RMSD between atoms of the trajectory frames and the 
corresponding atoms of the initial structure, where N is the number of atoms, xm, ym, zm 
are the Cartesian coordinates of the initial structure and xl, yl, zl are the Cartesian 








Equation 1.4. The RMSF of an atom, where T is the number of trajectory frames, and ?̅? 
is the time-averaged position.275  
 
The resulting trajectories are analyzed by the CHARMM22263 and VMD (version 
1.9.1).276 A simple geometry criterion was used to define a hydrogen bond: the distance 
between proton donor (D) and acceptor (A) atoms less than 3.5 Å, and the angle 
D − H⋯A greater than 120°.70 If the percentage of HBs occupation is higher than 50%, 
they are considered as the medium, whereas the strong HBs are determined by HBs 
occupations of greater than 75%.70 The hydrophobic contacts between the carbon atoms 
of non-polar parts of residues of proteins were also monitored with a cutoff distance of 
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4.0 Å.277-278 Clustering analysis was conducted using the Clustering Plugin in VMD for 
all of the snapshots from the trajectories. 
 
Clustering analysis involves the grouping of similar samples of data, joining the 
ensembles of data into the group to identify the most populated conformations sampled. 
Structural clustering is a useful method to reduce the sample size for conformational 
analysis to understand the molecular motion within conformational space.279 Principal-
component analysis uses a constructed matrix of atomic fluctuations to find the lowest 
modes, which represent the most of fluctuations. Quasi-harmonic analysis gives normal 
modes in the harmonic system, while correlations functions are used to measure the 
correlation of two fluctuating quantities over the time.244 
 
1.4.3.4 Combining molecular docking and MD simulations  
 
Docking and MD simulations have their own strengths and weaknesses, listed in Table 
1.5. Some reviews highlighted the improvement of computational protocols using a 
combination of MD simulations in docking procedures.280-281 MD simulations before 
docking may explore the conformational space of the protein receptor, while using MD 
simulations after docking helps to optimize the final structures, analyze protein 
flexibility, and stability of different complexes, account for solvent effects, and obtain 
accurate energetic properties.167 
 
Table 1.5. Strengths and weaknesses for docking and MD simulations280-281 
 Docking MD simulations 
Strengths Fast and inexpensive: docking 
explore conformation space of 
ligands in a short time, allowing the 
scrutiny of large libraries of drug-
like compounds at a reasonable 
cost. 
Accurate because it treats both 
ligand and protein in a flexible 
way, allowing for an induced fit 
of the receptor-ligand. The effect 
of explicit water molecules can 
be studied directly. 
Weaknesses Lack of or poor flexibility of the 
protein. Absence of a unique and 
widely applicable scoring function, 
necessary to generate a reliable 
ranking of the final complexes. 
Costly and time-consuming.  
The system can get trapped in 
local minima. 
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1.4.4 BINDING FREE ENERGY CALCULATIONS 
 
Given a protein (P) and a ligand (L), the ligand can bind to a protein to form a complex 
PL. The binding affinity of PL in an equilibrium concentration can be computed simply 
by using the following equation: 
K = [L][P][PL]               (Equation 1.5) 
This binding affinity can then be related to the free energy of binding (free energy 
change to changes in enthalpy and entropy) using: 
∆Gbind = −RTlnKd = ∆H − T∆S  (Equation 1.6) 
Where ΔGbind is the change in free energy of a binding process, ΔH and ΔS are the 
corresponding changes in enthalpy and entropy, respectively. R is a gas constant with 
R=8.314 JK-1mol-1, and T is the temperature of the system in Kelvin degree, and Kd is 
dissociation constant. 
 
The binding free energies (or binding affinities) are used as a criterion for 
differentiation of inhibitors from other small molecules (binders), and also selection of 
strong ligands based on their protein binding strengths. It has become a major interest in 
structure-based drug design. The computational approaches can be used to estimate the 
binding free energies together with the experimental assays. However, obtaining 
accurate values of binding free energies remains a challenge.282,283 Upon protein 
binding, the protein and ligand may be affected by conformational changes influenced 
by water and ions. Recently, there has been a very large number of approaches 
developed to solve this problem using different atomistic models.283-298 The approaches 
can have the simplicity of a scoring function (docking) or the complexity and 
sophistication of free energy methods.292 Most of them are still under active study, and 
have different trade-offs between accuracy and computational efficiency.  
 
As mentioned above, docking and scoring use a single bound conformation containing a 
simplified energy model, such as an empirical force field, with a simple solvent model. 
Thus, it can provide approximate binding affinities (scores) of ligand and protein. 
However, the docking results are system-dependent.292 The starting configuration of the 
protein–ligand complex is also considered.299 Some attempts have been made to 
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improve docking such as taking account redistribution of ligand charges (potential 
energy models), solvent models, protein flexibility, and considering changes of 
configuration entropy.292 In contrast to docking, free energy methods can give more 
accurate binding energy, but need more computational cost. These approaches generate 
thermodynamic averages (converged results) using a conformational sampling. They 
can be classified into two methods: end point and pathway methods. The end point 
methods require simulation of the bound and free states of the ligands to generate 
conformations of both states, and compute the binding free energy based on the 
difference between them. The pathway methods calculate binding free energy using the 
simulation of many immediate states to sum up all of small changes along a multistep 
pathway.292 A choice of calculating absolute or relative free energies using implicit or 
explicit solvent, and the length of the simulation will hugely impact computational time, 
the accuracy, and efficiency of the calculation. Popular methods include free energy 
perturbation (FEP), thermodynamic integration (TI), linear interaction energy (LIE), 
molecular mechanics-PBSA (MM-PBSA), and molecular mechanics-GBSA (MM-
GBSA), discussed below.  
 
1.4.4.1 Free energy perturbation (FEP) 
 
The FEP and TI approach are the theoretically rigorous methods, and offer accurate 
binding free energy; including the absolute binding free energy of a ligand, and relative 
binding energies between two ligands, X and Y, bound to the same protein (P).300 This 
approach depends on a thermodynamic cycle (Figure 1.9). The perturbation theory is 
that different binding free energy between the first state (before binding) and final state 
(after binding) can be calculated by the formula ∆G = −RTln〈e−∆U/RT〉 (Equation 1.7) 
in which ΔU is change of the energy function between two states, and the angle brackets 
are a Boltzmann average (ensemble average) obtained from MC or MD simulations.301  




Figure 1.9. Thermodynamic cycle for calculating relative binding free energies between 
two ligands bound to the same protein (from Michel J. et al300). 
 
Based on this theory, the difference of binding free energies of two ligands X and Y 
bound in the same protein in Figure 1.9 is calculated as follows: 
∆∆Gbind = ∆Gbind(Y) − ∆Gbind(X) = ∆GB − ∆GU (Equation 1.8) 
 
Where ΔGbind(X) and ΔGbind(Y) are binding free energies for ligand X, Y, respectively; 
and ΔGU and ΔGB are unphysical transmutation free energy from ligand X to ligand Y 
in the unbound and bound state, respectively.  
 
In the case where ligand X and Y are similar, the values of ΔGU and ΔGB are easier to 
obtain than ΔGbind(X) and ΔGbind(Y) because the mutation from ligand X to ligand Y is 
assumed to cause only localized changes. If ligand X and Y are too different, large 
changes between them may cause sampling problems. So, in the FEP method, the path 
of transformation is divided gradually into many small steps (intermediate) to allow 
smooth conversion of ligand X to Y.300 The binding free energy difference between two 
states, X and Y, is the sum of the contributions from all steps. The formula to calculate 
the value for each step is: 




i=1  (Equation 1.9)  
Where ΔG is the free energy difference between two states, X and Y. λi varies from 0 
(state X) to 1 (state Y); H(λi) and H(λi+1) represents Hamiltonian of the system at λi, 
λi+1; and 〈 〉𝜆𝑖 indicates an ensemble average. Absolute binding free energies can be 
obtained from FEP method by setting the interaction potential of the ligand to zero in 
one of the states. That means transforming the ligand into dummy atoms that do not 
interact with their surroundings.250  
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The FEP is currently considered the most powerful and promising approach.293-294 It 
takes into account entropic contributions to binding affinities arising from solvent 
effects and protein/ligand flexibility. However, the FEP results could have high 
precision, but low accuracy.302-303 Most of the computational time is spent on 
“perturbations”, meaning uninteresting configurations corresponding from unphysical 
paths (X to Y), which makes the method difficult for application.295   
 
1.4.4.2 Thermodynamic integration (TI) 
 
Another pathway approach, similar to FEP is TI.300 In the TI method, the difference in 
free energy between two states, A and B, is calculated based on using multiple 
intermediate states, defined by a coupling parameter λ.304-305 The average of the 
derivatives of the Hamiltonian at each λ, H(λ) is calculated and then TI uses numerical 
integration over λ to calculate the free energy difference between two states, where λ 
has the same meaning as in FEP: 
∆G = ∫ 〈∂H(λ)∂λ 〉dλ
1
0     (Equation 1.10) 
Where ∆G is the Gibbs energy difference between two states, 〈 〉 is an ensemble 
average obtained at λ. The pathway of intermediates between the states of interest can 
be parameterized between λ=0 and λ=1.284 
 
1.4.4.3 Molecular mechanics-Poisson Boltzmann surface area (MM-PBSA) or 
Molecular mechanics-Generalised Born surface area (MM-GBSA)  
 
Compared to the pathway methods, the end point methods such as MM-PBSA or MM-
GBSA are more computationally efficient, and widely applied for the estimation of the 
accurate relative binding free energies of related compounds.250, 306-309 The methods 
combine the Poisson Boltzmann (PB) or Generalised Born (GB) electrostatics with 
molecular mechanics (MM), and solvent accessibility (SA) models, or continuum 
solvent approaches, to estimate binding energies.299, 307-309 An initial MD simulation 
using continuum solvent approach provides a thermally average ensemble of structures. 
Several snapshots are then processed, removing all water and counterion molecules, and 
used to calculate the total binding free energy of the system with the equations: 
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∆Gbind = ∆H − T∆S ≈ ∆EMM + ∆Gsol − T∆S   (Equation 1.11) 
∆EMM = ∆Einternal + ∆Eelec + ∆Evdw    (Equation 1.12) 
∆Gsolv = ∆GPB/GB + ∆GSA       (Equation 1.13) 
 
Where ΔEMM is the change of the MM energy in the gas phase, which include ΔEinternal  
(corresponding to the bond, angle, and dihedral energies), ΔEelec (electrostatic energy) 
and ΔEvdw (van der Waals energy); ΔGsol is the solvation free energy which is sum of 
electrostatic solvation energy, ΔGPB/GB (polar contribution, calculated by solvent 
accessible surface area (SASA)) and the non-electrostatic solvation ΔGSA (nonpolar 
contribtion). The conformational entropy change, –TΔS, is the most difficult term to 
evaluate, estimated using quasi-harmonic analysis or normal mode analysis of the 
trajectory. The entropy change can be assumed to be cancelled if only the relative 
binding energies of a series of structurally similar compounds is required; however if 
the absolute energy is important, or if the compounds are notably different, then the 
contribution to the final free energy cannot be ignored.285 
 
Although the MM-PBSA and MM-GBSA have shown their successful application in 
biochemical systems,310-314 especially as post-docking methods in virtual screening,308 
their performances rely on the system in question. The modification in simulation 
protocols can affect the approach; such as the sampling strategy of generating 
snapshots, methods to calculate entropy, and other parameters (charges models, force 
fields, the solute dielectric constant, and radius parameters in continuum solvent 
models). In general, the MM-PBSA is more sensitive to the parameters of the systems 
than MM-GBSA.309 
 
1.4.4.4 Linear interaction energy (LIE) 
 
A new semi-empirical method for calculating binding free energies for ligands from 
MD simulations has recently been introduced.315 This method is based on a linear 
approximation of polar and non-polar free energy contributions from the MD averages. 
The idea originated from the problem that with a diversity of compounds with “small 
perturbations,” it would be very difficult to calculate their binding free energies using 
FEP. Therefore, the absolute binding free energy of a ligand is calculated as the change 
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in free energy when the ligand is transferred from aqueous solution (unbound or free 
state) to its solvated receptor binding site (bound state).316 In other words, two 
simulations are required: one with the ligand free in solution, and one with it bound to 
solvated receptor. The equation for binding free energy is used as follows: 
∆Gbind = α ∆〈Vl−svdw〉 +  β ∆〈Vl−selec〉 +  γ     (Equation 1.14) 
Where Δ 〈 〉 are differences between the averages of the nonbonded van der Waals 
(vdW) and electrostatic (elec) interactions in the bound or unbound states, collected 
from MD simulation averages between the ligand and its surrounding environment (l-s). 
The parameters are the weight coefficients α and β for the non-polar and polar binding 
energy contributions, respectively; and an additional constant, γ.  
 
Since its initial use, there have been a large number of studies showing LIE as a 
promising method for computation of binding free energy for protein-ligand.285, 295, 315-
330 LIE approach is considered to be a good alternative compared to other approaches 
such as FEP and TI as it estimates the absolute binding free energies; slower than 
scoring of single conformations, but faster than rigorous FEP approach.320 When 
examining the general validity of the electrostatic linear response approximation, the 
differences in electrostatic response properties between protein and water solvent were 
investigated by introducing different electrostatic scaling coefficients; βwat and βprot, and 
αwat and αprot. The constant term γ in solvation energy was also discussed and it depends 
linearly on surface area.319, 331-334 So the following LIE equation was: 
∆Gbind = αprot〈Vl−svdw〉bound − αwat〈Vl−svdw〉unbound 
−βprot〈Vl−selec〉bound − βwat〈Vl−selec〉unbound + γ     (Equation 1.15) 
 
The general equation with the values αprot = αwat, βprot = βwat and γ = 0 gave a significant 
improvement compared to the orginial one. Aqvist and Hansson reported the 
relationships between electrostatic free energies and the solvation energetic for several 
model compounds in different solvents.316 Some deviations from linear respone were 
found, in particular, for neutral dipolar solutes and for uncharged ligands having certain 
dipolar groups in the case of water solvent through effect of hydrogen bonding network. 
The optimal value of β  = 0.5 was suggested to be reconsidered, for instance β  < 0.5 to 
gain more accurate predictions. The α is an empirical constant which can be fitted to 
experimental binding free energies. In addition, the coefficients α and β converge to the 
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same values in both bound and unbound states. These findings supported the use of the 
basic LIE equation 1.14.  
 
A refined LIE model, the FEP-derived model showed that the value of β varies 
depending on the number of hydroxyl groups. The more hydroxyl groups the compound 
has, the lower the value of β (Table 1.6).316 
 
Table 1.6. Values of the β parameter as a function of the chemical nature of the ligand, 
according to Hansson et al.320  
Chemical nature β  
Charged compounds 0.5 
Neutral compounds 0.43 
Neutral compounds bearing a single hydroxyl group 0.37 
Neutral compounds bearing two or more hydroxyl groups 0.33 
 
So, the final binding energy is calculated as: 
∆Gbind = α 〈VboundvdW − VunboundvdW 〉  +  β 〈Vboundelec − Vunboundelec 〉  +  γ  (Equation 1.16) 
 
Where 〈Vboundelec − Vunboundelec 〉 represents the averages change in electrostatic energy 
between the bound and unbound (free or unbound or just solvent) states, and 〈VboundvdW −
VunboundvdW 〉 the average change in vdW from an aqueous solution to a protein 
environment. α, β and γ are empirically determined constants. The α, β is for the non-
polar, polar contributions, respectively; and are the same values in the bound and 
unbound state. 316 Applying a value of α = 0.18 has shown to successfully reproduce the 
experimental binding free energies in a wide variety of ligand-protein systems.328 
 
βFEP values can be assigned to each chemical group present in the ligand, as shown in 
Equation 1.17 and the values are provided in Table 1.7. The weighting factors depend 
on salvation energies of each chemical group. The value of wi is 1.0 for all neutral 
groups or 11.0 for the anions and cations.326 The advantage of this approach is that the β 
coefficient is flexible and provides higher accuracy, since deviations from the linear 
response due to chemical groups such as amides, amines, or carboxylic acids is 
explicitly taken into account.  
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β = β0 +
∑ wi∆βii
∑ wii
    (Equation 1.17) 
Table 1.7. Values for the β parameter in Equation 1.17, according to AlmlÖf M. et al.326 
Parameter Value Chemical nature 
Δβi -0.06 Alcohols 
Δβi -0.04 1°, 2° -Amines  
Δβi -0.02 1° Amides 
Δβi -0.03 Carboxylic acid 
Δβi +0.02 Anions 
Δβi +0.09 Cations 
 
In addition, a correlation of β and the hydrophobicity of the binding site using a 
weighted desolvation non-polar ratio (WNDR) has been investigated.321 The result 
suggested that the β is predictable by calculating the WNDR; in particular for systems 
in which different ligands bind to different binding sites of the same protein. The 
parameter γ is influenced by the hydrophobicity of the binding site.324  
 
1.5 PROJECT BACKGROUND AND AIMS 
 
In recent years, there has been an emergence or re-emergence of some alphaviruses in 
various countries; in particular the CHIKV. This presents a worldwide threat to human 
health, and creates an economic burden for the affected countries. However, there are 
currently no vaccines or effective drugs available for the treatment of CHIKV virus. In 
addition, there has been little research to find anti-CHIKV compounds. Therefore, a 
significant need for research into medicines to combat the virus exists. During the past 
decade, computational approaches have become an increasingly powerful tool in drug 
discovery and development. It has not only helped scientists succeed in developing 
many therapeutic compounds for specific diseases, but has also aided the development 
of  time-saving and cost-effective procedures.  
 
With this in mind, we aim to discover and develop an approach leading to the 
identification of a number of lead compounds to combat CHIKV disease. This study 
will primarily utilise computational techniques in all stages of the process. We will use 
all available information of CHIKV, together with a combination of computational 
tools, to maximize the efficiency of this study. The study has three principal objectives: 
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1. To identify potential inhibitors for CHIKV using a structure-based approach with 
molecular docking and virtual screening. 
2. To investigate the stability and flexibility of protein-hit compounds complexes with  
molecular dynamics simulations. 
3. To obtain accurate binding free energies from molecular dynamics simulations and 





CHAPTER 2. DISCOVERY OF INHIBITORS 




2.1.1 FUNCTION AND ROLE OF THE NSP3 OF CHIKV  
 
The nsP3 protein is considered an attractive target for CHIKV drug discovery72 due to 
its participation in the early stages of the transcription processes of viral replication, 
though the specific functions of the nsP3 protein remain elusive.8, 69, 84, 87 The nsP3 is 
the third non-structural protein in the CHIKV genome. It consists of two domains, the 
N-domain and the C-domain;70, 73 the N-domain is highly conserved, but the C-domain 
is not.73 The C-domain is phosphorylated on serine and threonine residues on up to 16 
positions.73, 85, 335-337 The role of this phosphorylation is still unclear, but deletion of the 
residues involved in the phosphorylated process has been shown to decrease the level of 
RNA synthesis.8, 73, 336 The N-domain contains the X-domain or a macrodomain, the 
region comprising the first 160 residues; is commonly present in eukaryotic organisms, 
bacteria, archea; and also many positive-strand RNA viruses such as hepatitis E, rubella, 
coronavirus, and alphaviruses.70 The alphavirus macrodomain has a highly positively 
charged patch on the surface, at the crevice of ADP-ribose 1"-phosphate active site and 
its periphery.73 The other side of the protein, far from the active site, possesses a 
negative charge. Thus, the nsP3 macrodomain is considered to complex with ADP- 
ribose derivatives and RNA. It is believed to control the metabolism of ADP-ribose 1"-
phosphate and/or other ADP-ribose derivatives with regulatory functions in the cell.8, 338  
 
In addition, studies based on the SINV reported that the nsP3 phosphoprotein is an 
essential component of the viral replication and transcription process.87 Functional 
analysis of the effects of mutations of nsP3 on RNA synthesis demonstrated that 
alterations may cause a loss of capacity for minus strand synthesis, or a failure to 
increase plus strand synthesis. A change of Ala68 to Gly leading to a modification of 
the His-Ala-Val peptide was predicted to form part of the active site of the conserved 
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nsP3 macrodomain.87 However, no effects on the ADP-ribose binding was found.73 In 
addition, the mutation of amino acids at the position Asn10 and Ala24 in ADP-ribose 
binding of nsP3 macrodomain in SINV affected the replication and viral RNA 
synthesis, without affecting the binding region.86-87  
 
Recent findings revealed that the CHIKV nsP3 was described to have a novel function 
as a regulator of the cellular stress response.339 Studies of SINV-infected cells indicated 
the importance of nsP3 in the interactions with alphavirus-host.340 Functional analysis 
of SFV at the C-terminal region of nsP3 showed that the mutations, where 10 residues 
at the C-terminal are lacking, suppresses the establishment of infection; while lacking 
the 30 C-terminal residues led to reduced synthesis of subgenomic RNA.341 The nsP3 
macrodomain has been shown to be responsible for SINV and SFV replication in 
neurons and neurovirulence in mice.85-86 
 
2.1.2 EARLY ATTEMPTS TO DISCOVER CHIKV NSP3 INHIBITORS 
 
The crystal structure of the nsP3 macrodomain of CHIKV was determined in 2010.73 
This structure includes four subunits; and the asymmetric unit consists of six-stranded 
β-sheets and four α-helices (Figure 2.1). The core β-sheet and positions of the α-helices 
have proven to be highly conserved. Also present in the nsP3 structure is the ligand 
ADP-ribose.70, 73 The active site is in the crevice, between the top of the β-strands 2, 4 
and 5 and is surrounded by two loops between β2-α1 and β5-α3.  
 
Currently, there is only one publication regarding molecular modelling for the CHIKV 
nsP3 macrodomain based on the crystal structures (PDB id: 3GPG) and its complex 
with ADP-ribose (PDB id: 3GPO).70 The study focused on an understanding of the 
specific binding of the ADP-ribose to the nsP3 macrodomain of CHIKV, while also 
comparing with VEEV. The results of MD simulations of the structure with ADP-ribose 
identified the binding modes and the key residues for interactions between ADP-ribose 
and the nsP3.70 The negatively charged PO42- component of ADP-ribose showed the 
strongest interaction with the protein, and the binding free energies estimated from MD 
simulations were in good agreement with previous experimental data. 




Figure 2.1. X-ray crystal structure of the macrodomain of CHIKV in complex with the 
ADP-ribose.73 
 
2.2 OVERVIEW OF THIS STUDY 
 
There is very little information available on the nsP3 macrodomain and its inhibitor. 
Therefore, this study focused on using a combination of computational approaches, 
including molecular docking, virtual screening, MD simulations, and binding free 
energy calculations to discover potential lead compounds that inhibit the nsP3 in 
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2.2.1 MOLECULAR DOCKING AND VIRTUAL SCREENING 
 
A docking protocol was established (details described in the Experimental procedures 
and methods section), which included the following stages:  
 
The nsP3 macrodomain protein was downloaded from the Protein Data Bank (PDB id: 
3GPG) and this was used as the receptor for docking. The protein structure was 
submitted to WhatIF website to correct manually chirality errors, and the conformation 
of sidechains of His, Asn, and Gln. 
 
The next step was to carry out energy minimization to relax the structure and remove 
steric overlaps using the CHARMM22 force field in the Accelrys Discovery Studio 
(DS) 2.0 software package.342 The steepest descent algorithm with 3,000 steps was 
applied. With a Cα RMSD of 0.59 Å between the minimized structure and the X-ray 
structure, the minimized structure was utilized for the subsequent docking process. 
Polar hydrogen atoms were added with AutoDock Tools (version 1.5.4). The ligand 
ADP-ribose was extracted from the complex crystal structure (PDB id: 3GPO) and 
prepared by AutoDock Tools for docking in Vina. The other ligands employed for 
virtual screening were taken from National Cancer Institute (NCI) Diversity Set II. 
 
Parameters of the grid box size and centre of the box were defined, and other parameters 
including a search space or exhaustiveness (E) and number of binding modes to 
generate (num_modes), were selected using AutoDock Tools. For docking, the grid box 
needs to be large enough to accommodate the ligands. Initially, in this case, the grid box 
size and its location of the binding site were defined based on the place where the ligand 
ADP-ribose was bound in the X-ray structure. During virtual screening, the location and 
the size of the grid box were carefully investigated via blind docking (in which the box 
is sufficiently large to cover the whole protein), and focused docking (in which a 
smaller box was centred on potential binding sites of interest). Blind docking can reveal 
potential binding sites in the nsP3. The parameters for docking were chosen such as E 
and the maximum num_modes set to the default values with E = 8 and num_modes = 9.  
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The docking protocol was validated by re-docking ADP-ribose to compare with the 
crystal structure of the nsP3-ADP-ribose complex. The re-docking results were 
evaluated in terms of RMSD value and the binding affinity. After evaluation, the 
established docking protocol was used for different virtual screenings. In an effort to 
identify potential inhibitors (hit compounds), 1541 compounds from the NCI Diversity 
Set II were screened by docking against the nsP3 macrodomain of CHIKV. Based on 
the starting point of docking with ADP-ribose at ADP-ribose binding site, virtual 
screening (VST) was carried out with three different setups. The first was a focused 
docking centred on the ADP-ribose binding site (Pocket 1: VST1 and VST2). The 
second setup was a blind docking centred either at the middle of the Pocket 1 (VST3) or 
the protein (VST4) with the box large enough to cover the whole protein. The third 
setup was a focused docking centred at the predicted binding sites by MetaPocket,343   
(Pocket 2: VST5 and Pocket 3: VST6). The focused dockings at Pocket 2 (VST5) and 
Pocket 3 (VST6) were also carried out. Interactions of ligands and protein were 
analyzed from docking results using Accelrys DS 3.5. The Lipinski’s rule was also used 
to give a general drug-likeness information for hits.206  
 
2.2.2 MD SIMULATIONS 
 
The program NAMD265 was used for MD simulations to investigate the stability and 
flexibility of the hit-target complexes, and study their interactions. The apo protein and 
the complexes of protein-hit compounds were prepared to run simulations (details of the 
procedure are given in the Experimental procedures and methods Chapter). The protein 
atoms were represented with the CHARMM22 force field,257 and the corresponding 
parameters for the ligands were generated with AmberTools.262 The systems were 
solvated under periodic boundary condition with explicit solvent model TIP3P and 0.15 
M NaCl. The Langevin algorithm was used to maintain the temperature at 298.15 K and 
pressure at 1 atm. The PME algorithm was used to compute long range electrostatic 
interactions.269 The cutoff distance for vdW interactions were set at 12 Å and the pair-
list distance was 13.5 Å. The minimization process was applied first and followed by 
equilibrium simulations with weak harmonic restraints on the heavy atoms for 3 ns. The 
production runs were continued for 50 ns.  
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The trajectories for analysis were saved every 10 ps. To determine the system stability, 
the RMSDs of the heavy atoms over 50 ns was calculated with respect to the starting 
structure versus the simulation time. The RMSF of Cα atoms during the simulations was 
measured to obtain information on local flexibility of the system. The resulting 
trajectories such as HBs and hydrophobic contact interactions were analyzed by the 
CHARMM22263 and VMD (version 1.9.1),276 (details in Experimental procedures and 
methods Chapter, section 5.2). The Clustering Plugin Tool in VMD is used for 
clustering analyses. 
 
2.2.3 BINDING FREE ENERGY CALCULATIONS 
 
Having obtained the simulation results of protein and its complexes, the simulations of 
ligands in solvent (water) were run to apply LIE approach to estimate the absolute 
binding free energies for ligands in complexes with the protein targets. Preparation of 
simulations for ligands are described in Chapter Experimental procedures and methods. 
NAMDEnergy plugin in VMD was utilized to compute the energy components over the 
frames obtained from the MD simulations.265, 276 The α, β, and γ in the LIE equation 
need to be defined based on the properties such as hydrophobicity of the ligand and 
binding site to estimate absolute free energies of binding.   
 
2.3 RESULTS AND DISCUSSION 
 
2.3.1 DOCKING RESULTS WITH ADP-RIBOSE 
 
The docking outcomes of ADP-ribose into the nsP3 protein were evaluated and 
compared with the available co-crystal structure (PDB id: 3GPO). The different ligand 
conformations were ranked based on their predicted binding affinities with the default 
scoring function in Vina (Table 2.1). The RMSD value was calculated between the 
docked structure and the initial structure (Table 2.1). The best docked pose had a 
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Table 2.1. Poses in the docking of ADP-ribose into the nsP3. RMSD refers to the 
heavy-atom RMSD from the co-crystal structure for ADP-ribose with the nsP3.  
Poses Binding affinity (kcal/mol) RMSD (Å) 
1 -10.2 0.6 
2 -8.9 8.6 
3 -8.9 1.8 
4 -8.9 5.5 
5 -8.6 8.4 
6 -8.5 4.4 
7 -8.4 5.7 
8 -8.3 10.0 
9 -7.8 4.5 
 
Details of analysis of interactions between the complex of the best docked of ADP-
ribose and the nsP3 are shown in Table 2.2 and Figure 2.3. The residues in the active 
site of nsP3, namely Ile11, Ala23, Asn24, Asp31, Val33, Leu108, Gly112, Val113, 
Tyr114, Tyr142, and Arg144, formed HBs with ADP-ribose. Most of the hydrogen 
bond donors arose from the protein residues, with corresponding acceptors contained in 
the ADP-ribose. The only exception is that the ribose component of ADP-ribose can be 
the donor in interactions with Tyr142. In addition, the diphosphate component of ADP-
ribose showed the strongest interaction compared to the rest of this ligand with the 
greatest number of HBs.  
 
Table 2.2. Analysis of interactions between the best docked of ADP-ribose and the 
nsP3 macrodomain.   
Part of ADP-ribose Number of HBs Interactions (Å) 
Adenine 2 Arg144(HH21)-N1=2.5 Ile11(HN)-N1=2.1 
























Figure 2.3. Re-docking ADP-ribose (A) into the active site of the nsP3: (B) The best 
docking pose of ligand ADP-ribose is represented as a stick model (coloured by atom 
type) while the protein nsP3 is shown in the solvent surface (coloured by interpolated 
charge with a probe radius of 1.4 Å). (C) The interactions of this pose and the nsP3 
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Moreover, the accuracy and reliability of docking were evaluated by superimposing 
both the docked structure and the X-ray structure. The heavy atom RMSD was 0.6 Å, 
smaller than the 2.0 Å (often used as a criterion for the correct bound structure 
prediction)344 (Table 2.1 and Figure 2.4), indicating that molecular docking reproduced 
the binding mode in the co-crystal structure. A comparison of interactions of docking 
results with published data (Table 2.3) confirms that there was a good agreement with 
the key interactions, and showed the current docking protocol was able to reproduce the 
correct pose. The differences in important residues from forming HBs and hydrophobic 
contacts were acceptable due to different methods used. 
  
Figure 2.4. Superimposition of the ADP-ribose after docking (in red, the top pose) and 
its structure in the co-crystal structure (in blue) at the active site of nsP3. The heavy-
atom RMSD between the two structures is 0.6 Å. 
 
Table 2.3. Comparison of the identified hydrogen bonding interactions in the nsP3-
ADP-ribose docked complex with the previously published data. In Ref [73], key 
residues including bonding residues (in bold), were identified by experimental work 
with the crystal structure of complex nsP3-ADP-ribose (3GPO) while residues in Ref 
[70] were determined by MD simulations of ADP-ribose in the nsP3 based on the above 
crystal structure.  
 Current work Ref73 Ref70 
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2.3.2 IDENTIFICATION OF INHIBITORS FOR THE NSP3 MACRODOMAIN  
 
Results of virtual screenings based on bind docking and focused docking are listed in 
the Table 2.4. The top ten compounds for each VST and their binding affinities were 
selected (structures appended in Appendix 1).   
 
In addition to the proposed ADP-ribose binding site (the active site, Pocket 1), two 
additional binding sites (Pocket 2 and 3) were identified based on blind docking. The 
residues making up each pocket are listed in Table 2.5.  
 
Pocket 1 and Pocket 3 share a number of interacting residues including Asn24, Asp31, 
Val33, Gly112, Val113, and Tyr114. Pocket 2 was found on the opposite side and 
behind Pocket 1. The locations of pockets in the nsP3 and the locations of top hit 
ligands in the three pockets are illustrated in the Figure 2.5. 
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Table 2.4. Results of the top ten compounds of different virtual screens for the nsP3. The binding affinities are shown in kcal/mol. 
(a) In VST1, the grid box is fixed at the centre of Pocket 1 (9.7 Å, 43.0 Å, -13.2 Å) with a dimension of 16 Å × 16 Å × 16 Å. (b) In VST2, the 
grid box is fixed at the centre of Pocket 1 (9.7 Å, 43 Å, -13.2 Å) with a dimension of 20 Å × 20 Å × 20 Å. (c) In VST3, the grid box is fixed at 
the centre of Pocket 1 (9.7 Å, 43 Å, -13.2 Å) with a dimension of 50 Å × 50 Å × 56 Å. (d) In VST4, the grid box is fixed at the centre of the 
protein (7.7 Å, 45.3 Å, -5.3 Å) with a dimension of 50 Å × 50 Å × 56 Å. (e) In VST5, the grid box is fixed at the centre of Pocket 2 (7.7 Å, 45.4 
Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å. (f) In VST6, the grid box is fixed at the centre of Pocket 3 (2.3 Å, 44.6 Å, -18.3 Å) with a 
dimension of 20 Å × 20 Å × 20 Å. 
VST1a VST2b VST3c VST4d VST5e VST6f 




3. NCI_309892  
(-10.3) 
4. NCI_109451  
(-10.2) 
5. NCI_127133  
(-10.2) 
6. NCI_328101  
(-10.2) 
7. NCI_372275_a  
(-10.2) 
8. NCI_45545  
(-10.2) 




   
1. NCI_34567_a 
 (-10.9) 




4. NCI_116702  
(-10.7) 
5. NCI_58052  
(-10.6) 
6. NCI_127133  
(-10.5) 
7. NCI_293778  
(-10.5)  
8. NCI_670283  
(-10.5) 
9. NCI_328101  
(-10.4)  
10. NCI_372499_b  
(-10.3) 

















 (-10.2)  
10. NCI_37168 
(-10.2)  




3. NCI_345647_a  
(-10.9) 































 (-7.2)  
10. NCI_400976  
(-7.2) 
1. NCI_670283  
(-10.6) 






5. NCI_372287_a  
(-10.0)  
6. NCI_84100_a  
(-9.9) 
7. NCI_97920 
 (-9.6)  
8. NCI_58502 
(-9.5)  
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Table 2.5. Pocket residues in the nsP3 macrodomain. 
Pocket Pocket residues 
Pocket 1 Asp10, Ile11, Ala22, Ala23, Asn24, Gly30, Asp31, Gly32, Val33, 
Cys34, Gly70, Pro107, Leu108, Leu109, Ser110, Thr111, Gly112, 
Val113, Tyr114, Tyr142, Cys143, Arg144, Asp145, Trp148 
Pocket 2 His-1, His0, Ala1, Pro2, Ser3, Tyr4, Phe129, Met132, Asp133, 
Ser134, Thr135, Asp136, Ala137, Asp138, Val139, Ile156, Gln157, 
Arg159, Thr160 
Pocket 3 Ala22, Ala23, Asn24, Pro25, Arg26, Leu28, Pro29, Gly30, Asp31, 
Gly32, Val33, Cys34, Pro51, Val52, Gly70, Pro71, Asn72, Tyr76, 
Leu108, Ser110, Thr111, Gly112, Val113, Tyr114 
 
 
Figure 2.5. Representation of three binding pockets identified in the nsP3 with top hit 
compounds binding in the pockets. Pocket 1 is the ADP-ribose binding site with ligand 
NCI_25457 (A, in burgundy), NCI_345647_a (B, in red), and NCI_61610 (C, in pink). 
Pocket 3 shares some residues with Pocket 1 with ligand NCI_670283 (E, in yellow). 
Pocket 2 is in the other side of Pocket 1 with ligand NCI_127133 (D, in dark green). 
 
In the focused dockings targeting Pocket 1 (the ADP-ribose binding site, VST1 and 
VST2), the top hits were NCI_25457 (-10.8 kcal/mol) and NCI_345647_a (-10.9 
kcal/mol) (Figure 2.6). Among the top ten hits, four are shared between VST1 and 
VST2, which differ in the size of the grid box used. It is worth noting that the change in 
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size of the grid box affected the searching process in Vina, with some new hits being 
identified. However, the binding affinity values between them are not significantly 
different from each other. To find more inhibitors, and other potential binding sites in 
the structure of nsP3, blind docking was used to dock into the entire protein with the 
grid box centred either at the middle of the ADP-ribose binding site (VST3) or the 
protein (VST4). For the blind docking (VST3 and VST4), six of the top ten hits are 
common to VST3 and VST4, and their binding affinities were reproduced within 1.0 
kcal/mol. This indicated that the blind dockings are likely to have converged. The 
results show that most of the top ten ligands fitted well in Pocket 1, and that this pocket 
can accommodate ligands of different size. However, ligands with bulky structures, 
such as NCI_293778, NCI_58052 and NCI_61610 (in both VST3 and VST4, Figure 
2.6), protruded from the binding site. Therefore, the other pockets surrounding Pocket 1 
may serve as alternative binding sites for potential inhibitors.  
 
Screenings in VST5 and VST6 produced hits already identified from previous screens, 
along with some new hits (Table 2.4). For virtual screening, changes to the size of the 
grid box and its location affected the searching process in Vina. An increase in the 
dimension of the box is likely to be suitable for larger molecules. For instance, in the 
blind docking (VST3 and VST4), NCI_61610 (-11.1 kcal/mol) was identified as a top 
hit, but it did not belong to the top 10 hits in VST1 and VST2. It was also important to 
note that the majority of hit compounds have a tighter binding in Pocket 1 compared to 
those in Pocket 2. Most compounds effectively occupied Pocket 2 and Pocket 3 with the 
significant interactions. Ligands NCI_127133 (-8.3 kcal/mol) and NCI_670283 (-10.6 
kcal/mol) (Figure 2.6) bind in Pockets 1, 2, and 3, though in different conformations. 
Interestingly, the ligand NCI_293778 appeared able to bind in all three pockets, and it 
may infer that Pocket 1 was more favourable for binding, given the binding affinity of  
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Detailed analyses of the interactions between the ligands and protein target were carried 
out in regard to HBs and hydrophobic contacts (Appendixes 2-7).224 The results showed 
that the hydrogen bonding interactions played a more important role in the binding to 
Pocket 1 and Pocket 3, whereas hydrophobic contacts were responsible for most 
interactions in the binding to Pocket 2. The contribution of aromatic rings by π-stacking 
or π-network was emphasized in the enzyme. Most of the ligands can fit very well in the 
Pocket 1 by forming hydrogen bonds with backbone nitrogen of Val113 or Thr111, 
and/or interacting through π-stacking or π-network with aromatic ring of Tyr114 or 
Trp148. For example, top-hit ligands NCI_25457 and NCI_61610 could interact with 
protein through HBs with residues Val113 and Gly112, respectively; and also π-
stacking with Trp148 (Figure 2.7). In addition, the residues located in the region 110-
114 play a crucial role in ligand binding to Pocket 1. Mostly, ligands served as 
hydrogen bonding acceptors while residues of protein were donors. Only interactions 
between ligands and Thr111, in some cases, this residue can change its role to be an 
acceptor. In agreement with previous reports,70 residues Ser110, Thr111, Gly112, and 
Tyr114 define Pocket 1 and were key residues in forming interactions with ligands. In 
addition, we found these residues concurrently define Pocket 3. Among them, Tyr114 
formed HBs with ligands, or interacted through the π-network on the aromatic ring with 
most of ligands in both Pockets 1 and 3. Residues Asp31 and Asn75 contributed in 
forming hydrogen bonds for ligands in Pocket 3. For ligands bound in the Pocket 2, we 
found residues Tyr4 or Met132, Asp133, and Thr135 are key residues in forming 
hydrogen bonding interactions between ligands and protein. Additionally, ligand 



























Figure 2.7. Binding pose and interactions of hit compounds in the nsP3 macrodomain: 
(A) NCI_25457 in Pocket 1: HBs with Val113 and π-π interaction with Trp148; (B) 
NCI_61610 in Pocket 1: HBs with Gly112 and π-π interaction with Trp148; (C) 
NCI_127133 in Pocket 2: HBs with Asp133; (D) NCI_670283 in Pocket 3: 
Hydrophobic contacts only. The ligands (in cyan) and the residues surrounding the 
ligands (in grey) were displayed in sticks and coloured by atoms (carbon in cyan in 
ligand or in grey in residues, nitrogen in blue, oxygen in red). 
 
 
2.3.3 MD SIMULATIONS  
 
MD simulations were undertaken to investigate the stability of the protein and its 
complexes as well as gain insights into the accurate binding modes of the protein and its 
inhibitors. The top-hit compounds NCI_61610, NCI_25457, NCI_345647_a, 
NCI_670283, and NCI_127133; and the tenth-hit compounds NCI_37168, 
NCI_372499_b, NCI_37168, NCI_324623, NCI_400976, and NCI_293778 from each 
screening were also subsequently submitted to MD simulations (Table 2.6). MD 
simulations were carried out with the NAMD package with the CHARMM force field 
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Table 2.6. Chemical structures of five top hit compounds for the nsP3 macrodomain 
and their properties.  
Compound’s 
name 




















































































































































(a) A calculated octanol-water partition coefficient; (b) H-D: Hydrogen bond donor; (c) 
H-A: Hydrogen bond acceptor; (d) MW: Molecular weight. 
 
2.3.3.1 Overall stability of the nsP3 and its complexes 
 
In order to assess overall stability, the values of positional RMSD for backbone from 
the starting structure are used as a major criterion. Backbone RMSD curves for the nsP3 
and its complexes with different ligands with respect to the starting structure after the 
systems reached equilibrium within 3 ns, are shown in Figure 2.8. The plots showed that 


































Figure 2.8. The backbone RMSD profiles for the apo protein nsP3 and its different 
complexes during MD simulations: (A) Complexes of the nsP3 and top-hit compounds; 
(B) Complexes of the nsP3 and tenth-hit compounds. 
 
2.3.3.2 Investigating the flexibility of the nsP3 and its complexes 
 
To understand the flexibility of the complex, the RMSF of the Cα atoms of each residue 
was calculated from the trajectory data for 50 ns for the protein nsP3 and its complexes. 
The RMSF profiles presented in Figure 2.9 show they are comparatively similar 
between the apo protein and the complexes.  
 
 





Figure 2.9. RMSF values of Cα atoms of the apo protein nsP3 and its different 
complexes during MD simulations: (A) Complexes of the nsP3 and top-hit compounds; 
(B) Complexes of the nsP3 and tenth-hit compounds. 
 
With regards to hit compounds in Figure 2.9 (A) and (B); the residues making up the 
binding pockets were quite stable during the simulations (the fluctuation within 1.0 Å). 
Subtle differences were observed for a few regions, including the loop at residue 31-34. 
It is worth noting that for three ligands NCI_61610, NCI_25457, and NCI_345647_a 
bound to the protein at Pocket 1, the RMSFs for the binding loop region 31-34 were 
decreased compared to those in the apo protein. However, this RMSF for this loop was 
not significantly perturbed for the ligands NCI_670283 and NCI_127133 when bound 
to Pocket 3 and Pocket 2, respectively.  
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2.3.3.3 Atomic interaction between the protein nsP3 and ligands 
 
Detailed analysis of the interactions between the ligands and nsP3 were carried out on 
the HBs interactions and hydrophobic contacts. The outcomes are listed in Table 2.7 
and Table 2.8. 
Table 2.7. Hydrogen bonding analyses on the trajectories sampled in MD simulations 
of hit compounds for the nsP3.  
 Number  Details of HBs % occupancy 
NCI_61610 5 Asn24 (HD22)-O1  98 
Tyr114 (HN)-O 92 
Gly112 (HN)-O 88 
Thr111 (OG1)-H1 13 
Cys34 (HG1)-O1 10 
NCI_25457 3 Val113 (HN)-N 29 
Val33 (HN)-N 21 
Val33 (HN)-O 20 
NCI_345647_a 7 Ile11 (HN)-O4 39 
Ile11 (HN)-O6 12 
Gly112 (HN)-O1 18 
Val33 (HN)-O 17 
Gly32 (O)-O5 14 
Thr111 (HN)-O1 13 
Arg144 (HE)-O3 10 
NCI_670283 4 Thr111 (HN)-O 77 
Gly112 (HN)-O 65 
Ser110 (HN)-O 25 
Thr111 (HG1)-O 10 
NCI_127133 1 Arg159 (HH12)-O2 22 
NCI_37168vst1 7 Asn24 (HD22)-N1 18 
Asn24 (HD22)-O2 20 
Asn24 (HD22)-O3 16 
Asp32 (HN)-N1 26 
Asp31 (HN)-O2 18 
Asp31 (HN)-O3 16 
Cys34 (HG1)-O2 10 
NCI_372499vst2 4 Asp145 (OD1)-H 13 
Asp145 (OD1)-H1 19 
Asp45 (OD2)-H 19 









13 Asn24 (HD22)-N1 25 
Asn24 (HD22)-O2 24 
Asn24 (HD22)-O3 24 
Gly30 (HN)-O3 10 
Cys34 (HN)-N1 12 
Cys34 (HN)-O2 12 
Cys34 (HN)-O3 11 
Leu108 (O)-H1 92 





Thr111 (HN)-O1 92 
Gly112 (HN)-O 90 
Gly112 (HN)-O1 69 
Val113 (HN)-O 49 
Tyr114 (HN)-O 90 
NCI_324623vst4 5 Asn24 (HD22)-O 56 
Val33 (HN)-O1 49 
Cys34 (HG1)-N1 11 
Thr111 (HN)-O 24 
Gly112 (HN)-O 34 
NCI_400976vst5 1 Tyr4 (HN)-N1 11 
NCI_293778vst6 4 Asn24 (HD22)-N 81 
Arg26 (HE)-N2 32 
Arg36 (HH12)-N2 12 
Asp31 (HN)-N1 13 
 
Table 2.8. Hydrophobic contact analyses on the trajectories sampled in the MD 
simulations of hit compounds for the nsP3.  
Ligand Non-polar part of residues 
NCI_61610 Ala22, Pro25, Leu28, Val33, Pro107, Val113, Tyr114, Trp148 
NCI_25457 Ala22, Val33, Pro107, Val113, Tyr114, Trp148 
NCI_345647_a Ile11, Val33, Ala36, Val113, Tyr114, Trp148 
NCI_670283 Ala22, Leu28, Val33, Pro107, Val113, Tyr114 
NCI_127133 Ala1, Pro2, Tyr4 
NCI_37168vst1 Ala22, Ala23, Val33, Pro107, Thr111, Val113, Tyr114, Arg144 
NCI_372499vst2 Val33, Arg144, Trp148 
NCI_37168vst3 Ala22, Ala23, Val33, Pro107, Val113, Tyr114, Trp148 
NCI_324623vst4 Ala22, Val33, Phe45, Pro107, Val113, Tyr114 
NCI_400976vst5 Ala1, Pro2, Tyr4, Phe129, Arg159 
NCI_293778vst6 Ala22, Ala23, Pro25, Arg26, Leu28, Val113, Tyr114 
 
For hit compounds, hydrogen bonding and hydrophobic contact analyses indicated that 
all investigated ligands are stabilized the protein by a number of HBs (Tables 2.7 and 
2.8). Complementary to the docking where the protein was kept rigid, MD simulations 
revealed that when the ligands bind to the nsP3, the ligand and/or the residues in the 
binding pockets fluctuate and adapt their structure in order to better accommodate the 
ligands by optimizing HBs and/or hydrophobic contacts. Most ligands at Pocket 1 and 
Pocket 3 bound strongly to the nsP3; always displaying strong HBs, particularly with 
Asn24, Val33, Cys34, Thr111, Gly112, Val113, and Arg114, while Tyr4 is important in 
Pocket 2.  
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Moreover, based on the occupancy of HBs for each ligand, the results showed that 
Pocket 1 could have the highest potential for ligand binding, as Pocket 1 had more HBs 
with higher occupancy than those in Pocket 3 > Pocket 2. As mentioned above, some 
residues, such as Val33, Val113, Tyr114, Arg144, and Trp148 (for compounds binding 
to Pocket 1), displayed noticeable movement upon binding. For the ligands 
NCI_127133 (Pocket 2), and NCI_670283 (Pocket 3), the results showed the fluctuation 
of residues Ala1, Pro2, and Tyr4 (at Pocket 2), and residues Val113, and Tyr114 
(Pocket 3), were required for a correct fit into the nsP3. In particular, some ligands 
(NCI_61610 and NCI_37168) established the strong HBs interactions with the nsP3 at 
Pocket 1, emphasized on the residues at region of 110-114. For instance, occupancy of 
HBs of NCI_61610 and residues at Pocket 1, namely Asn24, Tyr114, Gly112 was 98%, 
92%, and 88%, respectively. Ligand NCI_37168 hydrogen-bonded with residues 
Thr111 (92%), Gly112 (90%), Tyr114 (90%); and two medium hydrogen bonds 
between NCI_670283 and Thr111 (77%); and Gly112 (65%) at Pocket 3 were observed. 
For ligand NCI_61610 at Pocket 1, half of the ligand was quite stable, while the other 
half was flexible enough to fit well through interacting with Trp148 by π-π interaction 
and forming HBs with residues in the region 110-114 (illustrated in Figure 2.10). For 
ligand NCI_670283 at Pocket 3, the part of ligand which interacted with the region of 
residues from 110-114 was optimized to fit well in the pocket, even though the 
frequency of HBs interactions were medium with Thr111 (77%), Gly112 (65%), and 
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Figure 2.10. Hydrogen bonding interactions between the nsP3 and ligands: (A) Ligand 
NCI_61610 at Pocket 1 and (B) Ligand NCI_670283 at Pocket 3, with representation of 
ligands and key residues for interactions surrounding the ligands (in stick). 
 
Furthermore, the key residues interacting in the region 110-114 of the protein at Pockets 
1 and 3, served as hydrogen bond donors, except in the complex nsP3-NCI_61610, 
where residue Thr111 served as an acceptor. This observation is in close agreement with 
docking results as well as with earlier simulations and experimental data.70 In addition, 
it emerged that the structure of NCI_61610 and NCI_345647_a are more polar, thus 
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The solvent accessible surface areas (SASA) were also calculated to monitor the 
possible solvation environment change upon ligand binding (Appendix 8). It was 
expected that the SASA for hydrophobic interacting residues in the complex protein-
ligand would be decreased compared to those in apo protein. At Pocket 1, when the 
ligands bind to protein, it can be seen that the SASA of residue Tyr114 showed a 
decrease from 70.2 Å2 in the apo nsP3 to 63.4 Å2 for the nsP3-NCI_61610 complex, and 
63.8 Å2 for nsP3-NCI_345647_a complex. Also, the SASA of Val33 displayed a 
reduction from 68.8 Å2 in the apo state to 57.4 Å2 and 52.9 Å2 for the bound state in 
nsP3-NCI_25457, and NCI_345647_a, respectively. However, changes observed in 
SASA for Val33, Val113, and Trp148 are not consistent for different ligands. It can be 
rationalised that these residues were not only able to form hydrophobic contacts, but 
also form polar hydrogen bonding interactions. Thus, the change in SASA will be 
compromised by the polar interactions and both of protein and ligands will modulate the 
SASA values.  
 
2.3.3.4 Clustering analysis  
 
Throughout the simulations, the complex structure of the protein and ligands could vary 
under the effects of environment, so structural clustering was used to identify the most 
popular conformation during the simulation, and more important to compare the 
structures from MD simulation and docking. Clustering analysis was carried out on all 
of the snapshots from the trajectories, and the clusters were visualized and 
superimposed with the initial structure. The value of RMSD was used to evaluate the 
difference between clustering structures and initial structure. The different 
conformations of protein and its complexes at 0 ns, 10 ns, 20 ns, 30 ns, 40 ns, and 50 ns 
were superimposed. Slightly fluctuations were found in all complexes, though had very 
little significance. For example, for the ligand NCI_61610, in Figure 2.11, 
superimposition of the most popular conformations of protein obtained from 
simulations and RMSD value for the ligand was 1.2 Å (at 10 ns), 1.1 Å (at 20 ns), 1.8 Å 
(at 30 ns), 2.2 Å (at 40 ns), and 2.0 Å (at 50 ns), with respect to the initial structure. 




Figure 2.11. Superimposition of the different conformations of ligand and complexed 
ligand NCI_61610-nsP3 during simulation with the initial structure (red: at 0 ns, grey: 
at 10 ns, green: at 20 ns, pink: at 30 ns, orange: at 40 ns, and blue: at 50 ns). 
 
2.3.3.5 Combination of MD simulations and docking for the nsP3  
 
In order to probe the effects of the static protein structure used in the docking, multiple 
docking simulations and virtual screenings were carried out based on the sampled 
conformations of protein nsP3-NCI_61610 at the different timepoints (5 ns, 10 ns, 15 
ns, and 20 ns). This complex was selected as NCI_61610 showed the highest potential 
for interacting with the protein after analyzing the outcomes of docking and simulations. 
These results are listed in Table 2.9 and Table 2.10. The binding affinities of these 
docking runs in Table 2.10 were not significantly different from those obtained from 
previous docking based on the X-ray structure. Additionally, the binding modes are 
similar (details of interactions analysis in Appendixes 9-12). For virtual screening, most 
of the top hits were the same compounds as previous screening indicated although there 
were some new hits. That indicates that in the case of nsP3, the docking results were not 
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Table 2.9. Re-docking results for complex nsP3-NCI_61610 with different 
conformations of the nsP3 protein taken from the different timepoints in simulations at 
Pocket 1.  
nsP3 conformation Binding 
affinity 
(kcal/mol) 
Interaction between the inhibitor and residues 
of protein (with distance in Å) 
At 0 ns -11.1 Tyr114(HH)-N=2.0 
Val33(HN)-O=2.3 
Asn24(HD21)-O=2.4 
At 5 ns -10.3 Tyr114 (OH)-H1=1.9  
At 10 ns -11.3 Asn24 (HD22)-O=2.1  
Tyr114 (OH)-H1=2.3  
At 15 ns -10.6 Asn24 (HD22)-O1=2.5  
Ser110 (HN)-O=1.9 
At 20 ns -11.4 Tyr114 (OH)-H1=2.3 
 
Table 2.10. Virtual screening results for blind docking into Pocket 1 with different 
conformations of the nsP3 taken from the different timepoints in simulations. The 
binding affinities are shown in kcal/mol. 
(a) VST-5ns, the grid box is fixed at the centre of Pocket 1 (9.7 Å, 43.0 Å, -13.2 Å) 
with a dimension of 20 Å × 20 Å × 20 Å. (b) In VST-10ns, the grid box is fixed at the 
centre of Pocket 1 (9.7 Å, 43 Å, -13.2 Å) with a dimension of 20 Å × 20 Å × 20 Å. (c) 
In VST-15ns, the grid box is fixed at the centre of Pocket 1 (9.7 Å, 43 Å, -13.2 Å) with 
a dimension of 20 Å × 20 Å × 20 Å. (d) In VST-20ns, the grid box is fixed at the centre 
of the protein at the centre of Pocket 1 (9.7 Å, 43 Å, -13.2 Å) with a dimension of 20 Å 
× 20 Å × 20 Å. 
 






































9. NCI_59620_a  
(-10.5)  







































 (-10.7)  
10. NCI_328101 
(-10.7) 
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2.3.4 BINDING FREE ENERGY CALCULATIONS FOR THE LIGANDS 
BINDING TO THE NSP3 PROTEIN 
 
The converged trajectories of complexes obtained from simulations were used to 
calculate the binding free energy for the hit compounds. The average values of vdW and 
elec interactions for each ligand in the two states, bound state (Vbound) and unbound state 
(Vunbound) were calculated (Table 2.11). 
 
In applying the LIE equation, the vdW values of the ligands complexed with the 
enzyme were more negative than when only in solution, showing that the ligand has 
more favourable vdW interactions when complexed. The electrostatic interactions of 
ligands in all the complexes were significantly less favourable than those of the ligand 
in water. When using the values of empirical parameters α, β and γ, for example β = 
0.43 for neutral compounds, α = 0.18 and γ = 0.0,328 the value of binding free energies 
of all of complexes did not agree with the docking results (ΔG1 in Table 2.11). However, 
as it has been shown that α and γ need to be recalibrated depending on the different 
systems; the α value has been suggested to be dependent on the system and the force 
field used in the LIE calculations while the γ relies on the nature of the binding site. In 
this case, due to the lack of experimental data of complexes, the chemical nature of the 
ligands and the binding sites were taken into the consideration. Most binding sites are 
composed of both polar and non-polar residues, so the magnitude of hydrophobicity in 
the selection of γ is not easy to define in practice, the exact value of γ does not affect the 
relative ranking. A larger value of α = 1.043 was adopted as it had been shown to 
provide a better estimate in the study of cytochrome P450-camphor analogue 
complexes.324 The results of ΔG2, with α set to 1.043, are shown in Table 2.11, and 
revealed better agreement with the binding affinity obtained from docking. This gave a 
good explanation when comparing the binding free energies for different ligands at the 
same pocket. It could be explained that van der Waals and electrostatic results were 
compromised by hydrogen bonding interactions and hydrophobic contacts between the 
ligands and the nsP3 that contributes to the binding free energy.  
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Table 2.11. Average binding free energies (kcal/mol) of top-hit compounds and tenth-hit compounds for the nsP3 calculated by LIE method 
using data trajectories from the MD simulations: ΔG1 (in kcal/mol using α = 0.18, β = 0.43, and γ = 0) or ΔG2 (in kcal/mol using α = 1.043, β = 
0.43, and γ = 0).328 ΔG is the predicted binding affinity by Vina (in kcal/mol).  
Compound 𝐕𝐛𝐛𝐛𝐛𝐛𝐯𝐛𝐯  𝐕𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐯𝐛𝐯  𝐕𝐛𝐛𝐛𝐛𝐛𝐞𝐞𝐞𝐞  𝐕𝐛𝐛𝐛𝐛𝐛𝐛𝐛𝐞𝐞𝐞𝐞  ΔvdW ΔElec ΔG
1 ΔG2 ΔG 
NCI_61610 -75.5 -54.3 -76.9 -93.1 -21.2 16.2 3.6 -15.2 -11.1 
NCI_25457 -47.7 -36.2 -28.3 -32.9 -11.6 4.7 -0.1 -10.0 -10.8 
NCI_345647_a -64.3 -49.5 -36.9 -44.7 -14.8 7.8 0.7 -12.1 -10.9 
NCI_670283 -51.7 -37.7 -28.9 -32.4 -14.0 3.4 -1.1 -13.2 -10.6 
NCI_127133 -45.5 -36.6 -66.3 -65.8 -8.9 -0.6 -1.8 -9.6 -8.3 
NCI_37168vst1 -43.6 -29.7 -41.2 -47.0 -13.9 5.7 -0.04 -12.0 -10.1 
NCI_372499vst2 -36.3 -27.8 -49.9 -53.4 -8.5 3.5 -0.03 -7.3 -10.3 
NCI_37168vst3  -45.0  -30.1  -50.0  -44.4 -14.9 -5.6 -5.1 -17.9 -10.2 
NCI_324623vst4 -41.5 -29.8 -41.7 -49.2 -11.6 7.50 1.12 -8.9 -10.3 
NCI_400976vst5  -31.9 -23.2  -33.7 -70.8  -8.7 37.1 14.4 6.9 -7.2 
NCI_293778vst6 -72.2 -55.9 -38.1 -48.1 -16.3 10.1 1.4 -12.7 -9.4 
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The binding free energies in Table 2.11 indicated that most of hits compounds showed 
good interactions with Pocket 1 and Pocket 3, as the values of ΔG2 were higher than 
those obtained from docking, except the ligand NCI_400976vst5 at Pocket 2. A 
comparison of binding free energies results of top-hit compounds complexes and tenth-
hit compounds complexes revealed that the binding free energies of most of top-hit 
compounds were better than those of tenth-hit compounds even though they were 
similar in docking results, which supported a close agreement between docking results 
and MD simulations results (Table 2.11). Two ligands NCI_37168vst3 and 
NCI_293778vst6 were tenth-hits which had the binding free energies lower then those 
in top-hits. However, these two ligands showed better binding affinities than some top-
hits. These result emphasized important roles of MD simulations for investigating the 
binding affinity for ligand. Further work and results from experimental data are required 
to clarify the issue.  
 
2.3.5 ANALYSIS AND SELECTING LEADS FOR BIOLOGICAL TESTING 
 
In docking and virtual screening, based on the binding affinities and interaction 
analysis, the highest priority potential compounds would be top-hit compounds, namely 
NCI_61610 (-11.1 kcal/mol), NCI_345647_a (-10.9 kcal/mol), NCI_25457 (-10.8 
kcal/mol), NCI_670283 (-10.6 kcal/mol), NCI_37168 (around -10.0 kcal/mol), 
NCI_372499_b (-10.3 kcal/mol), and NCI_324623 (-10.3 kcal/mol). 
 
Throughout analyzing MD simulations and binding free energy calculations using 
simulation results, insights into the interactions of ligands and the protein nsP3 were 
analyzed at an atomic level. Therefore, the compounds considered would be NCI_61610 
(-15.2 kcal/mol), NCI_670283 (-13.2 kcal/mol), NCI_293778 (-12.7 kcal/mol), 
NCI_345647_a (-12.1 kcal/mol), NCI_37168 (-12.0 kcal/mol), and NCI_25457 (-10.0 
kcal/mol). 
 
Taking the results from docking, simulations and binding free energy calculations 
together, a list of compounds was proposed for biological testing would be NCI_61610, 
NCI_345647_a, NCI_25457, NCI_670283, and NCI_37168 (Table 2.12). 
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Table 2.12. Potential lead compounds for the nsP3 proposed for biological testing. 
















































In conclusion, with a combination of molecular docking, virtual screening, and MD 
simulations, we identified potential inhibitors for CHIKV against the nsP3 
macrodomain. So far, very little information is known in the literature about the nsP3 
macrodomain and its inhibitors. Therefore, this study is of great importance in the 
identification of potential novel inhibitors for the chikungunya virus. It is also the first 
in combining computational tools to identify potential inhibitors targeting CHIKV 
through taking advantages of the recently determined high-resolution crystal structure of 
nsP3 in complex with ADP-ribose. Considering the presence of a positive charge at the 
ADP-ribose binding site, this binding pocket may have the tendency to accommodate 
negatively charged ligands, which may not have acceptable pharmacokinetic properties. 
Therefore, we decided to identify all possible binding pockets based on available 
methods. Starting with re-docking ADP-ribose, the bound structure and the key 
interacting residues in the ADP-ribose binding pocket were successfully reproduced. It 
was evident that the binding affinity of ADP-ribose was less than -10 kcal/mol showing 
this negatively-charged ligand binds very tightly into the nsP3. This study also 
supported that the current docking protocol utilising AutoDock Vina is robust in 
reproducing experimentally determined binding modes.  
 
Subsequently, virtual screening with the NCI Diversity Set II was undertaken to identify 
inhibitors targeting CHIKV. In addition to the well-characterised adenine binding 
pocket (Pocket 1), two additional binding pockets (Pocket 2 and Pocket 3) were 
identified through blind docking and MetaPocket. Pocket 3 was overlapped partly by 
Pocket 1, while Pocket 2 was found on the opposite side of the protein. A comparison of 
the binding affinities at the three different binding pockets revealed that all the hits at 
Pocket 1 bind to the protein well, with binding affinities of less than -10 kcal/mol. This 
suggests that the Pocket 1 would be the most favourable for ligand binding. In contrast, 
Pocket 2 might not be a good place for binding compared to Pocket 1 and Pocket 3 as 
those had higher binding affinities. It is also important to note that some ligands were 
repeated many times in the list of virtual screening results. With the different 
conformations, these ligands can bind to different pockets e.g. the ligand NCI_127133 
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binds to Pocket 1 and 2; ligand NCI_670283 binds to Pocket 1 and 3; and ligand 
NCI_293778 binds to Pocket 1, 2, and 3. In such circumstances, these ligands present 
better prospects as inhibitors. 
 
By analysing the hydrogen bonding and hydrophobic interactions between the ligands 
and the nsP3, key residues were identified. The region of residues 110-114 was 
predicted as the most important area in interacting with ligands. This is consistent with 
previous work by Rungrotmongkol et al.70  
 
Furthermore, equilibrium MD simulations were carried out to validate the molecular 
docking results. Analysis of the simulations confirmed that the docked complex of most 
of the ligand-nsP3 were stable over the simulation of 50 ns. However, subtle structural 
rearrangements in the nsP3 were observed to better accommodate the ligands. MD 
simulations also confirmed that Pocket 1 is the more favourable pocket. 
 
Binding free energy calculations were conducted using MD simulations results. Most of 
the top-hit compounds were found to have higher potential inhibitory than the tenth-hit 
compounds in terms of the binding free energy calculations values. 
 
In future work, the detailed binding modes for the identified inhibitors will be better 
characterized, with more extensive computational free energy calculations, and the 
inhibitory effects will be verified by experimental studies. Additionally, our current 
work also provides important input for constructing a pharmacophore for future ligand-





CHAPTER 3. DISCOVERY OF INHIBITORS 




3.1.1 FUNCTIONAL IMPORTANCE OF THE NSP2 IN DRUG DESIGN 
 
The second non-structural protein in the CHIKV genome, nsP2, is a multifunctional 
enzyme,8, 345 and an attractive target for anti-CHIKV drug discovery and development. 
In its free form, the protein induces cytotoxicity, and may be responsible for 
transcriptional shut-off.68 The CHIKV nsP2 also inhibits the cellular response to type I346-
347 and type II347 interferons (IFN) to block the host antiviral response. The complete 
nucleotide sequence of the CHIKV genome reveals that the nsP2 protein is the largest 
non-structural protein, being 798 amino acids long, and possessing a large net positive 
charge.67 Nucleoside triphosphatase, helicase, and RNA-dependent 5'-triphosphatase 
activities reside in the N-terminal domain while activities of cysteine protease, also 
known as thiol protease, are present in the the C-terminal domain.345, 348-349 The nsP2 
protease plays an essential role in viral replication cycle through a cleavage of the non-
structural polyproteins into non-structural proteins.345 The mechanism of protease 
catalysis of VEEV (a virus in the same family of CHIKV) is related to the deprotonation 
of a thiol group of cysteine residue at the active site by assistance of an adjacent 
histidine residue (Figure 3.1).8 This could be explained by the reaction of imidazole ring 
of histidine and the thiol group of cysteine to form a thiolate/imidazolium ion pair 
which is highly nucleophilic.350 The ion pair attacks the scissile amide bond and the 
intermediated products are stabilized by the oxyanion. Through catalysis, the 
intermediate converts to the thioester and releases the C-terminal substrate fragment. 
Hydrolysis regenerates the active site and the N-terminal substrate fragment. In 
addition, based on a study on the nsP2 protease of the SINV (another alphavirus), the 
substitution of amino acids at the catalytic dyad, either cysteine or histidine at the active 
site, can completely abolish this enzyme function.346  
 
 







































































































Figure 3.1. Proposed mechanism of protease catalytic of the nsP2 (adapted from 
Andrew T. R. et al).350 
 
3.1.2 EARLY ATTEMPTS TO DISCOVER CHIKV NSP2 INHIBITORS 
 
Although the function and role of the nsP2 protease is well-known, few studies have 
focused on targeting inhibitors for this CHIKV enzyme. Several studies constructed 
homology models of the nsP2 protease based on the counterparts of the VEEV to assist 
in drug design for CHIKV,351-353 before a crystal structure of the nsP2 protease became 
available in late 2011. With the homology models, inhibitors of the nsP2 enzyme were 
screened, allowing compound designs based on the pharmacophore models.351-353 The 
active site was predicted to be in the major surface groove of the C-terminal-domain 
region, and likely binds to the substrate polyprotein sequences in the cleavage process.8 
The key residues responsible for interactions between the nsP2 protease and ligands 
were established and pharmacophore features of inhibitors were suggested.351 Based on 
docking results, the four best compounds, Compound 22-25 (Figure 3.2) were proposed 
as potential inhibitors of CHIKV nsP2. In another study, the structure-activity 
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relationships of the hit compounds were evaluated.353 Compound 28 and compound 29 
were reported as promising lead compounds with predictions of CHIKV replication 
inhibition at low µM concentrations, (compound 28 with EC50=5.0 µM; compound 29 
with EC50=3.2 µM). The structures of mentioned compounds were in Figure 3.2 
 
Overall, these studies have provided useful information for understanding ligand 
binding and key interacting residues for the nsP2 protease. However the possible 
limitation is that they were conducted using the homology models of the nsP2 protease. 
The recently determined crystal structure of the nsP2 protease opened a new pathway 
for drug design targeting this enzyme. 
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3.2 OVERVIEW OF THIS STUDY 
 
Based on the recently reported crystal structure of CHIKV nsP2 protease (PDB id: 
3TRK), this current study aimed to discover potential new inhibitors of the CHIKV 
nsP2 protease through structure-based approaches, by combining molecular docking and 
MD simulations. The same process with discovering inhibitors targeting the nsP3 
(described in Chapter 2) was applied for the nsP2 protease (more details in 
Experimental procedures and methods section). 
 
There was modification to the protocol in that the best four compounds 22-25 taken 
from Ref351 were docked in the binding site of the nsP2 protease to confirm its location. 
This binding site was assigned binding site 1 (Pocket 1). In addition, identification of 
the active site of the enzyme was discussed (see Results section), and the proposed 
active site was named Pocket 4 in this study. 
 
In silico virtual screening based on docking was then performed to explore inhibitors 
and potential binding sites of the nsP2 protease. Blind dockings and focused dockings 
centred at each of the potential pockets identified were carried out. Additionally, the 
potential binding pockets were predicted with the MetaPocket algorithm.343 The 
compounds from library NCI Diversity Set II were docked to the entire protein (the 
nsP2 protease) with a grid box placed at either the centre at Pocket 1 (VST1) or at the 
centre of the protein (VST2). The binding modes of the compounds were ranked by 
their predicted binding affinities. In total, there were five potential binding pockets 
(labeled as Pockets 1 to 5, shown in Figure 3.3) identified for the nsP2 protease 
(discussed in the Results section). The VST3/VST4, VST5, VST6, VST7, and VST8 
screenings were focused at Pocket 1, Pocket 2, Pocket 3, Pocket 4, and Pocket 5, 
respectively. The blind docking data initially revealed four potential binding sites in the 
nsP2 protease (Pockets 1, 3, 4, 5). Encouragingly, the four binding pockets identified in 
the blind docking were reproduced by the MetaPocket method, which also detected 
Pocket 2 (near Pocket 1) despite the methods being based on very different algorithms. 
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The top hit compounds were identified based on their binding affinities using the default 
scoring function in Vina. The modes of interaction between the ligands and the protein 
were analyzed in Accelrys DS 2.0. The drug-like properties of these compounds were 
subsequently evaluated using the Lipinski Guidelines.206  
 
To understand not only the rigid structures but also the dynamic behaviour, MD 
simulations were subsequently carried out to provide details of the motion, and 
flexibility of the nsP2 protease and its complexes upon binding of small molecules. 
Analysis of simulations was carried out from the trajectories, saved every 10 ps. The 
value of RMSD of the heavy atoms over 50 ns and the RMSF of Cα atoms during the 
MD simulations was measured with respect to the starting structure versus the 
simulation time, to obtain information on global stability, and local flexibility of the 
system. The interactions in terms of hydrogen bonding and hydrophobic contact were 
analyzed by the CHARMM22 and VMD (version 1.9.1).276 Clustering analysis was also 
conducted using the Clustering Plugin in VMD. Detail was described in Chapter 2, 
section 2.2.2. 
 
The binding free energies for docked structures binding to the enzyme were estimated 
based on MD simulations using the LIE method (see Experimental procedures and 
methods chapter). A combination of all these methods helped to propose the list of 
potential hits for biological testing. 
 
3.3 RESULTS AND DISCUSSION 
 
3.3.1 MOLECULAR DOCKING AND VIRTUAL SCREENING 
 
3.3.1.1 Docking to confirm the binding site 
 
The results of docking the four best compounds 22-25 from Ref351 into the Pocket 1, are 
listed in Table 3.1. Pocket 1 includes the key residues for interactions Lys1045, 
Gly1176, His1222, and Lys1239, which was taken from the previous data by Singh et al.351  
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Table 3.1. Docking results of the best compounds for the nsP2 taken from previous 
study [from Singh K. D. et al351] with the binding affinities (kcal/mol).  
Binding affinity 
(kcal/mol) 
Compound 22 Compound 23 Compound 24 Compound 25 
-6.6  -6.3  -6.3  -7.1  
 
The binding affinities (Table 3.1) along with analyses of the interactions of compounds 
and protein were in agreement with those published. The key residues for interactions at 
the active site (Figure 3.3) were re-confirmed, although the binding affinities of these 
















Figure 3.3. Binding pose and interactions of compounds 22-25 in the nsP2 protease: 
(A) Compound 22 in Pocket 1: HBs with Glu1043, Lys1045 and Lys1239; (B) 
Compound 23 in Pocket 1: HBs with Lys1045 and His1222; (C) Compound 24 in 
Pocket 1: HBs with Tyr1079 and Asp1246; (D) Compound 25 in Pocket 1: HBs with 
Glu1204 and His1222. Compound 22, 23 and 25 were in good position in the pocket, 
except compound 24 was in the rear and nearly out of the pocket. The ligands (in cyan) 
and the residues surrounding the ligands (in grey) were displayed in sticks and coloured 
by atoms (carbon in cyan in ligand or in grey in residues, nitrogen in blue, oxygen in 
red, sulphur in organge).  
 
 
3.3.1.2 Blind and focused dockings to identify potential binding sites and hit 
compounds for the nsP2 protease 
 
The outcomes of two blind dockings as mentioned above, one with the centre at Pocket 
1 and one at the centre of protein, are displayed in Table 3.2. The results of top ten 
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compounds and their binding affinities in focused dockings at each pocket are presented 
in Table 3.3. 
 
Table 3.2. Results of the top ten hit compounds from the blind dockings for the nsP2. 
The binding affinities ΔG are in kcal/mol.   
VST1a VST2b 
Hits  ΔG  Location Hits ΔG Location 
1. NCI_61610  -10.6 Pocket 1 1. NCI_293778 -10.3 Pocket 4 
2. NCI_293778 -10.3 Pocket 4 2. NCI_61610 -10.1 Pocket 1 
3. NCI_116702 -9.2 Pocket 3 3. NCI_670283  -9.7 Pocket 4 
4. NCI_37553 -9.2 Pocket 4 4. NCI_116702  -9.2 Pocket 3 
5. NCI_84100_a -9.2 Pocket 3 5. NCI_217697 -9.2 Pocket 1 
6. NCI_84100_b -9.1 Pocket 3 6. NCI_84100_a -9.2 Pocket 1 
7. NCI_25457  -9.0 Pocket 3 7. NCI_84100_b -9.2 Pocket 1 
8. NCI_670283 -9.0 Pocket 1 8. NCI_298892_b -9.1 Pocket 1 
9. NCI_97920 -9.0 Pocket 3 9. NCI_37553 -9.1 Pocket 5 
10. NCI_58052 -8.8 Pocket 3 10. NCI_25457 -9.0 Pocket 3 
a) In VST1, the grid box is centred at Pocket 1 of the nsP2 protease (12.4 Å, 34.3 Å, 
28.6 Å) with dimensions of 66 Å × 86 Å × 60 Å. b) In VST2, the grid box is centred at 
the centre of the nsP2 protease (14.3 Å, 25.5 Å, 22.3 Å) with dimensions of 60 Å × 70 
Å × 60 Å. The origin and axes of the coordinate systems were set the same as in the 
PDB structure (PDB id: 3TRK). 
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Table 3.3. Results of the top ten compounds of focused dockings for the nsP2. The binding affinities are in kcal/mol. 
 
(a) In VST3, the grid box is centred at Pocket 1 (12.4 Å, 34.3 Å, 28.6 Å) with a dimension of 16 Å × 16 Å × 16 Å. (b) In VST4, the grid box is 
centred at Pocket 1 (12.4 Å, 34.3 Å, 28.6 Å) with a dimension of 20 Å × 20 Å × 20 Å. (c) In VST5, the grid box is centred at Pocket 2 (28.1 Å, 
36.9 Å, 30.6 Å) with a dimension of 20 Å × 20 Å × 20 Å. (d) In VST6, the grid box is centred at Pocket 3 (30.4 Å, 42.1 Å, 14.8 Å) with a 
dimension of 20 Å × 20 Å × 20 Å. (e) In VST7, the grid box is centred at Pocket 4 (3.2 Å, 31.9 Å, 18.1 Å) with a dimension of 20 Å × 20 Å × 20 
Å. (f) In VST8, the grid box is centred at Pocket 5 (15.2 Å, 13.9 Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å.  









5. NCI_25457  
(-9.1) 
6. NCI_116702  
(-9.0) 
7. NCI_80997_a  
(-9.0) 
8. NCI_109451  
(-8.9) 




   
1. NCI_293778 
 (-9.8) 




4. NCI_670283  
(-9.3) 
5. NCI_25457  
(-9.2) 
6. NCI_298892_b  
(-9.2) 
7. NCI_61610  
(-9.2)  
8. NCI_84100_a  
(-9.2) 
9. NCI_84100_b  
(-9.2)  






















1. NCI_37553  
(-9.6) 






5. NCI_25457  
(-9.0)  
6. NCI_293778  
(-9.0) 
7. NCI_97920 
 (-9.0)  
8. NCI_67436 
(-8.9)  












5. NCI_61610  
(-9.2)  
6. NCI_319990  
(-8.9) 
7. NCI_328101 
 (-8.9)  
8. NCI_67436 
(-8.9)  












5. NCI_80735  
(-8.7)  
6. NCI_80997_a  
(-8.4) 
7. NCI_345845 
 (-8.1)  
8. NCI_5157 
(-8.1)  
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The blind docking data initially revealed four potential binding sites in the nsP2 
protease (Pockets 1, 3, 4, 5) where the hit compounds could potentially bind. 
Encouragingly, as mentioned above, a further pocket (Pocket 2) near Pocket 1 was also 
found by the the MetaPocket method together with four binding pockets identified in 
the blind docking. The top docked structures of each virtual screening are represented in 
Figure 3.3, showing the locations of five pockets. 
 
Figure 3.4. Representation of docked structures of top hit compounds in different 
virtual screenings at five different binding sites of the nsP2 protease with Pocket 4 being 
the active site of the nsP2 protease. Ligand NCI_61610 (A) and NCI_293778 (B1) in 
Pocket 1; ligand NCI_293778 (B2) in Pocket 2; ligand NCI_37553 (C) in Pocket 3; 
ligand NCI_293778 (B3) in Pocket 4; and NCI_293778 (B4) in Pocket 5. Ligand 
NCI_293778 (B) with different conformations, B1-B4 could bind to different pockets 
Pocket 1, 2, 4, and 5, respectively. 
 
Pocket 1 and Pocket 4 (Figure 3.3) were groove-like while Pocket 2 (adjacent to Pocket 
1, sharing some residues with Pocket 1 such as Tyr1177 and His1222), Pocket 3 
(behind) and Pocket 5 (behind) were shallow. Pocket 3 was below Pocket 1, Pocket 4 
was on the opposite site behind Pocket 1, and Pocket 5 was in the rear side behind 
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Pocket 1. Pocket 4, containing the catalytic dyad Cys1013 and His1083, is the active 
site. The residues making up each pocket are presented in Table 3.4. 
  
Table 3.4. The important residues in each pocket of the nsP2 protease with the key 
residues in bold involved in forming HBs and hydrophobic contacts between the protein 
and ligands.  
Binding 
pocket 
Residues making up the pocket 
Pocket 1 Gln1039, Ala1040, Glu1043, Lys1045, Ala1046, Tyr1047, Gly1176, Tyr1177, 
Pro1191, Leu1192, Gly1193, Val1194, Asn1202, Leu1203, Glu1204, Ile1221, 
His1222, Thr1223, Asp1235, His1236, Met1238, Lys1239, Met1242  
and Cys1233 
Pocket 2 His1151, Pro1153, Val1154, Lys1155, Gly1156, Glu1157, Arg1158, Met1159, 
Glu1160, Tyr1177, Asn1178, Leu1179, Ala1180, His1222, Thr1223, 
Pro1224, Phe1225, Gln1232, Arg1260, Tyr1262, Ser1293, Thr1292  
and Thr1295 
Pocket 3 Glu1157, Arg1158, Met1159, Trp1161, Leu1162, Lys1165, Ile1166, Asn1167, 
Gly1254, Ser1256, Arg1281, Ser1282, Arg1284, Leu1286, Lys1287, Pro1288, 
Pro1289, Cys1290, Leu1300, Ser1302 and Asn1303 
Pocket 4 Cys1013, Ala1046, Tyr1047, Ser1048, Pro1049, Glu1050, Val1051, Tyr1078, 
Tyr1079, Asn1082, His1083, Trp1084, Gly1090, Lys1091, Phe1093, 
Tyr1201, Asn1202, Glu1204, Leu1205, Gly1206, Pro1208, Ala1209, 
Met1238, Gln1241, Met1242, Gly1245, Asp1246 and Arg1249 
Pocket 5 Asn1040, Glu1050, Leu1053, Asp1064, Leu1065, Asp1066, Ser1067, 
Gly1068, Leu1069, Phe1070, Ser1071, Lys1091, Phe1093, Asn1096, Glu1098, 
Ala1099, Ile1102, Leu1103, Lys1106, Tyr1107, Asn1140, Arg1141, Arg1142, 
Leu1143, Pro1144, Arg1267, Glu1270, Arg1271, Cys1274, Val1275, 
Arg1278, Thr1313, His1314 and Asn1317 
 
In the docking VST1, six out of ten ligands preferred binding at Pocket 3 along with 
two ligands at Pocket 1 and two ligands at Pocket 4. In VST2, most of the ligands (five) 
occupied Pocket 1, two ligands occupied Pocket 3, two ligands occupied Pocket 4, and 
one ligand occupied Pocket 5. In VST4 with an increased box size, larger compounds 
were identified as top hits despite not being present in VST3; for example NCI_293778 
(-9.8 kcal/mol), NCI_84100_a (-9.2 kcal/mol), and NCI_84100_b (-9.2 kcal/mol) (their 
chemical structures in Figure 3.4). It is likely that the larger grid box accommodates the 
binding of these molecules better. Some hit compounds were present in different virtual 
screenings, that means they could bind into different pockets with varying 
conformations such as NCI_293778 (Pocket 1, 2, 3, 4, and 5); NCI_37553 (Pocket 1, 2, 
3, 4, and 5); and NCI_61610 (Pocket 1, 4, and 5); NCI_670283 (Pocket 1 and 4); 
NCI_84100_b (Pocket 1 and 3); and NCI_37553 (Pocket 3 and 5), the chemical 
structures presented in Figure 3.4. The binding affinities of all hit compounds were 
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approximately -9 kcal/mol, which indicate favourable interactions between the 
compounds and the nsP2 protease.  
 
Binding modes obtained from docking at potential binding sites were analysed to show 
details of interactions and to identify key residues through quantification of HBs or 
hydrophobic contacts. The results of the important residues involved in forming HBs 
and hydrophobic contact for each pocket are detailed in Appendixes 13-20. The residues 
surrounding ligands within 5 Å which make up each pocket are listed with the key 
residues involved in forming HBs and hydrophobic contacts between the protein and 
ligands in bold (Table 3.4). Most ligands were hydrogen bond donors, and the residues 
of protein were acceptors in Pocket 1 and Pocket 3 while they can exchange their roles 
in the other pockets. As mentioned earlier, the active site was Pocket 4 with Cys1013 
and His1083 in good positions to be a catalytic dyad. The residue Trp1084 is close to 
His1083 in Pocket 4 which is essential for interactions, as previously reported in the 
study of the nsP2 protease of SINV.346 Among the five pockets (with respect to ligands 
containing aromatic rings), π-stacking interactions and π-network interactions were 
often present with His1222 at Pocket 1; Tyr1177 at Pocket 2; and Tyr1079 and Trp1084 
at Pocket 4. 
 
It was interesting to analyse interactions of protein and ligands to look at the different 
conformations and how they bind to the different pockets. Intriguingly, for the top-hit 
NCI_293778, a high binding affinity was observed, though analysis revealed no HBs 
were formed at Pocket 5 (Figure 3.5). It could not explain why at Pocket 5, this ligand 
gained the higher binding affinity at this pocket than those at other pockets. This might 
be due to the strong compromise of degree of complementarity of protein and ligands as 










































































































Figure 3.6. Binding poses and interactions of hit compound NCI_293778 at different 
binding pockets and key residues for interactions at each pocket: (A) At Pocket 1: HBs 
with Lys1239; (B) At Pocket 2: π-π interactions with Tyr1177; (C) At Pocket 4: π-π 
interactions with Trp1084; (D) At Pocket 5: Hydrophobic contact only. The ligands (in 
cyan) and the residues surrounding the ligands (in grey) were displayed in sticks and 
coloured by atoms (carbon in cyan in ligand or in grey in residues, nitrogen in blue, 
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3.3.1.3 Identification of the active site of the nsP2 protease 
 
It is known that the nsP2 protease carries out its function through a conserved catalytic 
dyad with a cysteine and a histidine; however, these residues have not been conclusively 
identified in the CHIKV nsP2 protease. For instance, Bassetto et al. reported that 
Cys1013 and His1083 (the numbering is according to the CHIKV nsP2 sequence) in the 
homology model of the nsP2 protease were the catalytic residues,353 compared to 
Cys477 and His546 in the VEEV nsP2 protease through a sequence alignment between 
the CHIKV nsP2 protease and the VEEV nsP2 protease. In contrast, with a similarly 
based the sequence alignment, Singh et al. predicted that the active site residues 
interacting with the peptide substrate include Lys1045, Gly1176, His1222, and 
Lys1239, without explicitly identifying the catalytic residues.351 Structural alignment of 
the nsP2 proteases from three alphaviruses, CHIKV (PDB id: 3TRK), VEEV (PDB id: 
2HWK), and SINV (PDB id: 4GUA) were carried out with MUSTANG354 (Appendix 
21). The sequence identity between the CHIKV nsP2 protease sequence and the 
counterparts in VEEV and SINV sequences are 40% and 44%, respectively. This 
structural alignment revealed that Cys1013 and His1083 are the two catalytic residues in 
the nsP2 protease of CHIKV (Figure 3.6). Their catalytic roles are supported by their 
close proximity in the crystal structure. Cys1233 and His1222 in the C-terminal domain, 
identified in the homology model by Singh et al., are separated by 15 Å in the solved 
crystal structure (between the S atom in Cys and the N atom in His); thus, they are not 
likely to be the catalytic residues unless there is a structural transition upon substrate 
binding. Conversely, Cys1013 and His1083 in the N-terminal domain are sufficiently 
close enough to carry out proton transfer (with the distance of 4.8 Å between the S atom 
in Cys1013 and the N atom in His1083); thus, they are properly positioned to be a 
catalytic dyad. In addition, the presence of Trp1084 close to His1083 was proposed to 
be necessary for a functional protease.355 




Figure 3.7. Superimposition of three crystal structures, namely the CHIKV nsP2 
protease (PDB id: 3TRK, in blue), the VEEV nsP2 protease (PDB id: 2HWK, in red), 
and the structure of SINV (PDB id: 4GUA, in grey). The conserved catalytic residues, 
cysteine and histidine (in licorice), Cys1013 and His1083 in the CHIKV nsP2 protease 
(in blue), Cys477 and His546 in the VEEV nsP2 protease (in red); and Cys1021 and 
His1098 in the SINV structure (in gray) are also shown.  
 
3.3.2 MD SIMULATIONS  
 
The top-hit compounds (NCI_217697, NCI_61610, NCI_37553, and NCI_293778) and 
tenth-hit compounds (NCI_217697w, NCI_25457w, NCI_362639, NCI_84100b, and 
NCI_67436) obtained from virtual screenings were subjected to MD simulations using 
the NAMD package with the CHARMM force field (Table 3.5). In particular, ligand 
NCI_293778, which had different conformations at the different binding sites 
(NCI_293778vst4 at Pocket 1, NCI_293778vst5 at Pocket 2, NCI_293778vst2 and 
NCI_293778vst7 at Pocket 4, and NCI_293778vst8 at Pocket 5), was investigated. MD 
simulations were performed to study the stability and flexibility of the nsP2 protease 
and its complexes as well as to obtain the accurate binding modes. MD simulations 
were run for 50 ns following 3 ns equilibrium simulations.  
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Table 3.5. Chemical structures of hit compounds for nsP2 and their properties. 
Compound’s 
name 
































































































































(a) ΔG refers to the binding affinities by Vina in kcal/mol. (b) The logarithm of the 
partition coefficient between n-octanol and water calculated using ChemBioDraw Ultra 
14.0. (c) Number of hydrogen bond donor atoms. (d) Number of hydrogen bond 
acceptor atoms. (e) Molecular weight. (f) Located in Pocket 1 and Pocket 2. (g) Located 
in Pocket 4. (h) Located in Pocket 5.  
 
 
3.3.2.1 Overall stability of the nsP2 protease and its complexes 
 
The overall stability of the nsP2 protease and its complexes was evaluated by the values 
of backbone atomic positional RMSD. The results of backbone RMSD profile for the 
nsP2 enzyme and its complexes with different ligands with respect to the starting 








































Figure 3.8. The backbone RMSD profiles for the apo protein nsP2 and its different 
complexes during MD simulations from 4 ns to 53 ns: (A) Complexes of the nsP2 and 
top-hit compounds; (B) Complexes of the nsP2 and tenth-hit compounds. 
 
The plots showed that most of the systems were relatively stable during the 50 ns 
simulations within 1-2.5 Å. In simulation of the complex of ligand NCI_293778vst8 at 
Pocket 5, a large RMSD was observed around 47 ns (Figure 3.7 A). Examination of the 
structures revealed that it was due to the relative movement between two domains and 
the fluctuation of loops. This ligand was also found to gradually move from a position 
whereby part of the ligand was positioned out of the pocket, to the whole ligand being 
out of the pocket but still stuck at the rear after 40 ns, and finally dissociated from the 
pocket after 47 ns. 
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3.3.2.2 Investigation of flexibility of the nsP2 protease and its complexes 
 
For the flexibility of the nsP2 protease and its complexes, the RMSF curves of the Cα 





Figure 3.9. RMSFs values of Cα atoms of the apo protein nsP2 and its different 
complexes during MD simulations: (A) Complexes of the nsP2 and top-hit compounds; 
(B) Complexes of the nsP2 and tenth-hit compounds. 
 
For the flexibility, comparative analysis of the RMSF values of the apo protein and the 
complexes was focused on the binding sites of ligands. Most of the residues making up 
the binding sites were quite stable during the simulation with fluctuations within 2 Å. 
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Furthermore, no significantly reduced fluctuations were found in the binding pockets of 
the protein between the nsP2 protease (apo protein) and its complexes with the nsP2 
protease-ligand. 
 
3.3.2.3 Atomic interaction between the nsP2 protease and hit compounds 
 
Details of atomic interactions were obtained by HBs and hydrophobic contacts. The 
residues involved in forming hydrophobic contacts based on the trajectories of the MD 
simulations are listed in Table 3.6 and Table 3.7. 
 
Table 3.6. Hydrogen bonding analyses on the trajectories sampled in the MD 
simulations for hit compounds in complexed with the nsP2 protease. The HBs with 
occupancy more than 10% are in highlighted in bold.  








Lys1239(HZ3)-O  2.9 
Lys1239(HZ2)-O  2.7 
Lys1239(HZ1)-O      2.6 
His1222(HN)-O      1.8 
Lys1045(HZ3)-N1     0.3 
Lys1045(HZ1)-N1      0.3 
Lys1045(HZ2)-N1     0.3 
Lys1045(HZ2)-O 0.1 



















His1222(HD1)-N3     10.7 
Asn1202(HD21)-N3     0.5 
Lys1239(HZ1)-N  0.1 
Lys1239(HZ2)-N 0.1 
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Lys1045(HZ2)-N3      0.1 
Lys1045(HZ3)-N3      0.1 




Gly1156(HN)-N      1.4 
Lys1155(HZ2)-N       0.8 
Lys1155(HZ1)-N     0.5 
Lys1155(HZ3)-N      0.5 




Tyr1079(HH)-N3     8.6 
Asn1082(HD22)-N2     5.8 
Trp1084(HE1)-N3     3.4 
Asn1082(HD21)-N3     3.6 
Asn1082(HD21)-N2     0.4 
Tyr1079(HN)-N1     0.2 
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Table 3.7. Hydrophobic contact analyses on the trajectories sampled in the MD 
simulations for hit compounds in complexed with the nsP2 protease.   
Ligand Interacting non-polar parts of the residues  
NCI_61610 Ala1040, Tyr1177, Pro1191, Leu1203, Ile1221, Leu1243 
NCI_217697 Pro1191, Leu1243 
NCI_37553 Trp1161, Leu1162, Leu1286, Pro1288, Pro1289, Leu1300 
NCI_293778vst4 Pro1191, Leu1192, Leu1203, Ile1221, Leu1243 
NCI_293778vst5 Tyr1177, Pro1224 
NCI_293778vst2 Ala1046, Tyr1079, Trp1084, Leu1205 
NCI_293778vst7 Ala1046, Val1077, Tyr1079, Trp1084, Leu1205 
NCI_293778vst8 Ile1102, Leu1103 
NCI_217697w 
 
Ala1040, Lys1045, Tyr1047, Pro1191, Leu1192, Gly1193, Val1194, 
Glu1204, Ile1221, Hsd1222,, Met1238, Lys1239, Leu1243 
NCI_25457w Glu1157, Trp1161, Leu1162, Lys1165, Leu1285, Pro1289 
NCI_362639 Thr1292, Ser1293 
NCI_84100b 
 




Asp1066, Ser1067, Asn1140, Arg1141, Arg1142, Pro1144, Hsd1145, 
Glu1270, Arg1271, Cys1274, Val1275 
 
For most of the investigated hit compounds, the ligand or/and the residues in the 
binding sites fluctuate and adapt their structure in order to better accommodate the 
ligands by optimizing HBs, and/or hydrophobic contacts, compared to those in docking 
where protein was kept rigid. Most of their interactions with the nsP2 protease were 
maintained by hydrophobic contacts rather than HBs, as most of the HBs occupancy 
was found to be low (less than 10%, Table 3.6).  
 
Considering the structure of the ligands, the presence of both donor and acceptor atoms 
in the ligand, NCI_61610 and NCI_37553 could form more HBs than ligands 
NCI_217697 and NCI_293778. As expected, HBs were mostly formed with NCI_61610 
and NCI_37553. Ligand NCI_61610 showed HBs interactions with residues Lys1239, 
Glu1204, Leu1203, Tyr1177, Gly1176, and Lys1045, although these interactions were 
weak (occupancies less than 10%). The complex nsP2 protease-ligand NCI_37553 at 
Pocket 3 was maintained through strong HBs between its oxygen and Arg1284 (80.5%), 
Ser1302 (10.4%); or between its nitrogen and Arg1284 (26.3%), illustrated in Figure 
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3.9. Ligand NCI_67436 fitted in Pocket 5 by moderate HBs interactions during the 
simulations with residues of the enzyme such as Asn1140 (65.3%), Arg1142 (63.4%), 
Glu1270 (49.2%), and some weak HBs with Cys1274 (28.2%), His1314 (22.2%), and 
Asn1317 (26.1%), (Figure 3.9). In particular, this ligand plays the roles of donor and 
acceptor in forming the HBs. The interactions of ligand NCI_84100b and the nsP2 







Figure 3.10. Hydrogen bonding interactions between the nsP2 enzyme and ligands: (A) 
Ligand NCI_37553 at Pocket 3, (B) Ligand NCI_67436 at Pocket 5; with representation 
of ligands and key residues for interactions surrounding the ligands (in licorice), 
showing the interactions maintained between the ligands and residues of protein through 
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Interestingly, a comparison of NCI_293778 bound at different binding sites revealed 
that the nitrogen of this ligand could form one hydrogen bond (occupancy of 10.7%) 
with the residue His1222 at Pocket 1, accompanied by surrounding hydrophobic 
interactions (Figure 3.10). In contrast, NCI_293778 often lacked strong HBs at other 
pockets (with low occupancies, see Table 3.6). This indicates that NCI_293778 was 
more likely to be accommodated by Pocket 1 than other pockets, even though that the 
binding affinity obtained for this ligand was -9.8 kcal.mol; less than for Pocket 4 (-10.4 
kcal/mol), and Pocket 5 (-10.2 kcal/mol). However, the aromatic ring of this ligand 
could form π-stacking interactions or a π-network with Tyr1177 (Pocket 2); Tyr1079, 
and Trp1084 (Pocket 4) to maintain the interactions between the protein nsP2 protease 
and the ligand. 
 
 
Figure 3.11. The docked structure of ligand NCI_293778vst4 (in green) in Pocket 1 of 
the nsP2 protease, showing the residues forming Pocket 1 and the ligand-protein 
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Compound NCI_67436 played both donor and acceptor roles in the HBs interactions. 
For the other ligands, there was no significant contribution from HBs in the interactions, 
even though those ligands have donor and acceptor groups available for hydrogen 
bonding formations.  
The SASA used to monitor the possible solvation environment change upon ligand 
binding was expected to get a reduction of hydrophobic interacting residues in the 
complex protein-ligand compared to those in apo protein (Appendix 22). As mentioned 
in Chapter 2, section 2.3.3.3, the SASA is heavily influenced by interactions between 
protein and ligands. However, most of the involved residues were inconsistent for 
different ligands in the nsP2 protein. This could be explained by the formation of not 
only hydrophobic contacts but also polar hydrogen bonding interactions. Thus, the 
change in SASA will be compromised by the polar interactions, and both of protein and 
ligands will modulate the SASAs. 
 
3.3.2.4 Clustering analysis, comparison of simulations and docking results for the 
complexed nsP2 protease-ligands 
 
Throughout the simulations, structural clustering was used to identify the most popular 
conformation, and the interaction between these clusters and the nsP2 at the different 
binding sites was examined to compare with docking. Clustering analysis was 
undertaken on all of the snapshots from the trajectories, and the clusters were visualized 
and superimposed with the initial structure. The superimposition and the value of 
RMSD were used to evaluate between the different clustering structures and initial 
structure at 0 ns, 10 ns, 20 ns, 30 ns, 40 ns, and 50 ns were calculated. For example, the 
potential hit compound NCI_37553, superimposition of the most popular conformations 
of complex; and the RMSD value for the ligand was 1.7 Å (at 10 ns), 2.0 Å (at 20 ns), 
2.0 Å (at 30 ns), 1.9 Å (at 40 ns), and 2.2 Å (at 50 ns) with respect to the initial structure 
(Figure 3.11). The docking results were in close agreement with MD simulations, even 
though there was flexibility of residues in the protein and ligands in forming HBs or 
creating hydrophobic contacts. There was no major change in the important residues at 
the binding sites of the nsP2. Moreover, understanding the effects of ligand binding to 
other binding pockets on the active site was also of interest. Experimental validation is 
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required to confirm whether there is an allosteric site or a synergistic effect upon 
binding at different sites within the active site of the nsP2. 
 
Figure 3.12. Superimposition of the different conformations of ligand NCI_37553 and 
complexed with the nsP2 at Pocket 3 of the nsP2 during simulations with respect to the 
initial structure (red: at 0 ns, grey: at 10 ns, green: at 20 ns, pink: at 30 ns, orange: at 40 
ns, and blue: at 50 ns). 
 
3.3.2.5 Combination of simulations and docking for the nsP2  
 
Based on MD simulations results, the sampled conformations of protein nsP2-
NCI_67436 at the different timepoints (10 ns, 20 ns, 30 ns, 40 ns, and 50 ns) were used 
for docking and virtual screening, so as to probe the effects of the static protein structure 
used in the docking. This complex was selected as NCI_67436 showed higher potential 
after analyzing the outcomes of docking and simulations, listed in Table 3.8 and Table 
3.9. The binding affinities of the docking runs in Table 3.8 were not significantly 
different from those obtained by docking based on the X-ray structure. A comparison of 
complexes of different protein conformations and the initial docked structure showed 
there were changes in the binding mode, but always maintaining HBs of the ligand with 
the protein to maintain the interactions of ligand and the residues in the binding pocket 
during simulations (details of interactions analyses in Appendixes 23-27). For virtual 
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screening, the docking results were sensitive in the exact static structure used as most of 
the hits introduced were new in comparison of top hits lists in the screening results 
based on the X-ray structure. 
 
Table 3.8. Re-docking results for complex nsP2-NCI_67436 with different 
conformations of the nsP2 taken from the different timepoints of simulations at Pocket 
5. The binding affinity is in kcal/mol.  
nsP2 conformation Binding affinity (kcal/mol) HBs interaction (Å) 
At 0ns -8.1 No HBs  
(hydrophobic contacts only) 
At 10 ns -7.7 No HBs  
(hydrophobic contacts only) 
At 20 ns -8.3 Arg1142(HH11)-O=2.3 




At 40 ns -6.8 Arg1278(HH11)-N=2.2 
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Table 3.9. Virtual screening results for blind docking into Pocket 1 with different conformations of the nsP2 taken from the different timepoints 
of simulations. The binding affinities ΔG are in kcal/mol.  
(a) In VST-10nsa, the grid box is fixed at the centre of Pocket 3 (15.2 Å, 13.9 Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å. (b) In VST-
20nsb, the grid box is fixed at the centre of Pocket 3 (15.2 Å, 13.9 Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å. (c) In VST-30nsc, the grid 
box is fixed at the centre of Pocket 3 (15.2 Å, 13.9 Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å. (d) In VST-40nsd, the grid box is fixed at 
the centre of the protein at the centre of Pocket 3 (15.2 Å, 13.9 Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å. (e) In VST-50nse, the grid 
box is fixed at the centre of the protein at the centre of Pocket 3 (15.2 Å, 13.9 Å, 11.5 Å) with a dimension of 20 Å × 20 Å × 20 Å. 
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3.3.3 BINDING FREE ENERGY CALCULATIONS FOR THE LIGANDS 
BINDING TO THE NSP2 ENZYME 
 
The prediction of binding free energy is usually a challenge for docking and scoring in 
computational drug design. In this study, the converged trajectories of complexes 
obtained from simulations were used to calculate the binding free energy for the hit 
compounds. The average values of vdW and elec interactions for each ligand in the two 
states, bound state (Vbound) and unbound state (Vunbound) were calculated (Table 3.10). 
The results in Table 3.10 indicated that the van der Waals value of the ligands in the 
complex with the enzyme were much more negative than when only in solution, 
showing that the ligand has more favourable van der Waals interactions in the complex. 
However, it is striking that the electrostatic interactions of ligands in all the complexes 
were significantly less favourable than those of the ligand in water.  
 
Parameters selection proceeded with the same approach as for the nsP3 (see Chapter 2, 
section 2.3.4 for explanation of selecting parameters). The results of ΔG2 with α set to 
1.043 are shown in Table 3.10 and revealed better agreement with the binding affinity 
obtained from docking. This provided good agreement when comparing the binding free 
energies for different ligands at the same pocket; such as in the case of NCI_61610, 
NCI_217697, and NCI_293778vst4. For instance, ligand NCI_293778vst4, with the 
presence of stronger HBs (indicated by the higher value of HBs occupancy) had higher 
binding affinities compared to other ligands.  
 
A comparison of binding free energies of top-hit compound complexes and tenth-hit 
compound complexes was also carried out. The results revealed that most of the top-hit 
compounds had better binding free energies than the tenth-hit compounds, which 
supported a close agreement between docking results and MD simulations results (Table 
3.10). Ligand NCI_67436 showed the highest binding affinities compared to the value 
obtained from docking and also compared to the other compounds; while the ligand 
NCI_362639 had the lowest binding affinity. This is in accordance with the simulations 
results analysed above, as the ligand NCI_67436 fit well in the pocket by forming 
strong HBs with the residues of the pocket. 
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Table 3.10.  Average binding free energies (kcal/mol) of top-hit compounds and tenth-hit compounds for the nsP2 calculated by LIE method 
using data trajectories from the MD simulations: ΔG1 (in kcal/mol using α = 0.18, β = 0.43, and γ = 0) or ΔG2 (in kcal/mol using α = 1.043, β = 0.43, 
and γ = 0).328 ΔG is the predicted binding affinity by Vina (in kcal/mol).  





NCI_61610 -65.0 -54.4 -79.2 -91.0 -10.6 11.8 3.2 -6.0 -10.6 
NCI_217697 -50.0 -39.1 -30.4 -36.2 -10.9 5.8 0.5 -8.9 -9.3 
NCI_37553 -60.1 -48.6 -62.5 -73.1 -11.5 10.6 2.5 -7.4 -9.6 
NCI_293778vst4 -69.6 -54.6 -35.6 -48.0 -15.0 12.4 2.6 -10.3 -9.8 
NCI_293778vst5 -68.5 -54.4 -42.3 -47.8 -14.1 5.5 -0.2 -12.3 -9.8 
NCI_293778vst2 -69.2 -54.7 -38.9 -47.7 -14.5 8.8 1.1 -11.3 -10.3 
NCI_293778vst7 -72.7 -55.6 -40.9 -48.2 -17.1 7.3 0.1 -14.6 -10.4 
NCI_293778vst8 -65.6 -54.4 -43.2 -47.4 -11.2 4.2 -0.2 -9.9 -10.2 
NCI_217697w -50.6 -39.1 -29.7 -36.4 -11.4 6.7 0.8 -9.0 -9.1 
NCI_25457w -46.5 -35.4 -20.5 -32.0 -11.1 11.5 2.9 -6.6 -9.0 
NCI_362639 -28.7 -26.8 -76.9 -78.5 -1.9 1.6 0.4 -1.3 -8.2 
NCI_84100b -51.4 -40.8 -30.5 -42.8 -10.6 12.3 3.4 -5.7 -8.9 
NCI_67436 -62.7 -44.4 -81.3 -89.7 -18.3 8.4 0.3 -15.5 -8.1 
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However, between the binding affinities obtained from docking and the binding free 
energies estimated from simulations, three ligands, NCI_61610, NCI_217697, and 
NCI_37553 showed the lower binding free energies in simulations: -6.0 kcal/mol,  
-8.9 kcal/mol, -7.4 kcal/mol, respectively compared these in docking: -10.6 kcal/mol, 
-9.3 kcal/mol, -9.6 kcal/mol, respectively. Interestingly, in the case of NCI_293778, 
with different conformations binding at the different binding sites, the binding 
affinities in docking and from simulations indicated a consistent trend that binding at 
Pocket 4 (-14.6 kcal/mol) better than Pocket 2 (-12.3 kcal/mol) > Pocket 1 (-10.3 
kcal/mol) > Pocket 5 (-9.9 kcal/mol); whereas in analysis simulations above, with a 
presence of HBs, Pocket 1 may be as the better place for this ligand compared to 
others. In addition, HBs and hydrophobic contacts in some ligands (such as 
NCI_293778vst4 and NCI_37553) were maintained. These ligands were expected to 
have lower binding free energies, however this was not observed with LIE 
predictions. It may be deduced that there was a compromise between van der Waals 
and electrostatic results from HBs interactions and hydrophobic contacts between the 
ligands and the enzyme nsP2. More work and results from experimental data are 
required to clarify the issue. 
 
3.3.4 ANALYSIS AND SELECTING LEADS FOR BIOLOGICAL TESTING 
 
The outcomes of dockings and virtual screening showed the potential compounds to 
be considered are NCI_61610 (-10.6 kcal/mol), NCI_293778 (from -9.8 to around -
10.2 kcal/mol), NCI_37553 (-9.6 kcal/mol), NCI_217697 (-9.3 kcal/mol), and 
NCI_25457 (-9.0 kcal/mol). 
 
After analyzing MD simulations and binding free energy calculations, the 
compounds to be selected as leads are NCI_293778 (from -9.9 to around -13 
kcal/mol), NCI_67436 (-15.5 kcal/mol), NCI_217697 (-9.0 kcal/mol) as they have 
higher binding affinities than the others and the interactions were maintained during 
MD simulations. 
 
From a combination of these two outcomes (from simulations and docking), a list of 
compounds which have good binding affinities and the remained interactions 
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between them and the nsP2 protein during MD simulations, was proposed for 
biological testing; namely NCI_293778, NCI_217697, and NCI_67436 (Table 3.11). 
 
Table 3.11. Potential lead compounds for the nsP2 proposed for biological testing. 










In this work, the X-ray crystal structure of nsP2 protease was utilized to conduct a 
combination of molecular docking, virtual screening, and MD simulations to search 
for potential inhibitors. Starting with blind dockings and published information, we 
identified top hit compounds, together with the five potential binding pockets of the 
nsP2 protease. Subsequently, the focused dockings into these different binding sites 
were investigated to discover more hit compounds, and observe further binding 
modes at these pockets. The top hit compounds were then subjected to MD 
simulations for 50 ns after equilibration. The simulation results demonstrated the 
different binding affinities of different ligands through the number of HBs and 
hydrophobic contacts. Previous studies largely focused on Pocket 1 as the active site. 
However, in this study, Pocket 4, in the N-terminal domain of the nsP2 protease, was 
recognised as the active site by the presence of catalytic residues, Cys1013 and 
His1083. Importantly, the current work offers more opportunities to identify 
potential inhibitors. The effect upon the active site of ligands binding into different 
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simulations was utilized for the linear interaction energy to obtain accurate binding 
free energies. More experimental data is required to achieve a compromise between 
vdW and electrostatic interactions. A good agreement between docking results and 
MD simulations were confirmed by better binding free energies of top-hit 
compounds than tenth-hit compounds. Finally, it is worth emphasizing that this is the 
first instance where molecular modelling with more accurate data from X-ray 
structure has been studied. Our findings open up a promising approach in combining 
docking and MD simulations to assist in rational drug design, especially providing 






CHAPTER 4. DISCOVERY OF INHIBITORS 




4.1.1 ENVELOPE GLYCOPROTEINS AS POTENTIAL TARGETS FOR 
CHIKV DRUG DISCOVERY  
 
The CHIKV envelope glycoproteins (E1, E2, and E3) are promising targets for drug 
discovery as they play crucial roles in the virus attachment and entry.8, 68 Like other 
alphavirus in Togaviridae family, CHIKV has an icosahedral structure comprising a 
nucleocapsid enclosed within a phospholipid envelope. Structural analysis of CHIKV 
particles revealed that there are 20 icosahedral “i3” spikes (located on the icosahedral 3-
fold axes), and 60 quasi-3-fold “q3” spikes (located in general positions) that consist of 
a quasi-3-fold axis to form T=4 symmetry structure for the virus.65 Additionally, the 
virus particles contain 80 spikes that make glycoprotein shells with 240 copies of each 
of two glycoproteins, E1 and E2 heterodimers.68 The CHIKV genome, is divided into 
two open reading frames (ORF), encoding four non-structural proteins and five 
structural proteins (the capsid C; envelope glycoproteins E1 and E2; and two small 
peptides, E3 and 6K).67 The non-structural proteins are essential for virus replication, 
protein modification, and immune antagonism, while the structural proteins are products 
obtained from a cleavage of a polyprotein by an auto-protease and signalase.65 
 
The viral entry process is a receptor-mediated endocytosis in clathrin coated vesicles, 
which is controlled by two viral envelope glycoproteins, E1 and E2. In the acidic pH of 
the endosome environment, a conformational rearrangement of the surface glycoprotein 
shell causes a dissociation of the heterodimers p62-E1 (as known as pE2-E1) and 
formation of E1 homotrimers.356 This process induces a fusion of the virus and 
endosomal membranes, resulting in release of the viral nucleocapsid into the cytoplasm. 
The E1 has a hydrophobic fusion loop which invades the cell membrane during the 
membrane fusion. The E2 contributes to receptor binding and protects the loop at a 
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neutral pH. During replication, the capsid is released, and the precursors of structural 
proteins are processed in the Golgi complex, then transported to the plasma membrane.  
 
Structural and functional characterization of the envelope glycoproteins as well as the 
mechanism of neutralization with an interpretation of the cryo-electron microscopy 
structure of the CHIKV-like particles has been reported.68, 356-357 The mutations of four 
highly conserved residues of E1, namely Gly91, Val178, Ala226, and His230 were 
found to reveal their important roles in the cell fusion process.8, 358 Two highly 
conserved residues, Gly91 and His230, are important for membrane fusion 
functionality. A substitution of Gly91 with Glu91 caused a loss of E1 fusogenicity 
whereas any replacement of His230 into Ala230 resulted in the disappearance of this 
activity.358 On the other hand, Val178 and Ala226 are less conserved residues whose 
mutations do not lose E1 fusion capacity but these changes depend on pH and 
cholesterol.358 In particular, a change of Ala to Val in the position of 226 of E1 protein 
resulted in the reduction of cholesterol dependence to infect mosquito hosts.6 Moreover, 
the study on CHIKV E2 mutants identified the acid-sensitive region in the E2 (amino 
acid at 229, 231, 232, 233, and 234 positions).359 The results suggested that the E2 
amino acids 229 to 234 region was responsible for neutralizing antibodies, and that 
these amino acids could prevent the conformational change through interacting with 
antibodies, leading to initiate the viral fusion and entry.359 Also, the region of 229 to 
234 was found to be a crucial role for viral replication partly due to its participation of 
inducing pH-dependent conformational changes.359 In addition, the E2 glycoprotein 
interacts with the the host receptor protein at the 216 residue which is involved in 
initiating infection.360  
 
4.1.2 EARLY RESEARCH TARGETING ENVELOPE GLYCOPROTEINS  
 
Numerous studies in recent years have focused on the structural characterization of the 
envelope proteins of alphaviruses.7 However, little is known about changes of their 
conformation or structural intermediates during fusogenic activity or cell attachment.65 
With regards to CHIKV drug discovery, there have been few studies to identify 
potential inhibitors. Mostly, targets for CHIKV drug discovery are non-structural 
proteins.70, 351, 353, 361 Envelope glycoproteins are another class of attractive targets for 
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interfering with virus entry or virus attachment through inhibition of the viral envelope 
glycoproteins, to block the in vitro CHIKV infection.  
 
Preliminary, computational investigation of the envelope glycoprotein complexes (the 
immature and mature forms)153 has previously been explored within our group,362 
however a more rigorous exploration based on blind docking was deemed essential for 
full characterization of potential target sites. Virtual screenings based on blind docking 
and focused docking are a powerful approach in discovering the potential binding sites 
and hit compounds for CHIKV. Interaction analysis of hit compounds and these 
glycoprotein complexes provide useful information for CHIKV drug design. 
 
4.1.3 COMPARISON OF TWO ENVELOPE GLYCOPROTEIN COMPLEXES 
 
In order to identify inhibitors targeting the CHIKV envelope glycoproteins, 
characterization of the two complexes, the immature (PDB id: 3N40) and mature form 
(PDB id: 3N42) was necessary. As shown in Figure 4.1, the structures of precursor p62-
E1 heterodimer (the immature form) and the complex E3-E2-E1 heterodimer (the 
mature form) are similar with an association of E1 domains (E1 domain I, domain II, 
and domain III), E2 domains (E2 domain A, domain B, and domain C), and E3. 
Additionally, in both structures, E2 makes contact with E3, while E1 does not create 
any interactions with E3. The only major difference between the two complexes is the 
presence of a furin loop, located in the E1 of the immature 3N40, but not present in the 
mature 3N42.153 This loop becomes disordered in the cleavage process. In addition, 
furin maturation of p62 into E3 and E2 will prime the spikes for fusogenic activiation 
during cell entry. Moreover, the dissociation of E2-E1 heterodimer occurs under an 
acidic environment, which rearranges E1 into fusogenic homotrimers that induce fusion 
of viral and endosomal membranes. Therefore, residues in the region of the furin loop 













Figure 4.1. Structure of the envelope glycoprotein complexes: (A) The immature 
structure (PDB id: 3N40); (B) The mature structure (PDB id: 3N42). These structures 
are similar and the only difference is in the furin loop. 
 
4.2 OVERVIEW OF THIS STUDY 
 
In an attempt to discover hit compounds for the CHIKV targeting the envelope 
glycoproteins, this study used an in silico approach. The same process of docking and 
virtual screenings as used for the nsP3 and the nsP2 were undertaken. A docking 
protocol was established (described details in the Experimental procedures and methods 
chapter). Two X-ray crystal structures of envelope glycoprotein, an immature form 
(PDB id: 3N40) and a mature form (PDB id: 3N42), were downloaded from the Protein 
Data Bank. Initially, blind docking was carried out to identify the potential binding 
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sites, which were identified based on the locations of binding ligand. The dimensions of 
the box for covering 3N40 and 3N42 were 108 Å × 126 Å × 62 Å and 84 Å × 126 Å × 
74 Å, respectively. The value of E in docking was changed from the default value E=8 
to E=16, 32, 128, 256, and 1024 in order to investigate the sampling convergence in 
docking with AutoDock Vina. Potential binding sites were revealed by the place where 
ligand binds into the target (discussed in the following section). The next step was a 
focused docking, in which a smaller box (20 Å × 20 Å × 20 Å), was centred at the 
potential binding site of interest to confirm their likehood. Another aim of this process 
is to identify more hit compounds focusing on these binding sites, in order to achieve a 
better sampling. The sets were carried out for each glycoprotein complexes, 3N40 and 
3N42. Moreover, identification of potential binding sites was also investigated and 
compared with the previous published results by using a receptor cavities tool in 
Accelerys DS 3.5 and the MetaPocket program.343  
 
4.3 RESULTS AND DISCUSSION 
 
4.3.1 MOLECULAR DOCKING AND VIRTUAL SCREENINGS 
 
The outcomes of screenings using blind docking and focused docking for two 
glycoprotein complexes are shown in Tables 4.1, 4.2, 4.3, and 4.4. 
 
In Table 4.1, blind dockings showed that there were two potential binding pockets 
identified in the structure 3N42, and one in 3N40. However, analysis of docking results 
with the change to the E value in blind docking (Table 4.2 and Table 4.3) introduced 
some new binding pockets (discussed below). In total, two potential binding pockets 
(3N40_Pocket 1 and 3N40_Pocket 2) were identified in the immature 3N40; and four 
binding pockets (3N42_Pocket 1, 3N42_Pocket 2, 3N42_Pocket 3, and 3N42_Pocket 4) 
were in the mature structure 3N42, respectively. 3N40_Pocket 1 and 3N40_Pocket 2 are 
located in the similar location with 3N42_Pocket 1 and 3N42_Pocket 2.  
 
 
Chapter 4. Envelope glycoproteins 
119 
 
Table 4.1. Results of the top ten compounds of blind dockings with locations of pockets 
in the immature (PDB id: 3N40) and mature forms (PDB id: 3N42). The binding 
affinities ΔG are in kcal/mol.  
VST1a VST2b 
Hits   ΔG  Pocket Hits   ΔG  Pocket 
1. NCI_293778 -13.2 1 1. NCI_293778 -13.7 1 
2. NCI_61610 -12.2 1 2. NCI_37553 -11.4 1 
3. NCI_37553 -11.7 1 3. NCI_61610 -11.2 1 
4. NCI_156219_b -11.5 1 4. NCI_156219_b -11.1 1 
5. NCI_84100_b -10.9 1 5. NCI_84100_a -11.0 1 
6. NCI_84100_a -10.9 1 6. NCI_227186_b -10.9 1 
7. NCI_116702 -10.8 1 7. NCI_84100_b -10.9 2 
8. NCI_19990_a -10.8 1 8. NCI_7524_a -10.9 1 
9. NCI_227186_a -10.7 1 9. NCI_116702 -10.8 1 
10. NCI_227186_b -10.6 1 10. NCI_308835 -10.8 1 
(a) In VST1, the grid box is fixed at the centre of the structure (-23.7 Å, 1.8 Å, 23.4 Å) 
with dimensions of 108 Å × 126 Å × 62 Å (PDB id: 3N40). (b) In VST2, the grid box is 
centred at the centre of the structure (-26.4 Å, 7.1 Å, -24.5 Å) with dimensions of 84 Å 
× 126 Å × 74 Å (PDB id: 3N42). The origin and axes of the coordinate systems were set 
as in the PDB structure. 
 
Pocket 1 and Pocket 2 were found to be similar in both the immature and mature form 
structures, even though some residues from the E2 domain forming the pocket were 
different. This may be due to a difference in these two structures in the virus 
attachment. For the both structures, immature and mature structures, Pocket 1 was in 
between E2 domain A, E2 domain C, and E1 domain II which was a favourable place 
for most of the ligands. Pocket 2 located at the E2 β-ribbon. Pocket 1 was corresponding 
to the combined Site 1 and Site 2 identified previously.362 In the mature structure, 
Pocket 3 was in the region of between E2 domain C, E1 domain I, and E1 domain III 
while Pocket 4 was behind the fusion loop and between E2 domain A, E2 domain B, 
and E1 domain II. Pocket 2 was a novel binding pocket identified in the 3N40. Pocket 2 
and Pocket 3 were two new binding pockets in the 3N42, while Pocket 1 and Pocket 4 
have been reported.362 Most of the pockets included some E1 and some E2 residues. 
The locations of the pockets along with the top hit compounds, are illustrated in Figure 
4.2, and the residues making up each pocket are listed in Table 4.5. Using an increase of 
the value of a search space parameter (E) from the default value E=8 to E=16, 32, 128, 
256, and 1024 to investigate the sampling convergence in Vina, the results were 
presented in Table 4.2 and 4.3 for two glycoprotein complexes. 
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Table 4.2. Results of the top ten compounds of blind dockings for the immature structure. The binding affinities are in kcal/mol. 
The grid box is fixed at the centre of the structure (-23.7 Å, 1.8 Å, 23.4 Å) with dimensions of 108 Å × 126 Å × 62 Å (PDB id: 3N40): (a) VST3: 



































































































 (-11.0)  
8. NCI_60785_b 
(-11.0)  

















 (-10.8)  
8. NCI_202386 
(-10.8)  
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Table 4.3. Results of the top ten compounds of blind dockings for the mature structure. The binding affinities are in kcal/mol. 
The grid box is fixed at the centre of the structure (-26.4 Å, 7.1 Å, -24.5 Å) with dimensions of 84 Å × 126 Å × 74 Å (PDB id: 3N42): (a) VST3: 

























   
1. NCI_293778 
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8. NCI_84100_b  
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8. NCI_227186_b 
(-10.9)  
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Table 4.4. Results of the top ten compounds of focused dockings for the immature and mature structures. The binding affinities are in kcal/mol. 
(a) In VST1a, VST2a the grid box is fixed at the centre of Pocket 1 and Pocket 2 of the immature structure (-22.3 Å, 18.3 Å, 26.3 Å; -15.9 Å, 1.5 
Å, 19.7 Å; respectively) with dimensions of 20 Å × 20 Å × 20 Å (PDB id: 3N40). (b) In VST1b, VST2b, VST3b, and VST4b, the grid box is fixed 
at the centre of Pockets 1, 2, 3, and 4 of the mature structure (-21.3 Å, -11.7 Å, -24.9 Å; -22.4 Å, -4.2 Å, -11.9 Å; -5.7 Å, 31.2 Å, -8.9 Å, -44.7 Å, 
-39.8 Å, -38.2 Å respectively) with dimensions of 20 Å × 20 Å × 20 Å (PDB id: 3N42). The origin and axes of the coordinate systems were set 
the same as in the PDB structure. 









5. NCI_84100_b  
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(-10.0) 
5. NCI_116702   
(-9.9) 
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 (-9.9) 
7. NCI_121868_a 
 (-9.8)  
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5. NCI_116702  
(-10.8)  
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5. NCI_332670  
(-9.4)  
6. NCI_328101  
(-9.3) 
7. NCI_60785_a 























8. NCI_645330  
(-9.3) 
9. NCI_97920  
 (-9.2) 







Figure 4.2. Representation of docked structures of top hit compounds in different 
virtual screenings showing the location of the pockets: (A) Pocket 1 with ligand 
NCI_293778 (L1) and Pocket 2 with ligand NCI_67436 (L2) in the immature 
structure (PDB id: 3N40); (B) Pockets in the mature structure (PDB id: 3N42): 
ligand NCI_293778 (conformation L1) in Pocket 1, ligand NCI_67436 (L2) in 
Pocket 2, ligand NCI_61610 in Pocket 3 (L3), and ligand NCI_293778 
(conformation L4) in Pocket 4.  
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Table 4.5. Residues making up the pockets for two structures, the immature (PDB id: 3N40) and mature structure (PDB id: 3N42). 
 Location The immature structure  The mature structure 
Pocket 1 Between E2 domain 
A, E1 domain II, and 
E2 domain C 
E1 residues: Glu50, Tyr51, Lys52, Thr53, Val54, 
Ile55, Tyr180, Lys181, Asp183, Tyr185, Gln222, 
Tyr242, His230, Val231, Pro232, Tyr233, Gln235, 
Ser238, Lys241, Tyr242, Leu244, Lys245, Arg247, 
Gly248, Ala249, Ser250, His253 
E2 residues: His82, Glu99, Arg100, Ile101, Arg102, 
Asn103, Thr106, His191, Pro192, Phe193, His194, 
Asp196, Pro198,  Val199, Ile200, Gly201, Leu215, 
Pro216, Glu232, Tyr301, Asn302, Pro304, Leu305 
 
E1 residues: Glu50, Tyr51, Lys52, Thr53, 
Val54, Ile55, Tyr180, Lys181, Asp183, Tyr185, 
Gln222, Tyr242, His230, Val231, Pro232, 
Tyr233, Gln235, Ser238, Lys241, Tyr242, 
Leu244, Lys245, Arg247, Gly248, Ala249, 
Ser250, His253 
E2 residues: Glu35, Arg36, Ile37, Gln39, 
Glu40, Ala41, Thr42, His127, Pro128, Phe129, 
His130, His131, Glu168, Tyr237, Asn238, 
Pro240, Leu241 
Pocket 2 E2 β-ribbon E2 residues: Pro198, Val199, Phe205, His206, 
Arg208, Arg331 
E2 residues: Asp43, Arg104, Pro133, Pro134, 
Val135, Ile136, Lys140, Phe141, Arg144, 
Thr155, Val264, Cys266, Arg267 
 
Pocket 3 Between E2 domain 
C, E1 domain I, and 
E1 domain III 
 E1 residues: Gly12, Val13, Pro14, Ser310, 
Asp311, Phe312, Phe321, Ala336, Ala359,  
Asn389, Tyr390, Pro391, Ala392, Ser393, 
Ala336, Thr338, Ser357, Thr358 
E2 residues: Pro335, Tyr336, Lys337 
 
Pocket 4 Behind the E1 fusion 
loop and between E2 
domain B, E2 
domain A, and E1 
domain II 
 E1 residues: Lys61, Cys62, Tyr93, Phe95 
E2 residues: Asp174, Arg198, Tyr199, Lys200, 
Glu208, Gly209, His226, Ala228, Glu247 
 
Chapter 4. Envelope glycoproteins 
125 
 
4.3.2 IDENTIFICATION OF POTENTIAL BINDING POCKETS USING 
DIFFERENT METHODS 
 
The receptor cavities tool in Accelrys DS software and MetaPocket, were utilized to 
identify possible binding sites in the structures. Using Accelrys DS, four pockets 
mentioned above were found in both structures. Some additional pockets are also 
found in two structures (Appendixes 28-29). No potential binding site was detected 
using MetaPocket. Table 4.6 shows a comparison of identified binding pockets using 
different methods.  
 
Table 4.6. Comparison of locations of identified binding pockets in both structures 
using different methods, blind dockings and the receptor cavities tool in Accelrys 
Discovery Studio program, and compared with previous study.  




Between E1 domain II and E2 domain 
A, and E2 domain C 
Pocket 1 Pocket 1 Site 1 
Between E1 domain II and near the E2 
β-ribbon 
Pocket 1 Pocket 1 Site 2 
At the E2 β-ribbon Pocket 2 Pocket 2 No 
Behind the fusion loop, between E1 
domain II, E2 domain B, E2 domain A 
No Pocket 4 Site 4 
Between E1 domain I, E1 domain III, 
and E2 domain C 
No Pocket 3 No 
 
Among the pockets, Pocket 1 was the largest (with its volume 352 Å3 in the 3N40 
and 621 Å3 in the 3N42), accommodating most ligands, while the other pockets were 
narrower and shallower (Pocket 2 in 3N40, 3N42 were 123 Å3 and 156 Å3, 
respectively; Pocket 3 in 3N40, 3N42 were 42 Å3 and 129 Å3, respectively; and 
Pocket 4 in 3N40, 3N42 were in turn 26 Å3 and 523 Å3, respectively), illustrated by 
the volumes in Appendixes 28-29 for the 3N40 and 3N42, respectively. Additionally, 
a comparison of the volumes of these four pockets between the immature and mature 
forms revealed that Pocket 4 near the fusion loop was much bigger in the mature 
form (523 Å3) than the immature form (26 Å3). Therefore, small molecules can bind 
more easily to this pocket in the mature structure with significant effects; including 
blocking the relative movement of E2 domains A and B, and also freezing the fusion 
loop by stabilizing interactions; this could lead to prevention of the exposure of the 
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fusion loop. These findings were in accordance with the previous results.362 
However, because the Accelrys program also considered small cavities as potential 
binding pockets, the cavities (Appendixes 28-29) were located by Accelrys which 
were not found by docking.  
 
4.3.3 ANALYSIS OF INTERACTIONS BETWEEN HIT COMPOUNDS 
AND THEIR BINDING POCKETS  
 
The binding affinities of all of hit compounds were approximately -10 kcal/mol, 
which indicated favourable interactions with the two structures in all of the identified 
binding pockets. It should be noted that focused dockings introduce new hits 
compounds. Docking analysis revealed some key residues for interactions between 
both the 3N40 and 3N42 structures and the ligands, listed in Table 4.7. The 
interaction of these key residues are illustrated in Figures 4.3 and 4.4 (details in 
Appendixes 30-49). For Pocket 1 and Pocket 4, the key residues in Table 4.7 were in 
close agreement with the published findings.362 Interestingly, there was a change of 
key residues in E2 of Pocket 1 from the immature to mature structure; for example 
residues involved in forming hydrogen bonds in E2 were Arg100, Tyr301 in the 
immature form corresponding to Arg36, Tyr237 in the mature form. The ligands 
bound to Pocket 1 were expected to have higher affinities than others due to their 
interactions with E1 or E2 through formation of hydrogen bonds, which may 
stabilize the E1-E2 heterodimer and prevent dissociation.362 The residues in Pocket 4 
could interact with the E1 fusion loop including Gly91 and His230, which emphasize 
their importance in impairment of the fusion process. In particular, His230 was 
reported to be important in stabilization of the fusion loop. In most of the hydrogen 
bonding interactions in both structures, the ligands acted as donors; for example, 
ligands NCI_61610, NCI_84100_a, NCI_116702, NCI_156219_b, and 
NCI_227186_a in the immature form; or NCI_7524_a, NCI_61610, NCI_84100_b, 
NCI_116702, NCI_156219_b, and NCI_227186_b in the mature form. In contrast, 
some ligands, such as NCI_227186_b in the 3N40 or NCI_61610 in the 3N42, were 
hydrogen bonding acceptors.  
 
 



















Table 4.7. Key residues for interactions in both envelope glycoprotein structures at 
each of binding site.  
Binding 
pocket Immature structure (3N40) Mature structure (3N42) 
Pocket 1 E1 residues: Tyr51, Thr53, Tyr233, 
Ser238 
E2 residues: Arg100, Ile101, Asn103, 
Pro192, Tyr301 
E1 residues: Glu50, Tyr51, 
Lys52, Thr53, Ile55, Tyr242, 
Ser238 
E2 residues: Arg36, Pro128, 
Tyr237 
 
Pocket 2 E2 residues: Arg168, Pro170, Pro198, 
Val199, Ile200, Phe205, His206 
 
E2 residues: Asp43, Ile136, 
Arg144, Arg267 
Pocket 3  E1 residues: Phe312, Tyr390 
E2 residues: Tyr336 
 
Pocket 4  E1 residues: Lys61, Cys62 and 
Tyr93 


























































Figure 4.3. Hydrogen bonding analysis of compounds with the immature structure in 
docking: (a) NCI_61610, (b) NCI_84100_a, (c) NCI_116702, (d) NCI_156219_b,  
(e) NCI_227186_a. The key residues involved in the interactions between 
glycoproteins and ligands are shown. The ligands (in cyan) and the residues 
surrounding the ligands (in grey) were displayed in sticks and coloured by atoms 
(carbon in cyan in ligand or in grey in residues, nitrogen in blue, oxygen in red, 
sulphur in organge).  
 
  

















































































Figure 4.4. Hydrogen bonding analysis of compound with the mature structure: (a) 
NCI_7524_a, (b) NCI_61610, (c) NCI_156219_b, (d) NCI_227186_b, (e) NCI_84100_b. 
The key residues involved in the interactions are also shown. The ligands (in cyan) and 
the residues surrounding the ligands (in grey) were displayed in sticks and coloured 
by atoms (carbon in cyan in ligand or in grey in residues, nitrogen in blue, oxygen in 
red, sulphur in organge).  
 
 
4.3.4 SAMPLING CONVERGENCE IN AUTODOCK VINA 
 
As previously mentioned, the value of exhaustiveness (E) or a search space 
parameter in AutoDock Vina was increased from the default value E=8 to E=16, 32, 
128, 256, and 1024 to investigate the searching convergence in docking. The results 
of top hit compounds are listed above in Table 4.2 and Table 4.3. These tables 
demonstrate that the exhaustiveness parameter greatly affected the searching process 
for ligands conformations in docking. Analysis of docking results revealed that the 
blind dockings with an increase in the exhaustiveness allowed new binding pockets. 
For instance, in the immature structure, Pocket 2 appeared in docking for E = 16-
1024, though was not present for E=8. In the mature structure, Pocket 2 and Pocket 3 
were introduced in docking with E = 16, 32, 128 instead of using E=8. It is 
encouraging to see the frequent presence of top hit compounds in most blind docking 
procedures. Interestingly, the hit compounds maintained their conformations at the 
same binding site despite changes to the E value, which brings further confidence in 
sampling convergence. 
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4.3.5 ANALYSIS AND SELECTION OF HIT COMPOUNDS FOR 
BIOLOGICAL TESTING 
 
The results obtained from all dockings showed that some compounds could bind in 
many docking procedures. They seem to possess higher potential than other 
compounds. The binding affinities of most of them were from -10 to -13 kcal/mol 
indicating good binding affinities between the ligands and the envelope glycoprotein 
complexes. As mentioned previously, the compounds which bound to Pocket 1 and 
Pocket 4 were expected to be inhibitors targeting the glycoprotein complexes, as they 
could interact with the residues involved in the process of virus attachment and virus 
entry. Therefore, based on the binding affinities of hit compounds obtained from 
blind and focused dockings, and analysis of the interactions between the compounds 
and the envelope glycoproteins complexes, the proposed potential lead compounds 
for biological testing are NCI_293778 (from -11.4 to -13.7 kcal/mol), NCI_61610 
(from -11.6 to -12.3 kcal/mol), NCI_37553 (-11.5 kcal/mol), and NCI_156219 (-11.1 
kcal/mol). (Table 4.8). 
 
In docking, the protein structure was kept rigid, so the selection of hit compounds 
from molecular docking is a good starting point for anti-CHIKV drug discovery. 
More accurate binding free energies are expected to gain from molecular dynamics 
simulations, however, given the larger sizes of these glycoproteins complexes, this 
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Table 4.8. Potential lead compounds for the envelope glycoproteins proposed for 
biological testing.  


































































Taking advantage of the envelope glycoprotein complexes, virtual screening based 
on blind docking and focused dockings explored the potential binding pockets and 
inhibitors for both the immature and mature structures of envelope proteins. 
Promising hit compounds were identified for two complexes of the envelope 
glycoproteins. Pocket 2 was a novel binding site in the immature structure. Pocket 2 
and Pocket 3 were novel binding sites for the mature complex of the glycoproteins. 
The key residues involved in stabilizing the complex or participating in the fusion 
process were confirmed. This study also supported the current docking protocol 
utilising AutoDock Vina as robust and with a good accuracy, and could be used to 
indentify inhibitors. However, due to larger size of two complexes of glycoproteins, 
the immature and mature structures, molecular dynamics simulations could not be 
carried out during the project. Therefore, the results of hit compounds and their 
binding modes obtained from docking are a good starting point for further studies. 
Further experiments are required to test the inhibitory effects for the anti-CHIKV 





CHAPTER 5. DISCUSSION OF FINDINGS  
As there is little information available investigating CHIKV drug discovery, this 
study undertook to establish a computational framework to identify novel inhibitors 
for CHIKV. This combined the strength of molecular docking, virtual screening, 
molecular dynamics simulations and free energy calculations. The X-ray crystal 
structures used were of high resolution and the results provide valuable information 
about inhibitors of CHIKV, not previously available from previous studies involving 
homology modeling. The information could also be used for further steps to optimize 
the hit compounds into lead compounds. This chapter extends the discussion from 
each chapter in an attempt to gain a comprehensive of the various strengths and 
limitations.  
 
5.1 SELECTION OF LEAD COMPOUNDS FOR BIOLOGICAL 
TESTING FOR CHIKV 
 
The potential lead compounds for CHIKV were identified based on the results of 
molecular docking, molecular dynamics simulations and binding free energy 
calculations for each protein targets of CHIKV, including nsP3 macrodomain, nsP2 
protease and envelope glycoproteins.  
 
Virtual screening based on docking has shown successfully the ability to predict 
binding affinities of ligands when they interact with the protein of interest. The top 
ten hits (or the best binders), with high binding affinities, were selected as potential 
inhibitors. They all showed a good fit in the binding sites through interacting with 
protein residues such as H-bonds or hydrophobic contacts. For each docking run, the 
real difference between binding affinities for the top ranked compounds was in the 
diversity of chemical structures as well as the shape and size of binding site. There 
appears to be little correlation between structures and the binding affinities. 
However, the smaller molecules may not utilise the full binding potential of the 
pocket. Most pockets are hydrophobic and of the resulting hits therefore contained 
aromatic rings such as benzimidazole, quinoline, quinoxaline, oxazole, and 
thiophene. These rings could interact with the aromatic rings of protein residues Tyr, 
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Trp, Phe and His in the pockets by π-π stacking or π-network to stabilize and 
maintain the interaction of protein and ligands. The phenyl rings made hydrophobic 
contacts with protein residues. The ligand backbone containing nitrogen and oxygen 
atoms in combination with functional groups such as OH-, NH-, C=O in the side 
chains contributed in forming H-bonds with protein residues as the hydrogen 
bonding acceptors mostly and occasionally donors. These key interactions between 
protein and ligands are defined based on the chemical features of ligands. This study 
demonstrated that depending on each protein target, hydrophobic interactions or 
hydrogen bonding interactions would play an important role in stabilizing the 
binding. For example, in the case of nsP3 protein, H-bonds showed more 
contribution in Pocket 1 and Pocket 3 while hydrophobic interactions are more 
favourable in Pocket 2. For the nsP2 protease, in the active site, interactions were 
stabilized by forming H-bonds with the catalytic dyad. Suggestions for regions of 
modifying the structure to aid the design of new compounds with higher affinities 
were considered, e.g, the adding of heteroatom into the aromatic rings or functional 
groups to balance the hydrophobicity of ligands. Further, a pharmacophore model for 
CHIKV inhibitors, could be constructed in the next step. For instance, the case of 
targeting CHIKV nsP2 protease, it is likely that a model would include an aromatic 
ring, a hydrophobic and two hydrogen bond donor sites. 
 
In addition, it is also apparent that the size of compounds with diverse spatial 
orientations of aromatic rings or the conformational complexity of compounds, as 
well as the shape and the size of binding sites would affect their binding affinities. It 
was found that some hits having bulky structures molecules, for example 
NCI_61610, NCI_293778, could fit well in the large binding sites, for example, in 
the case of Pocket 1 of nsP3, so they would show good binding scores. Conversely, 
in the case of ligands of bigger size or the binding size not particular large, the 
molecules protruded and did not bind correctly, such as in the Pocket 2 of nsP3.  
 
The application of Lipinski’s Rule of Five to the top ten hits does not provide good 
immediate outcomes. This procedure would help to evaluate the drug-likeness of 
these specific derivatives for oral drugs. The results revealed that some compounds 
did not satisfy the conditions, however they were still selected for biological testing. 
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The major reason for that as there is not a current drug for CHIKV treatment, the 
need for a treatment means that the lack of oral administration requires alternative 
administration, e.g. intravenous route delivery. More importantly, the revealed hit 
compounds were never actually considered to be possible drugs themselves, 
however, as hits, medicinal chemistry studies investigate modifications to allow for 
the synthesis of more drug-like compounds. For instance, NCI_293778 has a logP of 
10.87 and although it showed good interactions and a high binding affinity, 
modification would be required for them to be considered in the future as orally 
available drugs. 
 
Furthermore, when combing the results of all three targets, some virtual hits overlap 
multiple times with different pockets of a single protein, and also appear in different 
protein targets. It could also be the nature of the molecules themselves that makes 
them in the top of different screens. A prime example of this is the NCI_61610 
molecule, which was the top hit for both protein nsP3 and nsP2 and one of the 
highest scoring inhibitors for envelope glycoproteins. Thus, this could be a promising 
lead compound for multi-pathway inhibitions, however, it may require studies of 
structure-activity relationship to avoid non-specific activity. For example, 
NCI_61610 has also shown anti-inflammatory effect in mice model.363  
 
Molecular dynamics simulations and linear interaction energy calculations were 
subsequently carried out which helped to look at insights into the interactions 
between proteins and ligands and to obtain more accurate binding affinities. 
Importantly, the outcomes also confirmed the stability of the complexes and 
validated the docking outcomes. The results revealed that the systems were stabilized 
during 50 ns simulations. Although there are some fluctuations, as discussed in each 
case in the previous chapters, the interactions of lead compounds and proteins were 
also maintained by H-bonds or hydrophobic contacts. The residues of protein and 
ligands adapted to enhance these interactions. For example, some H-bonds in 
docking were weak and not sufficiently stable, but were enhanced after the molecular 
dynamics simulations to new, stronger H-bonds, improving the binding in the case of 
nsP2 protease. Interestingly, with the ligands that could bind to the different binding 
pockets, the simulation results provided details of intermolecular interactions through 
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occupancy of H-bonds and hydrophobic contacts to compare the binding affinities 
for ligand. Therefore, the more accurate binding energies were gained from the 
simulations results. However, there was a place for discussion of a challenge in the 
binding free energy calculations in the cases.  
 
Finally, analysis of the results showed that one of the next vital steps would be the 
building of scaffolds for CHIKV inhibitors based on the obtained lead compounds. 
More importantly, identified leads should be further validated in the laboratory for 
their ability to actually bind to the protein target and modulate its activity, and 
whether there are some allosteric sites in the protein targets or not. 
 
5.2 IDENTIFICATION OF POTENTIAL BINDING SITES IN A 
PROTEIN TARGET 
 
There are different methods to explore binding pockets in the protein (outlined in the 
Introduction chapter). Because the ligand is not co-crystalised explicitly with the 
protein nsP2 or envelope glycoproteins, the location of binding site is not defined. 
Blind docking into an entire protein is a common approach to see which residues the 
ligand associates with. By analysing in a 5Å radius from where the ligand binds, 
these residues may be detected, and thus inferred in making up the binding pocket. 
The most important aspect is its ability to differentiate the real binding site from non-
specific and energetically unfavorable ones based on the inbuilt scoring function. 
The ligand binding assay is required to verify the data in this case as there is no 
literature published about on this area. 
 
Using the other programs such as MetaPocket or detection of cavities tool in 
Accelrys Discovery Studio can search for potential binding sites. There was an 
agreement between them in terms of location of binding sites. In particular, the 
MetaPocket program combining eight programs showed better correlations with 
blind docking. However, limitations discussed previously in the studies involving the 
envelope glycoproteins were that some detected sites were not large enough for 
ligand binding. 
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5.3 EVALUATION OF COMPUTATIONAL APPROACHES 
AND THEIR COMBINATION 
 
Molecular docking is a computationally efficient method which helps to screen a 
large library of compounds with efficient time and low cost. Notwithstanding, it also 
shows some methodological deficits, for example, using one conformation of protein 
with the protein kept rigid, ignoring protein desolvation and most entropic terms, 
neglecting internal energies of docking molecules and using simplified models of 
solvation energies for the ligand. Therefore, a critical assessment of docking and 
virtual screening was undertaken. First was the evaluation of the ability to replicate a 
protein-bound conformation. In this study, a docking protocol was evaluated by 
reproducing results from experimental data. Docking provided multiple docking 
poses for each ligand and a RMSD for all poses with respect to the top hit. The 
results of the RMSD for ligand heavy atoms was within 2 Å and also showed high 
binding affinities with the similar residues for interactions in the nsP3-ADP-ribose 
complex. The scoring function, with a semi-empirical algorithm, was successful in 
identifying the pose similar to the co-crystal structure. Different binding 
conformations for each individual ligand are ranked based on affinities and the 
highest for each ligand compared to determine the best lead. In addition, the accuracy 
of docking was examined carefully by investigation of the searching convergence of 
docking. The increasing of a searching parameter indicated some new hits (Section 
4.3.4). However, decoy molecules, which are competitive binding with ligands were 
not used in the screenings. Therefore, experimental studies such as ligand binding 
assays and cell-based assays are needed to obtain the IC50 value, to evaluate the 
accuracy of scoring i.e. to eliminate false positives, and to determine the validity of 
the screens which answer the question of whether docking provides a true ligand 
among top scoring compounds. 
 
Molecular dynamics simulations were applied to consider protein flexibility and the 
solvent effect which are missing in docking. The simulation required significantly 
more computing-time and power than the docking approach, and convergence of 
simulation ensured. Furthermore, the similar chemical structures were clustered to 
search for the most popular conformation during simulations. The resulting 
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simulations were used to calculate binding free energy more accurately than the 
results from docking. However, the challenge in the LIE method lies in the 
parameterization of the required co-efficients, which rely on the availability of 
experimental data. The final limitation was the time and computational cost for 
simulations, such as with large protein, for example envelope glycoproteins, which 
could be rectified given more time.  
 
In summary, a combination of docking and MD simulations showed a potential 
approach that balances the computational cost and accuracy. More importantly, the 
procedure can be applied in discovering therapeutic compounds for other diseases. It 





CHAPTER 6. EXPERIMENTAL PROCEDURES          
AND METHODS 
 
6.1 GENERAL PROCEDURE FOR MOLECULAR DOCKING AND 
VIRTUAL SCREENING  
 
The process of docking and virtual screening was carried out using AutoDock Vina 
(version 1.1.2).203 AutoDock Vina is an open-source program which can be downloaded 
from the website http://vina.scripps.edu. This program is designed in a similar manner 
to AutoDock, based on pairing an empirical-weighted scoring function with a global 
optimization algorithm.227 Vina significantly improves the accuracy of binding mode 
predictions and ranking for larger molecules in terms of molecular weight and rotatable 
bonds.203, 227 Vina also shortens running time in screening compared to AutoDock by 
using multiple CPU or CPU cores on the system. Vina can be run on 32-bit binaries or 
modern 64-bit machines with Windows, Linux, and Mac operating systems. In general, 
the protein was kept rigid while the ligands were fully flexible, however, some 
sidechains of residues in the protein can be selected as flexible residues in docking. The 
Lamarckian genetic algorithm was used to search space for docking and the binding 
affinity of a complex was calculated on the basis of a set of weighted energies in 
empirical-scoring function (a united-atom scoring function involving the heavy atoms). 
Calculating grid maps and assigning atom charges are not required in Vina.  
 
A protocol was established to carry out docking and in silico screenings (described 
below). The key docking parameters were defined by the location of the docking site 
(centre x, y, z) and the size of a grid box of search space. The size of the box was no 
less than 15 Å in each dimension and larger than the size of the ligand, and no less than 
22.5 Å total.344 For virtual screening, the location and the size of the grid box were 
carefully investigated via blind docking (in which the box is sufficiently large to cover 
the whole protein) and focused docking (in which a smaller box was centred on the 
potential binding site of interest).  
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After docking, the results were analyzed and compared with available experimental 
data. The top ten compounds (“hits”) were identified according to their binding 
affinities using the default scoring function in Vina. The modes of interaction between 
the ligands and the protein were analyzed in Accelrys DS 3.5.  
 
6.1.1 DOCKING PROTOCOL 
 
The docking protocol using AutoDock Vina (Figure 5.1), includes three main steps: 
Step 1: Prepare a protein and a ligand (file *.pdbqt). 
Step 2: Define parameters for the grid box size and centre of the box, and other 
parameters such as exhaustiveness and number of binding modes to generate 
(num_modes). 


















Figure 6.1. A diagram of the docking procedure in AutoDock Vina. 
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6.1.1.1 Preparation of a protein target 
 
The 3D crystal structure of the protein (file *.pdb) was obtained from the Protein Data 
Bank website (http://www.rcsb.org), and served as the protein target in molecular 
docking. Details of preparation procedure were presented as follows:  
• Edit and correct this structure by using Procheck (WhatIF) website 
(http://swift.cmbi.ru.nl/servers/html/) to upload the file to detect potential errors.  
• Correct the errors from chirality (atoms CG2, CG1), side chain flip of amino acids 
residue His (atoms CD2, ND1, NE2 and CE1), Asn (atoms ND2 and OD1), Gln 
(atoms OE1 and NE2). Missing residues for a protein were added. 
• Minimize the structure energy in Accelrys DS visualizer 2.0 software342: Apply 
CHARMM22 force field and set up parameters for minimization such as steepest-
descent algorithm (3000 steps), and default for other parameters. 
• Prepare file *.pdbqt for protein and ligand: Using AutoDock Tools to generate file 
*.pdbqt automatically by uploading the file pdb of protein and ligand, and then add 
polar hydrogens.  
 
6.1.1.2 Preparation of a ligand  
 
The ligand structure was generated by OpenBabel 2.3.1 based on the ChemDraw 
formula. In a case there is a co-crystal structure, the ligand structure could be extracted 
from the PDB file. The chemical libraries of the NCI Diversity Set II, which contains 
diverse drug-like compounds, were selected for screening. The potential hits obtained 
from docking can be ordered from the Open Chemical Repository Collection for future 
activity testing. 
 
6.1.1.3 Docking parameters 
 
The grid box size was chosen to be large enough to cover the ligand but as small as 
possible to ensure sufficient conformational sampling within available searching space. 
The value of search space should be no bigger than 30 Å × 30 Å × 30 Å, otherwise the 
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search algorithm may suffer from insufficient sampling. An increase to the value of the 
exhaustiveness is thus applied in the case of blind docking.  
 
The preparation of the grid parameter file was done by using AutoDock Tools 1.5.4: 
Adjust the grid box manually to get the suitable parameters which cover the entire 
protein or the binding site, and taking note the x, y, z coordinates of the centre and sizes 
in the x, y, z dimension (Å) of the grid box. 
 
Other parameters are the number of CPUs to use (--cpu), explicit random seed (--seed), 
exhaustiveness of the global search (--exhaustiveness, E), maximum number of binding 
modes to generate (--num_modes), maximum energy difference between the best 
binding mode and the worst one (--energy_range, unit: kcal/mol), and weight of 
docking algorithm (--weight). The docking parameters can be set with default values 
(listed in Table 5.1) or changed depending on the aims of the study. E value can be 
increased to expand the search space for searching conformations of complex. 
 
Table 6.1. Default values of docking parameters. 
Docking parameter Default value 
Number of CPUs 1 





6.1.1.4 Preparation of a configuration file (conf.txt) 
 
File configuration includes protein and ligand file inputs (*.pdbqt), the values of centre 
and size of of a grid box (centre_x, centre_y, centre_z; and size_x, size_y, size_z), and 
docking parameters. 
 
Details for molecular docking with different CHIKV protein targets in this study were 
described as follows. 
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6.1.2 PREDICTION OF BINDING SITES ON PROTEIN 
 
In docking with AutoDock Vina, the grid box used for docking will be defined easily if 
the location of ligand binding is known. However, in some cases where the binding sites 
are unknown or one would like to explore alternative binding sites, computational 
methods such as blind docking, MetaPocket, Accelrys DS can be applied to predict 
potential binding sites. 
 
6.1.2.1 MetaPocket 2.0343 
 
The procedure includes three stages, namely calling based methods, meta-pocket site 
generation, and mapping binding residues. Given protein structure, there will be 8 
predictors, namely LIGSITEcs, PASS, Q-SiteFinder, SURFNET, Fpocket, GHECOM, 
ConCavity, and POCASA to identify pocket sites on the protein surface. All the 
predictors are run in parallel and a ranking-scores comparable, z-score is calculated 
separately for each pocket site in different predictors. The pockets will be clustered in 
terms of their spatial similarity and total z-score values. The final pocket sites are the 
potential ligand binding sites on protein surface. The potential binding pockets were 
obtained by the webserver http://projects.biotec.tu-dresden.de/metapocket/index.php, 
taking 5-10 minutes to get the potential pockets depending on the protein size. 
 
6.1.2.2 Receptor cavities tool in Accelery Discovery Studio 3.5 
 
Accelerys DS 3.5 package342 was also applied to explore potential binding sites using a 
receptor cavities tool. Based on a grid search and “eraser” algorithm, the program 
defines location of binding sites from receptor cavities in the structure of protein. The 
binding sites were displayed as a set of points (points count), and their volumes were 
calculated as the product of number of site points and the cube of the grid spacing. 
These pockets were compared to those identified in blind dockings in terms of location 
for both of the envelop glycoprotein structures. 
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6.1.3 APPLYING A DOCKING PROCEDURE  
 
6.1.3.1 The nsP3 macrodomain 
 
The nsP3 macrodomain protein was downloaded from the Protein Data Bank (PDB id: 
3GPG) and this was used as the receptor for docking. The docking protocol was 
established by re-docking the ADP-ribose into the nsP3 as observed in the co-crystal 
structure (PDB id: 3GPO). The ligand ADP-ribose was extracted from the complex 
crystal structure. The protein structure was edited and uploaded into the Procheck 
(WhatIF) website, and manually corrected some errors present in sidechains of His, 
Asn, and Glu flips. The next step is running energy minimization to relax the structure 
and remove steric overlaps. With a Cα RMSD of 0.59 Å between the minimized 
structure and the X-ray structure, the minimized structure was utilized for the docking 
process. Polar hydrogen atoms were added and save into file *.pdbqt format in 
AutoDock Tools. 
 
Using AutoDock Tools, the binding site was defined as the place where ADP-ribose 
binds. The values of different grid box dimensions and its centre were used for docking 
and screenings, listed in Table 5.2, (See more discussion in Chapter 2). 
 
Table 6.2. Parameters of a grid box in different docking and virtual screenings for the 
nsP3 protein.  
Docking and virtual screening x, y, z coordinates Dimension of a grid box 
Pocket 1 9.7 Å, 43.0 Å, -13.2 Å 16 Å × 16 Å × 16 Å 
Pocket 2 9.7 Å, 43 Å, -13.2 Å 20 Å × 20 Å × 20 Å 
Blind docking  
(at the centre of Pocket 1) 
9.7 Å, 43 Å, -13.2 Å 50 Å × 50 Å × 56 Å 
Blind docking  
(at the centre of the protein) 
7.7 Å, 45.3 Å, -5.3 Å 50 Å × 50 Å × 56 Å 
Pocket 2  7.7 Å, 45.4 Å, 11.5 Å 20 Å × 20 Å × 20 Å 
Pocket 3 2.3 Å, 44.6 Å, -18.3 Å  20 Å × 20 Å × 20 Å 
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6.1.3.2 The nsP2 enzyme 
 
The 3D crystal structure of the nsP2 protease of CHIKV was obtained from the Protein 
Data Bank (PDB id: 3TRK) and served as a protein target in docking. Using Procheck 
(WhatIF), no errors were found. Water molecules and the other co-factors were deleted. 
 
The structures of the four best compounds taken from the previous study351 were drawn 
in ChemDraw (ChemBioDraw Ultra 13.0) and then converted to 3D structure using 
OpenBabel. These compounds were docked into the nsP2 protease based on the key 
residues of Pocket 1 identified in the previous study.351 The preparation of docking was 
the same as previously, and Pocket 1 was confirmed. The blind dockings, with a grid 
box size of 60 Å × 70 Å × 60 Å at the  centre of protein,  and with a grid box size of 66 
Å × 86 Å × 70 Å at the centre of the binding site, were carried out. Focused docking 
with a smaller box (20 Å × 20 Å × 20 Å), centred on the potential binding sites of 
interest was then undertaken. Additionally, the MetaPocket was used to identify 
potentially pocket sites of the nsP2 other than the active site.343  
 
The values of different grid box dimensions and its centres were used for docking and 
different screenings, listed in Table 5.3, (See more discussion in Chapter 3). 
 
Table 6.3. Parameters of a grid box in different docking and virtual screenings for the 
nsP2 protease.  
Docking and virtual screening x, y, z coordinates Dimension of a grid box 
Blind docking  
(at the centre of Pocket 1) 
12.4 Å, 34.3 Å, 28.6 Å  66 Å × 86 Å × 60 Å 
Blind docking  
(at the centre of Pocket 2) 
14.3 Å, 25.5 Å, 22.3 60 Å × 70 Å × 60 Å 
Pocket 1  12.4 Å, 34.3 Å, 28.6 Å  16 Å × 16 Å × 16 Å 
Pocket 1  12.4 Å, 34.3 Å, 28.6 Å 20 Å × 20 Å × 20 Å 
Pocket 2  28.1 Å, 36.9 Å, 30.6 Å 20 Å × 20 Å × 20 Å 
Pocket 3  30.4 Å, 42.1 Å, 14.8 Å 20 Å × 20 Å × 20 Å 
Pocket 4  3.2 Å, 31.9 Å, 18.1 Å  20 Å × 20 Å × 20 Å 
Pocket 5  15.2 Å, 13.9 Å, 11.5 Å 20 Å × 20 Å × 20 Å 
 
Chapter 6. Experimental procedures and methods 
147 
 
6.1.3.3 The envelope glycoproteins 
 
Two X-ray crystal structures of envelope glycoprotein, an immature form (PDB id: 
3N40) and a mature form (PDB id: 3N42), were downloaded from the Protein Data 
Bank. The dimensions of the box covering 3N40 and 3N42 were set to 108 Å × 126 Å × 
62 Å and 84 Å × 126 Å × 74 Å, respectively. Potential binding sites were revealed by 
the location of ligands binding into the target. The next step was a focused docking, in 
which a smaller box (20 Å × 20 Å × 20 Å), was centred at the potential binding site of 
interest. The receptor cavities tool in Accelrys DS and MetaPocket program were also 
used to predict other potential binding sites of the envelope proteins.343 
 
The values of different grid box dimensions, and their centres, were used for docking 
and different screenings, listed in Table 5.4, (See more discussion in Chapter 4). 
 
Table 6.4. Parameters of a grid box in different docking and virtual screenings for 
envelope glycoprotein complexes.  
Docking and virtual screening x, y, z coordinates Dimension of a grid box 
Blind docking  
(at the centre of the 3N40) 23.7 Å, 1.8 Å, 23.4 Å 108 Å × 126 Å × 62 Å 
Blind docking 
(at the centre of the 3N42) 
26.4 Å, 7.1 Å, -24.5 Å 84 Å × 126 Å × 74 Å 
Pocket 1 of the 3N40 -22.3 Å, 18.3 Å, 26.3 Å 20 Å × 20 Å × 20 Å 
Pocket 2 of the 3N40 -15.9 Å, 1.5 Å, 19.7 Å 20 Å × 20 Å × 20 Å 
Pocket 1of the 3N42 -21.3 Å, -11.7 Å, -24.9 Å 20 Å × 20 Å × 20 Å 
Pocket 2 of the 3N42 -22.4 Å, -4.2 Å, -11.9 Å 20 Å × 20 Å × 20 Å 
Pocket 3 of the 3N42 -5.7 Å, 31.2 Å, -8.9 Å 20 Å × 20 Å × 20 Å 
Pocket 4 of the 3N42 -44.7 Å, -39.8 Å, -38.2 Å 20 Å × 20 Å × 20 Å 
 
6.2 MOLECULAR DYNAMICS SIMULATIONS 
 
The program NAMD265 was used for MD simulations to investigate the stability and 
flexibility of the hit-target complexes and study their interactions. In this study, a 
general strategy for MD simulations was performed as followings (Figure 5.2): 
 






Figure 6.2. A general scheme for MD simulations. 
 
It includes the following steps: 
Step 1: Generation of the force field parameters (including the parameter and topology 
files) for simulation for protein and ligand. The protein atoms were treated with the 
CHARMM22 force field257 and the corresponding parameters for the ligands were 
generated with AmberTools.262  
Step 2: The systems were solvated in a cubic box of TIP3P water molecules that 
extends 10 Å from the edge. Sodium counterions were added to neutralize the system by 
randomly replacing the water molecules to mimic the physiological concentration of 
0.15 M NaCl. All simulations were run under the periodic boundary conditions. 
Step 3: Energy minimization for the system was conducted using a conjugate gradient 
method to remove the bad contacts. 
Step 4: The system was subjected to a heating procedure. The temperature was set to 
298.15 K, and the pressure to 1 atm. The Langevin algorithm was used to maintain the 
temperature and pressure coupling. The PME algorithm was used to compute long range 
electrostatic interactions.269 The cutoff distance for vdW interactions was set at 12 Å, 
and the pair-list distance was 13.5 Å.  
Step 5: Running equilibrium and production simulations. The equilibrium phase with 
weak harmonic restraints on heavy atoms for 3 ns was carried out. This brings the 
system to equilibration state when the calculated average temperature, pressure, and 
energies were converged or stabilized.  The production phase of the simulation was run 
subsequently and results of MD simulations were analysed based on the production phase. 
 
All of the simulations were run on the high performance computation (HPC) clusters. 
The HPC cluster is comprised of large compute nodes (Model Dell PowerEdge C6145) 
with 16 core-processors, and 256 GB memory. System software provided includes 
Linux or Mac OS client and Windows system operating system. The clusters are 
connected with Interconnect technology from the Linux OS or MS Windows or DOS. 
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Time for running depends on system size. For the nsP3 macrodomain and its 
complexes: 12 simulations were run, including one simulation of apo protein and 11 for 
the complexes of nsP3 and ligands. For the nsP2 protease and its complexes: the 
number of systems was 14 including one simulation of apo protein and 13 for the 
complexes of nsP2 enzyme and ligands. For envelope glycoprotein complexes: due to 
the large sizes of these glycoproteins complexes, the simulations for these complexes 
could not be done in this study. 
 
Analysis of simulations: The trajectories for analysis were saved every 10 ps. To 
determine the system stability, the value of RMSD of the heavy atoms over 50 ns was 
calculated with respect to the starting structure versus the simulation time. The RMSF 
of Cα atoms during the MD simulations was measured to obtain information on the 
local flexibility of the system. The resulting trajectories such as hydrogen bonding and 
hydrophobic contact interactions were analyzed by the CHARMM22263 and VMD 
(version 1.9.1).276 A hydrogen bond was defined as the distance between proton donor 
(D) and acceptor (A) atoms was ≤ 3.5 Å, and the angle D − H⋯A was ≥ 120°.70 If 
occupancy of HBs was more than 75%, they were considered as strong HBs whereas 
HBs occupations of less than 50%, were designated as medium.70 The hydrophobic 
contacts were also monitored based on a cutoff distance between the carbon atoms of 
non-polar parts of residues of proteins and of ligand of 4.0 Å.277-278 The Clustering 
Plugin in VMD is applied for clustering analysis for the snapshots from the trajectories. 
 
6.2.1 SIMULATIONS FOR PROTEIN 
 
MD simulations were conducted for the apo protein and the hit-target complexes 
obtained from virtual screening.  
 
6.2.1.1 The nsP3 macrodomain 
 
MD simulations were carried out for the apo state (PDB id: 3GPG), and 11 ligand-nsP3 
complexes. The total number of atoms (including protein, water, and counterions) in the 
CHIKV system was about 18,000; and the size of the initial water box was about 58 Å × 
58 Å × 58 Å.  
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6.2.1.2 The nsP2 enzyme 
 
MD simulations were conducted for the apo state (PDB id: 3TRK), the 13 complexes of 
the nsP2 protease, and hit compounds obtained from virtual screening. The total number 
of atoms of protein, water, and counterions in the CHIKV system was about 70,000; and 
the dimension of the initial water box was about 90 Å × 90 Å × 90 Å.  
 
6.2.2 SIMULATIONS FOR LIGANDS 
 
Additional simulations of ligands in water were conducted to calculate the binding free 
energies with the LIE method, described in 5.3 section. The other parameters of setting 
up MD simulations were the same as previously used for protein. 
 
6.3 BINDING FREE ENERGY CALCULATIONS  
 
There have been different approaches developed over the years to calculate the ligand 
binding free energies such as free energy perturbation, thermodynamic integration, and 
LIE.316, 328 In this study, an LIE approach was applied to calculate the absolute binding 
free energies for ligands in complexes with the protein targets, the nsP3 macrodomain 
and the nsP2 enzyme. The main reason for this approach is that this method 
compromises between speed and accuracy, and so is more practically feasible for large 
ligands. In addition, we can utilize the results of MD simulations of proteins. Derived 
from the linear response theory, the binding free energies is approximated as  
∆Gbind= α 〈Vboundvdw − Vunboundvdw 〉 + β 〈Vboundelec − Vunboundelec 〉 + γ       (Equation 1.16) 
 
The various van der Waals and electrostatic components can be obtained from two 
simulations: one with the ligand in aqueous solution, and the other with the protein 
(nsP3 or nsP2)-ligand complex in aqueous solution. The NAMDEnergy plugin in VMD 
was utilized to compute the energy components over the frames obtained from the MD 
simulations.265, 276  
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In Equation 1.16, α, β, and γ are empirical parameters. α is often set to 0.18 for a wide 
variety of ligand-protein systems. The β represents a function of the chemical nature of 
the ligand, so in principle the value of β can be parameterized from explicit solvent free 
energy calculations of different chemical entities. The γ parameter can be set γ = 0 or γ ≠ 
0 depending on the hydrophobicity of the binding site to estimate absolute free energies 




CHAPTER 7. OUTLOOK AND FUTURE DIRECTIONS 
 
During the past decade, computational approaches have shown their success and power 
in assisting drug discovery and development. With the emergence or re-emergence of 
some alphaviruses, such as CHIKV, a neglected tropical disease in more than 55 
countries in the word, searching for potential inhibitors to combat the virus in efficient 
time, and in a cost-effective manner is significantly important. Taking advantage of all 
available information on CHIKV, this study examined major potential targets of 
CHIKV. The non-structural proteins nsP3 macrodomain and nsP2 protease were used to 
target the viral replication and transcription (Chapter 2 and Chapter 3). The envelope 
glycoprotein complexes were another potential target as they direct virus entry and 
attachment (Chapter 4). A combination of computational tools; including molecular 
docking, virtual screening, molecular dynamics simulations, and binding free energy 
calculations, were used to identify a number of lead compounds for potential CHIKV 
disease treatment. The insights into the CHIKV inhibitors and their complexes, as well 
as their interaction energies, were elucidated. Our findings provide a foundation which 
would be helpful for further research on rational antiviral drug design, especially the 
design of CHIKV inhibitors. 
 
7.1 NSP3 MACRODOMAIN PROTEIN 
 
Chapter 2 described the attempts at drug discovery targeting the nsP3 macrodomain. 
The nsP3 is considered a potential target for CHIKV drug discovery because of its 
crucial role in the early stages of transcription for viral replication. With the goal of 
identifying potential novel inhibitors for the CHIKV, this study utilised the available 
crystal structures, nsP3 macrodomain (PDB id: 3GPG) and its complex with ADP-
ribose (PDB id: 3GPO) as a starting point. Initially, reproducing the experimental data 
with respect to the co-crystal structure of nsP3-ADP-ribose showed that ligand ADP-
ribose binds tightly into the nsP3 (binding affinity of less than -10 kcal/mol). This 
indicated a successful and robust docking protocol with AutoDock Vina. Virtual 
screening based on this protocol was conducted with the library database compounds 
(NCI Diversity Set II). The top hit compounds and three binding pockets were 
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identified. In virtual screening, blind dockings covering the entire protein, followed by 
focused dockings to a specific pocket of protein, were a robust strategy to detect 
potential binding pockets. An additional strategy used the MetaPocket program to 
confirm these pockets, with consistent results. Pocket 1 is the well-characterised 
adenine binding pocket, and Pocket 2/Pocket 3 are two additional binding pockets. 
Moreover, in terms of binding affinity, Pocket 1 appears to be the most favourable for 
ligand binding (binding affinities of less than -10 kcal/mol), while Pocket 3 appears to 
be the least favourable one. Some ligands bind to different pockets with the different 
conformations. Based on the binding affinities and analysis of interactions, some 
ligands showed greater potential than others. They are NCI_61610 (-11.1 kcal/mol), 
NCI_345647_a (-10.9 kcal/mol), NCI_25457 (-10.8 kcal/mol), NCI_670283 (-10.6 
kcal/mol), NCI_37168 (around -10.0 kcal/mol), NCI_372499_b (-10.3 kcal/mol), and 
NCI_324623 (-10.3 kcal/mol). However, the question of ligand selectivity to the pocket 
requires more experimental work. Analysis in terms of HBs and hydrophobic 
interactions revealed key residues for interactions with the ligands in the nsP3.  
 
Furthermore, equilibrium MD simulations for most of the top docked ligand-nsP3 
complexes were carried out to validate the molecular docking results. The stability of 
these complexes over 50 ns was reported, and there were subtle structural 
rearrangements in the nsP3 observed to better accommodate the ligands. Throughout 
analysis of MD simulations and binding free energy calculations, insights into the 
interactions between ligands and the protein nsP3 were observed at an atomic level. 
Consequently, the compounds to be considered for biological testing, are NCI_61610  
(-15.2 kcal/mol), NCI_670283 (-13.2 kcal/mol), NCI_293778 (-12.7 kcal/mol), 
NCI_345647_a (-12.1 kcal/mol), NCI_37168 (-12.0 kcal/mol), and NCI_25457 (-10.0 
kcal/mol). 
 
Utilizing the simulation results of the nsP3 and its complexes, the LIE approach was 
applied to calculate binding free energies for the top hits obtained from docking. The 
LIE method is one of the most powerful approaches in the estimation of binding free 
energy for a ligand. Given the approximations used in the LIE approach, careful 
selection of parameters was provided. The comparison between the top-hit compounds 
and the tenth-hit compounds in terms of their binding free energy showed a close 
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agreement of docking and simulations in predicting binding affinities. The combination 
of the results from docking, MD simulations and binding free energy calculations 
provides a list of compounds was proposed for biological testing including NCI_61610, 
NCI_345647_a, NCI_25457, NCI_670283, and NCI_37168. 
 
For further work, the identified potential inhibitors should be experimentally tested their 
ability to inhibit CHIKV verified by in vivo studies. The key residues for interaction 
will be further investigated on their contributions, e.g. through HBs interactions, or the 
vdW to probe their influence on the binding process. The results are also useful for 
constructing a pharmacophore for future ligand-based drug design to generate the 
chemical libraries for novel inhibitors targeting CHIKV. Strategies for the synthesis and 
subsequent lead optimization are also a major next consideration. 
 
7.2 NSP2 PROTEASE ENZYME 
 
Drug discovery targeting the nsP2 protease was presented in Chapter 3, using the same 
process as described in Chapter 2. The nsP2 protease is a potential target with an 
important role in the cleavage of the non-structural polyproteins into non-structural 
proteins in the viral replication cycle, and transcription shut-off. This study is the first 
instance where molecular modelling using the X-ray structure has been undertaken. Due 
to lack of the structural information about the binding between ligands and the nsP2 
protease, no information about its potential binding pockets was forthcoming; blind 
docking was crucial to discover the possible binding pockets in the enzyme, and to 
detect hit compounds which may bind to these sites. Blind dockings were also based on 
previously published information, defining the binding site based on a homology model 
of the nsP2 protease and its potential inhibitors. In our study, the top hit compounds and 
five potential binding pockets of the nsP2 protease were identified. Focused dockings 
into these different binding sites offered more hit compounds and provided further 
binding modes at these pockets. Pocket 4 in the N-terminal domain of the nsP2 protease 
was identified based on structural alignment as the active site (through the presence of 
catalytic residues, Cys1013 and His1083) while most of previous studies reported 
Pocket 1 as the active site. The results from docking and virtual screenings indicate that 
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the potential compounds are NCI_61610 (-10.6 kcal/mol), NCI_293778 (from -9.8 to 
around -10.2 kcal/mol), NCI_37553 (-9.6 kcal/mol), NCI_217697 (-9.3 kcal/mol), and 
NCI_25457 (-9.0 kcal/mol). 
 
The results of top hit compounds after equilibrium MD simulations for 50 ns indicated 
most of the systems were maintained by interactions from hydrophobic contacts rather 
than hydrogen bonds. The LIE approach was used to obtain the accurate binding 
affinities of different ligands based on their trajectories from MD simulations. The 
different binding energies were explained by the contribution of varying numbers of 
HBs and hydrophobic contacts. The lead compounds selected were NCI_293778 (from  
-9.9 to around -13 kcal/mol), NCI_67436 (-15.5 kcal/mol), and NCI_217697 (-9.0 
kcal/mol). The relative ranking of binding free energies of top-hit compounds gave a 
good agreement between docking results and MD simulations results. 
 
After combining the results obtained from docking, MD simulations and binding free 
energy calculations, proposed compounds for biological testing including NCI_293778, 
NCI_217697, and NCI_67436. 
 
Moreover, as there are some potential binding pockets other than the active site in the 
structure of nsP2 enzyme, so further experimental work is required to investigate the 
effect upon binding to these alternate pockets. More experimental data is also needed to 
elucidate the contribution and influence of vdW, and electrostatic energy on ligand 
binding. Calculations of interaction energy components from key residues should be 
considered. The study opens up a promising approach to rational drug design 
(pharmacophore constructing with the generated scaffold) for the design of inhibitors 
for CHIKV. Synthesis of the lead compounds followed by lead optimization, is also an 
important next step. 
 
7.3 ENVELOPE GLYCOPROTEINS 
 
Envelope glycoproteins are another class attractive targets for inhibition of virus entry 
or virus attachment as inhibition of the viral envelope glycoproteins can block the in 
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vitro CHIKV infection. Chapter 4 focused on the discovery of inhibitors for CHIKV 
targeting the envelope glycoproteins complexes. Computational investigation of the 
envelope glycoproteins complexes (the immature and mature forms) has previously 
been explored within our group, however a more rigorous exploration based on blind 
docking was deemed essential to the full characterization of potential target sites. 
Virtual screenings based on blind docking and focused docking explored the potential 
binding pockets and inhibitors for both the immature and mature structure of envelope 
proteins. Promising hit compounds were identified for two complexes of the envelope 
glycoproteins. Pocket 2 was a novel binding pocket in the immature structure. Pocket 2 
and Pocket 3 were detected as novel binding sites for the mature complex of the 
glycoproteins. The key residues involved in stabilizing the complex or participating in 
the fusion process were confirmed. This study also investigated the convergence of 
conformational sampling in AutoDock Vina. The results demonstrated that this 
parameter affected a searching process for conformations of ligand in docking however 
in the current study, the different screening provided a semi-quantitatively consistent 
picture. The binding affinities of most of top hits compounds were about -10 to -13 
kcal/mol indicating good binding between the ligands and the envelope glycoprotein 
complexes. The compounds bound into Pocket 1 and Pocket 4 were expected to be 
promising targeting the glycoprotein complexes, as they could interact with the residues 
involved in the process of virus attachment and virus entry. Therefore, the potential 
compounds proposed for biological testing include NCI_293778 (from -11.4 to around  
-13.7 kcal/mol), NCI_61610 (from -11.6 to -12.3 kcal/mol), NCI_37553 (-11.5 
kcal/mol), and NCI_156219 (-11.1 kcal/mol).  
 
This work supported the current docking protocol, utilising AutoDock Vina as a robust 
strategy, which could be used to identify inhibitors and understand the binding modes. 
However, in docking, the protein structure was kept rigid and this might affect both the 
docking and scoring process. More accurate binding free energies are expected to be 
obtained from explicit solvent based MD simulations, however, due to the larger sizes 
of these envelope glycoprotein complexes, this could not be conducted within the time 
frame of this work. 
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In future work, experimental studies are required to determine the inhibitory effects of 
hit compounds on these membrane proteins. It would be useful to investigate the 
stability and flexibility of the systems. The mechanism of virus entry and virus 
attachment through the envelope glycoproteins would require further MD simulations 
experimental data. The binding free energy calculations would be also needed to guide 
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Appendix 1. Chemical structures of top hit compounds in all dockings for the nsP3 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1. NCI_25457 -10.8 
HBs: Val113 (HN)-O 
π-π interaction with Trp148 
2. NCI_116702 -10.7 HBs: Val113 (HN)-O 
π-π interaction with Tyr114 
3. NCI_309892  -10.3 
HBs: H-Thr (111) 
π-system with Tyr114 
4. NCI_109451  -10.2 π-system with Tyr114 
5. NCI_127133  -10.2 π-system with Trp148 
6. NCI_328101  -10.2 
HBs: Val113 (HN)-N, Arg144 (HE)-O 
π-system with Trp148 
7. NCI_372275_a  -10.2 π-system with Trp148 
8. NCI_45545  -10.2 HBs: Val113 (HN)-N, H-Asp31 (O) 
9. NCI_84100_b  -10.2 HBs: Val113 (HN)-O 
π-system with Tyr114 
10. NCI_37168 -10.1 π-system with Trp148 
 





1. NCI_34567_a -10.9 Hydrophobic contacts 
2. NCI_37553  -10.9 π-π interaction with Trp148 
3. NCI_25457 -10.8 Hydrophobic contacts 
4. NCI_116702  -10.7 Hydrophobic contacts 
5. NCI_58052  -10.6 Hydrophobic contacts 
6. NCI_127133  -10.5 Hydrophobic contacts 
7. NCI_293778  -10.5 Hydrophobic contacts 
8. NCI_670283  -10.5 Hydrophobic contacts 
9. NCI_328101  -10.4 Hydrophobic contacts 














1. NCI_61610  
 -11.1 
HBs: Gly112 (HN)-O 
π-π interaction with Trp148, Tyr114 
2. NCI_293778 -11.0 Hydrophobic contacts 
3. NCI_345647_a  
 -10.9 
HBs: Gly112 (HN)-O 
Thr111 (HG1)-O 
4. NCI_25457 -10.8 π-π interaction with Trp148 
5. NCI_58052 -10.6 
HBs: Gly112 (HN)-N 
Thr111 (HG1)-N 
6. NCI_127133 -10.5 π-π interaction with Trp148, Tyr114 
7. NCI_372499_b  -10.3 
HBs: Arg144 (HN)-O 
Asp145 (HN)-O 
π-π interaction with Trp148 
8. NCI_37553 -10.3 
HBs: Asp31 (HN)-O 
π-π interaction with Trp148 
9. NCI_309892 -10.2 HBs: H-Thr111 (O) 
10. NCI_37168 -10.2 π-π interaction with Trp148 
 




1. NCI_61610  
 
-11.1 HBs: Val113 (HN)-O 
π-π interaction with Trp148 
2. NCI_37553 -11.0 π-π interaction with Trp148 
3. NCI_345647_a  
 
-10.9 
HBs: Gly112 (HN)-O 
Thr111 (HN)-O 
H-Thr111 (OG1) 
4. NCI_25457 -10.8 HBs: Val113 (HN)-O 
π-π interaction with Trp148, Tyr114 
5. NCI_293778 -10.8 HBs: Val113 (HN)-N 
6. NCI_127133 -10.7 π-π interaction with Trp148, Tyr114 
7. NCI_116702  -10.6 
HBs: Val113 (HN)-O 
π-π interaction with Tyr114,  
π-system with Trp148 
8. NCI_58052 -10.6 
HBs: Gly112 (HN)-N, Thr111 (HN)-N 
Asp31 (HN)-O 
9. NCI_670283 -10.5 Hydrophobic contacts 











1. NCI_127133 -8.3 HBs: H-Asp133 (O), H-Thr135 (O) 
2. NCI_293778 -8.2 π-system with His-1 
3. NCI_338042 -7.6 Hydrophobic contacts 
4. NCI_132232 -7.5 HBs: H-Asp133 (O) 
5. NCI_310326 -7.5 Hydrophobic contacts 
6. NCI_328101 -7.4 HBs: Tyr4 (HH)-F, His-1(HT1)-O 
7. NCI_69359_a -7.3 Hydrophobic contacts 
8. NCI_90737 -7.3 Hydrophobic contacts 
9. NCI_122819_a -7.2 HBs: Tyr4 (HN)-O 
10. NCI_400976 -7.2 Hydrophobic contacts 
 





1. NCI_670283 -10.6 Hydrophobic contacts 
2. NCI_319990 -10.2 HBs: Tyr144 (HH)-O 
3. NCI_80731 -10.1 HBs: Tyr144 (HH)-O, H-Asp31 (O) 
4. NCI_84100_b -10.1 HBs: H-Tyr114 (OH) 
5. NCI_372287_a -10.0 HBs: Thr111 (HN)-O, Asp31 (HN)-O 
6. NCI_84100_a -9.9 HBs: H-Tyr114 (OH) 
7. NCI_97920 -9.6 HBs: H-Asp31 (O) 
8. NCI_58052 -9.5 HBs: H-Asp31 (O), Asn75 (HD22)-O 
9. NCI_227186_a -9.4 Hydrophobic contacts 







Appendix 8. SASA’s values (Å2) in the simulations of the apo nsP3 and its complexes with different ligands: A: Ligand NCI_61610, B: Ligand 
NCI_25457, C: Ligand NCI_345647, D: Ligand NCI_670283, E: Ligand NCI_127133, F: Ligand NCI_37168vst1, G: Ligand NCI_372499vst2, 
H: Ligand NCI_37168vst3, I: Ligand NCI_324623vst4, J: Ligand NCI_400976vst5, K: Ligand NCI_293778vst6. 
 
nsP3 nsP3-A nsP3-B nsP3-C nsP3-D nsP3-E nsP3-F nsP3-G nsP3-H nsP3-I nsP3-J nsP3-K 




36.9  42.3 41.4  38.4 
Pro25 75.5 57.8 
    
     65.9 




     113.1 
Val33 68.8 81.7 57.4 52.9 79.7 
 
58.2 71.9 75.3 53.7   




30.6  28.4 21.9   
Val113 129.8 146.5 138.8 130.8 142.2 
 
138.2  137.8 147.7  140.4 
Tyr114 70.2 63.4 69.3 63.8 87.4 
 
63.5  55.8 54.8  49.7 
Trp148 84.0 88.4 90.2 95.5 
  










      
Ala1 74.5     81.2     80.6  
Pro2 37.9     56.4     62.3  
Tyr4 39.2     41.7     50.2  
Ala23 10.5      13.4  14.9   10.6 
Arg144 172.0      185.7 172.0     
Phe45 14.6         27.0   
Phe129 17.8          25.3  
Arg159 129.1          145.9  
Arg26 202.8           202.5 










1. NCI_293778 -11.6 Π-stacking with Tyr114 
2. NCI_84100_b -10.7 Π-stacking with Tyr114 
3. NCI_84100_a -10.6 Π-stacking with Tyr114 
4. NCI_80997_b -10.5 Hydrophobic contacts 
5. NCI_37553 -10.4 Hydrophobic contacts 
6. NCI_61610 -10.3 Hydrophobic contacts 
7. NCI_670283 -10.2 Hydrophobic contacts 
8. NCI_59620_a -10.2 Hydrophobic contacts 
9. NCI_308835 -10.2 HBs: Ser110(HN)-O 
10. NCI_60785 -10.2 HBs: H-Leu108(O) 
 
Appendix 10. Interactions analysis for each ligand at Pocket 1 of nsP3 in VST-10nsa 





1. NCI_37553 -11.1 HBs: Asn24(HD22)-O 
2. NCI_293778 -11.1 HBs: Val33(HN)-N 
3. NCI_60785_a -11.0 HBs: H-Thr111(OG1) 
4. NCI_59620_a -10.8 
HBs: Thr111(HN)-O, Leu108(HN)-O, 
Asn24(HD22)-O 
5. NCI_27592_a -10.7 Hydrophobic contacts 
6. NCI_670283 -10.7 Hydrophobic contacts 
7. NCI_82802_a -10.7 HBs: Ile11(HN)-F 
8. NCI_328101 -10.5 





HBs: Thr111(HN)-O, Leu108(HN)-O, 
Asn24(HD22)-O 








Appendix 11. Interactions analysis for each ligand at Pocket 1 of nsP3 in VST-15nsa 





1. NCI_293778 -10.5 Hydrophobic contacts 
2. NCI_308835 -10.3 Hydrophobic contacts 
3. NCI_37553 -10.3 HBs: Asn24(HD22)-O 
4. NCI_97920 -10.0 HBs: H-Asp31(O) 
5. NCI_84100_b -9.9 Hydrophobic contacts 
6. NCI_59620_a -9.8 HBs: Gly112(HN)-O, Asn24(HD22)-O 
7. NCI_84100_a -9.8 Hydrophobic contacts 
8. NCI_37627 -9.8 HBs: Gly112(HN)-O 
9. NCI_60785_b -9.7 Hydrophobic contacts 
10. NCI_25457 -9.7 HBs: Asp31 (HN)-N 
 
Appendix 12. Interactions analysis for each ligand at Pocket 1 of nsP3 in VST-20nsa 





1. NCI_37553 -12.1 HBs: Asn24(HD22)-O 
2. NCI_61610 -11.9 HBs: Asn24(HD22)-O 
3. NCI_670283 -11.7 HBs: Asp31(HN)-O 
4. NCI_293778 -11.3 Hydrophobic contacts 
5. NCI_60785_a -11.1 HBs: H-Leu108(O) 
6. NCI_63680 -11.1 Hydrophobic contacts 
7. NCI_82802_a -11.0 HBs: H-Thr111(OG1) 
8. NCI_219894 -10.8 HBs: Leu108(HN)-O, Ser110(HN)-O 
9. NCI_80997_b -10.7 HBs: H-Leu108(O), Asn24(HD22)-O 
















1. NCI_61610 -10.6 HBs: Tyr1177 (HH)-N 
2. NCI_293778 -10.3 Hydrophobic contacts 
3. NCI_116702 -9.2 HBs: Cys1290 (HG)-N 
4. NCI_37553 -9.2 HBs: H-Tyr1079 (OH) 








7. NCI_25457 -9.0 HBs: Cys1290(HG)-N 
8. NCI_670283 -10.2 
HBs: Lys1045(HZ1)-O, 
Lys1239(HZ1)-O 
9. NCI_97920 -9.0 Hydrophobic contacts 
10. NCI_58052 -8.8 HBs: Asn1167(HN)-O 
 





1. NCI_293778 -10.3 π -system with Trp1084 
2. NCI_61610 -10.1 π -system with His1151, Phe1225 
3. NCI_670283 -9.7 π -system with Tyr1078 
4. NCI_116702 -9.2 Hydrophobic contacts 
5. NCI_217697 -9.2 Hydrophobic contacts 
6. NCI_84100_a -9.2 π -system with Tyr1177 
7. NCI_84100_b -9.2 π -system with Trp1084 
8. NCI_298892_b -9.1 
HBs: His1222(HN)-O, 
Lys1239(HZ1)-N 
9. NCI_37553 -9.1 Hydrophobic contacts 













1. NCI_217697 -9.3 Hydrophobic contacts 
2. NCI_60783 -9.3 
HBs: Lys1045(HZ1)-O, 
Lys1239(HZ1)-O 
3. NCI_298892_b -9.2 
HBs: Lys1045(HZ1)-N, 
Lys1239(HZ1)-N, His1222(HN)-O 
4. NCI_328101 -9.2 Hydrophobic contacts 
5. NCI_25457 -9.1 Hydrophobic contacts 
6. NCI_116702 -9.0 
HBs: Lys1045(HZ1)-N, 
Lys1239(HZ1)-N 
7. NCI_80997_a -9.0 Hydrophobic contacts 
8. NCI_109451 -8.9 Hydrophobic contacts 
9. NCI_93427 -8.9 Hydrophobic contacts 
10. NCI_127133 -8.8 Hydrophobic contacts 
 





1. NCI_293778 -9.8 H-bonds: Lys1239(HZ1)-N 
2. NCI_37553 -9.7 H-bonds: Lys1045(HZ1)-O 
3. NCI_328101 -9.3 Hydrophobic contacts 
4. NCI_670283 -9.3 HBs: Lys1239(HZ1)-O, Lys1045(HZ1)-O 
5. NCI_25457 -9.2 Hydrophobic contacts 
6. NCI_298892_b -9.2 
HBs: Lys1239(HZ1)-N, Lys1045(HZ1)-N, 
His1222(HN)-O 
7. NCI_61610 -9.2 HBs: Lys1239(HZ1)-N, Lys1045(HZ1)-N 
8. NCI_84100_a -9.2 π -system with Tyr1177 
9. NCI_84100_b -9.2 π -system with Tyr1177 














1. NCI_293778 -9.8 π -stacking with Tyr1177 
2. NCI_37553 -9.4 π -stacking with Tyr1177 
3. NCI_269148_a -8.5 HBs: Lys1155(HZ3)-O, His1222(HD1)-O 
4. NCI_146771 -8.3 
HBs: Gln1232(HE22)-O, Thr1295(HG1)-O, 
H-Thr1292(O) 
5. NCI_227186_b -8.3 
HBs: Tyr1177(HH)-O. Ala1180(HN)-O, H-
Glu1160(OE2), H-Glu1160(OE1) 
6. NCI_308835 -8.3 Hydrophobic contacts 
7. NCI_7524_b -8.3 HBs: Lys1155(HZ3)-O 




HBs: Gln1232(HE22)-O, Phe1225(HN)-N, 
Tyr1177(HH)-F 
10. NCI_362639 -8.2 HBs: Phe1225(HN)-O, Thr1295(HG1)-O 
 





1. NCI_37553 -9.6 Hydrophobic contacts 
2. NCI_319990 -9.4 HBs: Asn1167(HN)-N 
3. NCI_116702 -9.2 HBs: Cys1290(HG)-N 
4. NCI_61610 -9.2 Hydrophobic contacts 
5. NCI_25457 -9.0 HBs: Cys190(HG)-N 
6. NCI_293778 -9.0 Hydrophobic contacts 
7. NCI_97920 -9.0 Hydrophobic contacts 
8. NCI_67436 -8.9 HBs: H-Ser1256(OG) 
9. NCI_80997_b -8.9 Hydrophobic contacts 














1. NCI_293778 -10.4 Hydrophobic contacts 
2. NCI_670283 -9.7 Hydrophobic contacts 
3. NCI_121868_a -9.3 HBs: Trp1084(HE1)-O 
4. NCI_37553 -9.2 Hydrophobic contacts 
5. NCI_61610 -9.2 HBs: Tyr1079(HH)-O 
6. NCI_319990 -8.9 
HBs: Trp1084(HE1)-O, H-Leu1205(O), 
Tyr1079(HH)-O 
7. NCI_328101 -8.9 HBs: Ser1048(HG)-F, Lys1091(HZ3)-F 
8. NCI_67436 -8.9 HBs: H-Tyr1079(OH) 
9. NCI_227186_a -8.8 HBs: H-Leu1205(O) 
10. NCI_122819_b -8.7 HBs: Trp1084(HE1)-O, Lys1091(HZ3)-O 
 





1. NCI_293778 -10.2 Hydrophobic contacts 




3. NCI_61610 -9.1 
HBs: Arg1142(HH21)-O, H-
Thr1313(OG1) 
4. NCI_37553 -9.0 Hydrophobic contacts 
5. NCI_80735 -8.7 
HBs: H-Glu1270(OE1), Arg1271(HH21)-
O 
6. NCI_80997_a -8.4 HBs: H-Glu1270(OE1) 
7. NCI_345845 -8.1 HBs: H-Ser1067(O), H-Ala1099(O) 
8. NCI_5157 -8.1 HBs: H-Asp1066(O), Ag1142(HH21)-O 
9. NCI_58052 -8.1 HBs: H-Asp1066(O), Ag1140(HH21)-O 






Appendix 21. Sequences alignment of three crystal structures, namely the nsP2 
protease of CHIKV (PDB id: 3TRK), the nsP2 protease of VEEV (PDB id: 2HWK) 
and the nsP2 protein of SINV (PDB id: 4GUA). The catalytic cysteine and histidine 







Appendix 22. SASA’s values (Å2) in the simulations of the apo nsP2 and its complexes with different ligands: A: Ligand NCI_61610, B: Ligand 
NCI_217697, C: Ligand NCI_37553, D: Ligand NCI_293778vst4, E: Ligand NCI_293778vst5, F: Ligand NCI_293778vst2, G: Ligand 
NCI_293778vst7, H: Ligand NCI_293778vst8, I: Ligand NCI_217697w, J: Ligand NCI_25457w, K: Ligand NCI_362639, L: Ligand 
NCI_84100_b, M: Ligand NCI_67436. 
 nsP3 nsP3-A nsP3-B nsP3-C nsP3-D nsP3-E nsP3-F nsP3-G nsP3-H nsP3-I nsP3-J nsP3-K nsP3-L 
nsP3-
M 
Lys1045 89.6 90.6 89.8  115.4     96.5     
Gly1176 42.6    40.0          
Pro1191 43.4 59.0 45.8            
Val1194 46.1 50.3 45.8            
Leu1203 21.5 27.2 22.6  34.3          
Glu1204 35.9 69.9   110.1     67.7     
Ile1221 27.5 46.4 36.5  38.1     41.2     
Met1238 17.3 29.3 30.6  44.5  24.4   31.0     
Lys1239 49.1 68.8 90.2  85.3     75.1     
Met1242 46.2 51.6   56.7          
Leu1243 2.6 11.0 10.8  16.3     13.5     
Tyr1047 24.7  35.4    21.4   25.8     
Trp1161 140.8   137.0       144.6  142.3  
Leu1162 25.1   27.9       29.3  24.9  
Lys1165 170.7   168.6       175.2  182.3  
Ile1166 24.8   26.1         22.0  
Ser1282 57.8   53.6           
Ser1283 33.6   19.1           
Arg1284 123.8   132.7           
Leu1286 37.5   39.7         33.9  




Pro1289 77.6   101.4       100.4  95.2  
Leu1300 20.5   32.0         25.6  
Ser1302 27.6   31.6           
Ala1046 24.9    54.4  42.7 43.1       
Hsd1222 95.2    95.9 64.3    99.4     
Thr1223 11.4    32.4          
Pro1224 94.1    117.5 106.3         
Hsd1236 8.1    14.6          
Met1242 46.2    56.7          
Lys1155 205.1     210.6         
Gly1156 50.0     66.7         
Glu1157 90.5     87.5     94.0  90.1  
Arg1158 152.8     152.4         
Met1159 10.8     64.0         
Gly1176 42.6     38.3         
Tyr1177 115.5     84.6         
Leu1179 -15.3     21.5         
Thr1292 73.8     42.6      51.9   
Ser1048 21.2      27.5        
Tyr1078 88.6      79.5        
Tyr1079 114.2      129.2 129.8       
Asn1082 121.9      138.2        
Trp1084 59.4      63.6 49.2       
Leu1205 109.2      110.9 129.2       
Val1077 6.9       11.3       
Ile1102 103.9        105.2      




Pro1191 43.2         43.2     
Leu1192 116.0         115.5     
Gly1193 67.0         76.2     
Val1194 46.6         46.1     
Ser1293 5.4           5.8   
Asp1066 93.8             79.3 
Ser1067 28.6             37.5 
Asn1140 63.4             69.0 
Arg1141 46.0             47.8 
Arg1142 211.6             216 
Pro1144 38.7             34.0 
His1145 11.7             10.9 
Glu1270 45.6             37.6 
Arg1271 127.2             122.0 
Cys1274 40.8             31.7 










1. NCI_293778 -8.6 Hydrophobic contacts 
2. NCI_37553 -8.5 Hydrophobic contacts 
3. NCI_59620 -8.4 HBs: Thr308(HN)-O 
4. NCI_7524_b -8.3 Hydrophobic contacts 
5. NCI_308835 -8.2 Hydrophobic contacts 
6. NCI_227186_a -8.0 
HBs: Thr308(HN)-O, His309(HE2)-O,  
Arg137(HN)-O 
7. NCI_328101 -8.0 HBs: Thr308(HN)-N, Thr308(HN)-O 
8. NCI_339161 -7.8 HBs: Thr308(HG1)-O 
9. NCI_270738_b -7.8 HBs: Asn135(HD22)-O 
10. NCI_58052 -7.8 HBs: N-Thr308(OG1), Asn135(HD22)-O 
 





1. NCI_345647_a -9.0 
HBs: Lys101(HZ1)-O, H-Asp59(OD2), 
Arg136(HH12)-O 
2. NCI_338042 -8.8 Hydrophobic contacts 
3. NCI_293778 -8.7 HBs: Thr308(HG1)-N 
4. NCI_67436 -8.3 HBs: H-Asn135(O), Arg137(HH11)-O 
5. NCI_80997_a -8.3 HBs: Lys101(HZ1)-O 
6. NCI_338963 -8.2 Hydrophobic contacts 
7. NCI_319990 -8.2 HBs: His309(HD1)-N 
8. NCI_25457 -8.0 Hydrophobic contacts 
9. NCI_670283 -7.9 Hydrophobic contacts 











1. NCI_293778 -8.3 Hydrophobic contacts 
2. NCI_3045647_a -8.0 Hydrophobic contacts 
3. NCI_97920 -8.0 Hydrophobic contacts 
4. NCI_327702 -7.9 HBs: Gln236(HE22)-N 
5. NCI_156516 -7.9 Hydrophobic contacts 
6. NCI_80313 -7.8 HBs: Gln236(HE22)-O, Gln236(HE21)-N 
7. NCI_116709_b -7.8 Hydrophobic contacts 
8. NCI_37553 -7.8 HBs: Arg266(HH12)-O 
9. NCI_326757 -7.6 HBs: H-Val270(O) 
10. NCI_154585 -7.6 HBs: H-Gln236(O) 
 





1. NCI_293778 -8.5 Hydrophobic contacts 
2. NCI_61610 -7.9 Hydrophobic contacts 
3. NCI_122819_b -7.7 HBs: H-Thr307(OG1), Thr308(HN)-O 
4. NCI_671136 -7.6 HBs: Thr308(HN)-O 
5. NCI_19990_a -7.6 
HBs: H-Thr307(OG1), His309(HD1)-O, H-
Glu265(OE2), Arg137(HN)-O 
6. NCI_37641_b -7.5 
HBs: Thr308(HN)-O, H-Thr307(OG1), 
His309(HN)-O 
7. NCI_269148_b -7.4 
HBs: H-Arg137(O), Thr308(HN)-O, H-
Thr307(OG1), H-Asn305(OD1),  
Arg273(HH22)-O 
8. NCI_319990 -7.4 
HBs: Arg137(HN)-N, H-Arg137(O),  
H-Thr137(OG1) 
9. NCI_156219_b -7.4 
HBs: H-Thr302(OG1), Thr308(HN)-O, H-
Thr308(OG1), Asn312(HD21)-O, 
His309(HN)-O 










1. NCI_61610 -8.2 HBs: H-Thr308(OG1) 
2. NCI_84100_a -7.2 HBs: Thr308(HN)-O, H-Thr308(OG1) 
3. NCI_146771 -7.2 Hydrophobic contacts 
4. NCI_84100_b -7.1 HBs: Thr308(HN)-O, H-Thr308(OG1) 
5. NCI_25457 -7.0 Hydrophobic contacts 
6. NCI_116702 -7.0 Hydrophobic contacts 
7. NCI_37553 -7.0 Hydrophobic contacts 
8. NCI_80731 -7.0 HBs: His309(HD1)-O, H-Glu265(OE1) 
9. NCI_35691 -7.0 HBs: H-Leu138(O) 






Appendix 28. Binding sites identified in the immature form (PDB id: 3N40) using 
receptor cavities tools in Accelerys Discovery Studio software. The binding site 
detected is based on X, Y, Z coordinates; volume; and a set of points (point count). 
 




Between E1 domain II and E2 domain C 
(Pocket 1) 
-25.6 21.1 24.9 131.8 1054 
Between E1 domain II and the E2 β-ribbon 
(Pocket 1) 
-13.8 -4.7 19.7 352.3 2818 
At the E2 β-ribbon (Pocket 2) -22.4 -0.2 8.9 123.5 988 
Behind the fusion loop, between E3, E2 
domain A, E2 domain B (Pocket 4) 
-9.6 -7.3 8.2 26.8 214 
Between E1 domain I-domain III and E2 
domain C (Pocket 3) 
-11.1 -58.4 19.7 42.3 338 
Between E1 domain II-E3 -34.1 21.1 39.4 49.0 392 
Between E1 domain I-E1 domain III -11.1 -58.4 19.7 42.3 338 
Between E1 domain II-near E2 β-ribbon -26.6 -4.4 25.2 38.8 310 
Between E1 domain II-E1 domain I -6.9 -23.9 33.7 36.1 289 
Between E1 domain I and E2 domain C -2.9 -25.2 19.4 32.8 262 
Between E1 domain I-E1 domain III -4.9 -37.4 12.9 31.8 254 
Between E1 domain II-E2 domain A and E3 -33.1 33.3 25.2 27.6 221 
Between E2 domain B-E3 -54.4 32.1 29.4 27.1 217 
Between E2 domain C -9.6 -7.3 8.2 26.8 214 
Between E2 domain A and E2 β-ribbon -17.6 7.3 8.2 23.4 187 
 
Appendix 29. Binding sites identified in the mature form (PDB id: 3N42) using 
receptor cavities tools in Accelerys Discovery Studio software. The binding site 
detected is based on X, Y, Z coordinates; volume; and a set of points (point count). 




Between E1 domain II and E2 domain C 
(Pocket 1) 
-16.7 2.0 -19.9 621.2 4970 
At the E2 β-ribbon (Pocket 2) -19.7 -2.9 -9.9 156.0 1248 
Behind the fusion loop, between E3, E2 
domain A, E2 domain B (Pocket 4) 
-33.4 -14.2 -34.9 523.0 4184 
Between E1 domain I-domain III and E2 
domain C (Pocket 3) 
-6.4 24.3 -26.2 129.6 1037 
Between E1 domain II, E2 β-ribbon -16.7 2.0 -19.9 621.2 4970 
E2 domain A -43.4 -28.7 -22.9 143.5 1148 
Between E1 domain I-E1 domain III -6.4 37.8 -13.4 139.7 1118 
Between E1 domain I-E1 domain II and 
E2 domain C 
-6.4 24.8 -26.2 129.6 1037 
Between E2 domain A-E3 -46.7 -14.7 -22.9 100.5 804 
Between E2 domain B-E2 domain A -53.2 -31.2 -27.7 35.8 283 
E1 domain I  -16.2 51.3 -22.4 25.4 203 
E2 domain C -10.7 7.8 -0.9 25.2 202 
E2 domain A -47.2 -12.9 -12.2 23.5 188 









1. NCI_293778 -13.2 π-system with Tyr51 
2. NCI_61610 -12.2 HBs: H-Glu99(O) 
3. NCI_37553 -11.7 Hydrophobic contacts 
4. NCI_156219_b -11.5 HBs: H-Ile101(O) 
5. NCI_84100_b -10.9 HBs: H-Tyr233(OH) 
6. NCI_84100_a -10.9 HBs: H-Tyr233(OH) 
7. NCI_116702 -10.8 HBs: H-Tyr233(OH) 
8. NCI_19990_a -10.8 Hydrophobic contacts 
9. NCI_227186_a -10.7 
HBs: Ser238(HN)-O, H-Thr53(O), 
Tyr301(HH)-O, H-Tyr301(OH) 
10. NCI_227186_b -10.6 
HBs: Ile55(HN)-O, Thr53(HN)-O, H-
Tyr51(O) 
 





1. NCI_293778 -13.7 π-system with Tyr129 
2. NCI_37553 -11.4 Hydrophobic contacts 
3. NCI_61610 -11.2 HBs: H-Pro128(O), Ile55(HN)-O 
4. NCI_156219_b -11.1 HBs: H-Glu50(OE2) 
5. NCI_84100_a -11.0 π-system with Tyr242, Pro237 
6. NCI_227186_b -10.9 HBs: Ser238(HN)-O, H-G;u50(OE2) 
7. NCI_84100_b -10.9 HBs: H-Asp43(OD2) 
8. NCI_7524_a -10.9 
HBs: H-Glu50(OE2), Thr53(HN)-O, 
Arg36(HH12)-O, Lys52(HZ1)-O 
9. NCI_116702 -10.8 π-stacking with Pro133 











1. NCI_293778 -13.1 π-system with Tyr51 
2. NCI_61610 -11.9 Hydrophobic contacts 
3. NCI_37553 -11.7 Hydrophobic contacts 
4. NCI_156219_b -11.5 HBs: H-Ile101(O) 
5. NCI_84100_b -10.9 π-system with Pro216 
6. NCI_84100_a -10.9 HBs: H-Tyr233(OH) 
7. NCI_116702 -10.8 HBs: Arg100(HE)-N 
8. NCI_19990_a -10.8 Hydrophobic contacts 
9. NCI_227186_a -10.7 
HBs: Ser238(HN)-O, H-Thr53(O),  
H-Asn103(OD1) 
10. NCI_227186_b -10.7 HBs: Ser238(HN)-O 
 





1. NCI_293778 -13.1 π-system with Tyr233 
2. NCI_61610 -12.3 HBs: H-Glu99(O) 
3. NCI_156219_b -11.5 Hydrophobic contacts 
4. NCI_308835 -11.0 Hydrophobic contacts 
5. NCI_84100_a -10.9 HBs: H-Tyr233(OH) 
6. NCI_84100_b -10.9 HBs: H-Tyr233(OH) 
7. NCI_37553 -10.8 Hydrophobic contacts 
8. NCI_116702 -10.8 HBs: Arg100(HE)-N 
9. NCI_67436 -10.6 Hydrophobic contacts 















1. NCI_293778 -13.1 Hydrophobic contacts 
2. NCI_61610 -12.3 HBs: H-Glu99(O) 
3. NCI_37553 -11.7 Hydrophobic contacts 
4. NCI_156219_b -11.5 HBs: H-Pro192(O), H-Tyr51(O) 
5. NCI_260594 -11.4 Hydrophobic contacts 
6. NCI_308835 -11.1 Hydrophobic contacts 
7. NCI_84100_a -11.0 Hydrophobic contacts 
8. NCI_84100_b -10.9 Hydrophobic contacts 
9. NCI_227186_a -10.9 HBs: Tyr301(HH)-O, Asn103(HD22)-O 
10. NCI_19990_a -10.8 HBs: H-Tyr233(OH) 
 





1. NCI_293778 -13.1 Hydrophobic contacts 
2. NCI_61610 -12.3 HBs: H-Glu99(O) 
3. NCI_37553 -11.7 Hydrophobic contacts 
4. NCI_156219_b -11.5 HBs: H-Pro192(O), H-Ile101(O) 
5. NCI_260594 -11.4 Hydrophobic contacts 
6. NCI_308835 -11.4 Hydrophobic contacts 
7. NCI_84100_a -11.0 Hydrophobic contacts 
8. NCI_84100_b -10.9 Hydrophobic contacts 
9. NCI_227186_a -10.9 
HBs: H-Thr53(O), Ser238(HN)-O, H-
Asn103(OD1) 















1. NCI_293778 -13.1 Hydrophobic contacts 
2. NCI_61610 -12.3 HBs: H-Glu99(O) 
3. NCI_37553 -11.7 Hydrophobic contacts 
4. NCI_156219_b -11.5 Hydrophobic contacts 
5. NCI_260594 -11.5 Hydrophobic contacts 
6. NCI_308835 -11.4 Hydrophobic contacts 
7. NCI_84100_a -11.0 Hydrophobic contacts 
8. NCI_84100_b -11.0 HBs: H-Glu50(OE2) 
9. NCI_227186_a -10.9 
HBs: H-Thr53(O), Ser238(HN)-O, 
Tyr301(HH)-O, Asn103(HD22)-O 
10. NCI_19990_a -10.9 Hydrophobic contacts 
 





1. NCI_293778 -13.0 Hydrophobic contacts 
2. NCI_37553 -11.7 Hydrophobic contacts 
3. NCI_37553 -11.5 Hydrophobic contacts 
4. NCI_156219_b -11.4 Hydrophobic contacts 
5. NCI_260594 -11.4 Hydrophobic contacts 
6. NCI_308835 -10.9 
HBs: Asn103(HD22)-O, Ser238(HN)-O, 
Tyr301(HH)-O 
7. NCI_84100_a -10.8 HBs: H-Tyr233(OH), H-Thr53(O) 
8. NCI_84100_b -10.8 HBs: Arg247(HH21)-O 
9. NCI_227186_a -10.8 HBs: Arg100(HE)-N 














1. NCI_293778 -13.7 π-system with Pro128, Pro129 
2. NCI_37553 -11.5 Hydrophobic contacts 
3. NCI_61610 -11.3 HBs: H-Pro128(O), Ile55(HN)-O 
4. NCI_156219_b -11.1 HBs: H-Glu50(OE2) 
5. NCI_84100_a -11.0 Hydrophobic contacts 
6. NCI_7524_a -10.9 HBs: Ser238(HN)-O 
7. NCI_84100_b -10.9 HBs: H-Asp43(OD2) 
8. NCI_25457 -10.8 
HBs: Thr53(HN)-O, Arg36(HH12)-O, 
Lys52(HZ1)-O 
9. NCI_116702 -10.8 Hydrophobic contacts 
10. NCI_122819 -10.7 Hydrophobic contacts 
 





1. NCI_293778 -13.7 Hydrophobic contacts 
2. NCI_37553 -11.5 Hydrophobic contacts 
3. NCI_61610 -11.4 π-stacking with Tyr390 
4. NCI_156219_b -11.1 HBs: H-Tyr51(O) 
5. NCI_227186_b -10.9 HBs: Ser238(HN)-O 
6. NCI_84100_a -10.9 Hydrophobic contacts 
7. NCI_7524_a -10.9 HBs: Arg36(HH11)-O, Thr53(HN)-O 
8. NCI_84100_b -10.9 Hydrophobic contacts 
9. NCI_308835 -10.8 Hydrophobic contacts 















1. NCI_293778 -13.7 Hydrophobic contacts 
2. NCI_61610 -11.5 π-stacking with Tyr390 
3. NCI_37553 -11.4 Hydrophobic contacts 
4. NCI_156219_b -11.1 
HBs: H-Pro128(O), π-system with 
His127 
5. NCI_84100_a -11.0 Hydrophobic contacts 
6. NCI_227186_b -10.9 HBs: Ser238(HN)-O, H-Glu50(OE2) 
7. NCI_7524_a -10.9 
HBs: Arg36(HH11)-O, Thr53(HN)-O, 
Lys52(HZ1)-O 
8. NCI_84100_b -10.9 HBs: H-Asp43(OD2) 
9. NCI_308835 -10.8 Hydrophobic contacts 
10. NCI_25457 -10.8 Hydrophobic contacts 
 





1. NCI_293778 -13.7 Hydrophobic contacts 
2. NCI_61610 -11.6 Hydrophobic contacts 
3. NCI_37553 -11.4 Hydrophobic contacts 
4. NCI_156219_b -11.1 HBs: H-Glu50(OE2) 
5. NCI_84100_a -11.0 Hydrophobic contacts 
6. NCI_84100_b -10.9 
HBs: Arg36(HH11)-O, Thr53(HN)-O, 
Lys52(HZ1)-O, H-Tyr51(OH) 
7. NCI_7524_a -10.9 HBs: Ser238(HN)-O 
8. NCI_227186_b -10.9 HBs: H-Asp43(OD2) 
9. NCI_116702 -10.8 HBs: H-Glu50(OE2) 













1. NCI_293778 -13.7 Hydrophobic contacts 
2. NCI_61610 -11.6 Hydrophobic contacts 
3. NCI_37553 -11.5 Hydrophobic contacts 
4. NCI_156219_b -11.1 HBs: H-Pro128(O) 
5. NCI_84100_a -11.0 Hydrophobic contacts 
6. NCI_84100_b -10.9 HBs: H-Asp43(OD2) 
7. NCI_7524_a -10.9 
HBs: Arg36(HH11)-O, Thr53(HN)-O, H-
Tyr51(OH) 
8. NCI_227186_b -10.9 HBs: Ser238(HN)-O, H-G;u50(OE2) 
9. NCI_116702 -10.8 Hydrophobic contacts 
10. NCI_308835 -10.8 Hydrophobic contacts 
 





1. NCI_293778 -13.7 Hydrophobic contacts 
2. NCI_37553 -11.5 Hydrophobic contacts 
3. NCI_156219_b -11.1 Hydrophobic contacts 
4. NCI_25457 -10.8 Hydrophobic contacts 
5. NCI_121868 -10.8 Hydrophobic contacts 
6. NCI_308835 -10.8 Hydrophobic contacts 
7. NCI_116702 -10.8 Hydrophobic contacts 
8. NCI_122819 -10.7 
HBs: Val231(HN)-O, Ile37(HN)-O, 
His230(HD1)-O 
9. NCI_156219 -10.7 HBs: Ile37(HN)-O, His230(HD1)-O 











Appendix 44. Interactions analysis for each ligand in VST1a in focused docking in 





1. NCI_293778 -13.1 Hydrophobic contacts 
2. NCI_37553 -11.4 Hydrophobic contacts 
3. NCI_156219_b -11.3 HBs: H-Ile101(O) 
4. NCI_19990_a -10.9 HBs: H-Thr53(O) 
5. NCI_84100_b -10.8 Hydrophobic contacts 
6. NCI_84100_a -10.8 Hydrophobic contacts 
7. NCI_116702 -10.7 HBs: Arg100(HE)-N 
8. NCI_60785_b -10.5 Hydrophobic contacts 
9. NCI_308835 -10.5 Hydrophobic contacts 
10. NCI_227186_b -10.4 HBs: H-Thr53(O) 
 
Appendix 45. Interactions analysis for each ligand in VST2a in focused docking in 





1. NCI_293778 -11.4 HBs: Ile200(HN)-S 
2. NCI_37641_b -10.7 HBs: Arg168(HH21)-O 
3. NCI_37553 -10.0 HBs: Arg168(HH22)-O 
4. NCI_328101 -10.0 HBs: Arg168(HH21)-F 
5. NCI_116702 -9.9 Hydrophobic contacts 
6. NCI_37641_a -9.9 HBs: H-Pro197(O), Arg168(HH21)-O 
7. NCI_121868_a -9.8 Hydrophobic contacts 
8. NCI_308835 -9.7 HBs: Arg168(HH21)-O 
9. NCI_24951_a -9.5 HBs: O-Pro197(O) 













Appendix 46. Interactions analysis for each ligand in VST1b in focused docking in 





1. NCI_293778 -13.7 Hydrophobic contacts 
2. NCI_37553 -11.4 Hydrophobic contacts 
3. NCI_61610 -11.3 HBs: H-Glu35(O) 
4. NCI_25457 -10.8 Hydrophobic contacts 
5. NCI_116702 -10.8 Hydrophobic contacts 
6. NCI_308835 -10.7 Hydrophobic contacts 
7. NCI_97920 -10.6 Hydrophobic contacts 
8. NCI_7524_b -10.4 Hydrophobic contacts 
9. NCI_671136 -10.3 Hydrophobic contacts 
10. NCI_84100_a -10.2 Hydrophobic contacts 
 
Appendix 47. Interactions analysis for each ligand in VST2b in focused docking in 





1. NCI_61610 -11.6 π-π interaction with Phe141 
2. NCI_37553 -11.1 HBs: Arg144(HE)-O, H-Cys266(SG) 
3. NCI_308835 -11.1 HBs: Arg104(HH12)-O 
4. NCI_84100_b -10.9 HBs: H-Asp43(OD2) 
5. NCI_84100_a -10.8 Hydrophobic contacts 
6. NCI_82802 -10.7 Hydrophobic contacts 
7. NCI_670283 -10.5 Hydrophobic contacts 
8. NCI_7524_b -10.4 HBs: Arg144(HE)-O 
9. NCI_293778 -10.4 HBs: His142(HE2)-N 













Appendix 48. Interactions analysis for each ligand in VST3b in focused docking in 





1. NCI_61610 -11.5 π-stacking with Phe312, Tyr15 
2. NCI_293778 -11.0 π-stacking with Phe312, Tyr15 
3. NCI_37553 -9.9 HBs: H-Gly12(O) 
4. NCI_670283 -9.4 Hydrophobic contacts 
5. NCI_332670 -9.4 Hydrophobic contacts 
6. NCI_328101 -9.3 HBs: Lys16(HZ3)-F 
7. NCI_60785_a -9.2 Hydrophobic contacts 
8. NCI_50648 -9.2 Hydrophobic contacts 
9. NCI_60785_b -9.2 Hydrophobic contacts 
10. NCI_308835 -9.1 Hydrophobic contacts 
 
Appendix 49. Interactions analysis for each ligand in VST4b in focused docking in 





1. NCI_121868_a -10.7 HBs: Lys61(HZ2)-O 
2. NCI_24951_b -10.6 Hydrophobic contacts 
3. NCI_24951_a -10.2 HBs: Lys200(HZ2)-O 
4. NCI_332186 -9.7 HBs: H-Tyr93(O) 
5. NCI_332670 -9.6 Hydrophobic contacts 
6. NCI_3391_a -9.6 HBs: Lys61(HZ2)-O 
7. NCI_80313 -9.5 HBs: Lys200(HZ2)-N 
8. NCI_310326 -9.3 Hydrophobic contacts 
9. NCI_645330 -9.3 Hydrophobic contacts 
10. NCI_97920 -9.2 Hydrophobic contacts 
 
 
 
 
 
